ID   TITIN_HUMAN             Reviewed;       34350 AA.
AC   Q8WZ42; Q10465; Q10466; Q15598; Q2XUS3; Q32Q60; Q4U1Z6; Q6NSG0;
AC   Q6PDB1; Q6PJP0; Q7KYM2; Q7KYN4; Q7KYN5; Q7LDM3; Q7Z2X3; Q8TCG8;
AC   Q8WZ51; Q8WZ52; Q8WZ53; Q8WZB3; Q92761; Q92762; Q9UD97; Q9UP84;
AC   Q9Y6L9;
DT   13-JUN-2006, integrated into UniProtKB/Swiss-Prot.
DT   13-JUN-2006, sequence version 2.
DT   02-NOV-2010, entry version 87.
DE   RecName: Full=Titin;
DE            EC=2.7.11.1;
DE   AltName: Full=Connectin;
DE   AltName: Full=Rhabdomyosarcoma antigen MU-RMS-40.14;
GN   Name=TTN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), NUCLEOTIDE SEQUENCE [MRNA] OF
RP   3336-12202 (ISOFORM 4), AND VARIANTS ILE-498; GLU-1201; ARG-1572;
RP   MET-2610; SER-2831; MET-3261; ASN-3419; HIS-12383; GLU-12679;
RP   ILE-19762; ILE-20718; ASN-23807; MET-24980 AND THR-27755.
RC   TISSUE=Skeletal muscle;
RX   MEDLINE=96026330; PubMed=7569978; DOI=10.1126/science.270.5234.293;
RA   Labeit S., Kolmerer B.;
RT   "Titins, giant proteins in charge of muscle ultrastructure and
RT   elasticity.";
RL   Science 270:293-296(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND VARIANTS
RP   PRO-4215 AND PHE-4283.
RX   MEDLINE=20309627; PubMed=10850961;
RA   Freiburg A., Trombitas K., Hell W., Cazorla O., Fougerousse F.,
RA   Centner T., Kolmerer B., Witt C., Beckmann J.S., Gregorio C.C.,
RA   Granzier H., Labeit S.;
RT   "Series of exon-skipping events in the elastic spring region of titin
RT   as the structural basis for myofibrillar elastic diversity.";
RL   Circ. Res. 86:1114-1121(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, TISSUE
RP   SPECIFICITY, INTERACTION WITH OBSCN, AND VARIANTS PRO-4215 AND
RP   PHE-4283.
RX   MEDLINE=21573839; PubMed=11717165;
RA   Bang M.-L., Centner T., Fornoff F., Geach A.J., Gotthardt M.,
RA   McNabb M., Witt C.C., Labeit D., Gregorio C.C., Granzier H.,
RA   Labeit S.;
RT   "The complete gene sequence of titin, expression of an unusual ~700
RT   kDa titin isoform and its interaction with obscurin identify a novel
RT   Z-line to I-band linking system.";
RL   Circ. Res. 89:1065-1072(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-626 AND 34071-34350
RP   (ISOFORM 3).
RC   TISSUE=Muscle, and Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 405-709 (ISOFORMS 1 AND 2).
RC   TISSUE=Heart muscle;
RX   MEDLINE=97092327; PubMed=8937992;
RA   Gautel M., Goulding D., Bullard B., Weber K., Furst D.O.;
RT   "The central Z-disk region of titin is assembled from a novel repeat
RT   in variable copy numbers.";
RL   J. Cell Sci. 109:2747-2754(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2023-2060, AND TISSUE SPECIFICITY.
RC   TISSUE=Heart muscle;
RX   MEDLINE=95119041; PubMed=7819249; DOI=10.1021/bi00002a021;
RA   Musco G., Tziatzos C., Schuck P., Pastore A.;
RT   "Dissecting titin into its structural motifs: identification of an
RT   alpha helix near the N-terminus.";
RL   Biochemistry 34:553-561(1995).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 3455-4473, AND VARIANTS PRO-3491;
RP   PRO-4215 AND PHE-4283.
RX   PubMed=10051295;
RA   Siu B.L., Niimura H., Osborne J.A., Fatkin D., MacRae C., Solomon S.,
RA   Benson D.W., Seidman J.G., Seidman C.E.;
RT   "Familial dilated cardiomyopathy locus maps to chromosome 2q31.";
RL   Circulation 99:1022-1026(1999).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 9806-12017 (ISOFORM 5).
RC   TISSUE=Heart ventricle;
RX   PubMed=12785098; DOI=10.1023/A:1023410523184;
RA   Greaser M.L., Berri M., Warren C.M., Mozdziak P.E.;
RT   "Species variations in cDNA sequence and exon splicing patterns in the
RT   extensible I-band region of cardiac titin: relation to passive
RT   tension.";
RL   J. Muscle Res. Cell Motil. 23:473-482(2002).
RN   [10]
RP   PROTEIN SEQUENCE OF 11773-11783; 17908-17931; 18656-18669;
RP   26545-26553; 28758-28774 AND 32920-32928, AND MASS SPECTROMETRY.
RC   TISSUE=Fetal brain cortex;
RA   Lubec G., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 12947-13797.
RC   TISSUE=Embryonic rhabdomyosarcoma;
RA   Behrends U., Gotz C., Mautner J.;
RT   "Serological identification of rhabdomyosarcoma antigens.";
RL   Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE OF 14257-14543.
RX   MEDLINE=93354576; PubMed=8351016;
RA   Gautel M., Lakey A., Barlow D.P., Holmes Z., Scales S., Leonard K.,
RA   Labeit S., Mygland A., Gilhus N.E., Aarli J.A.;
RT   "Titin antibodies in myasthenia gravis: identification of a major
RT   immunogenic region of titin.";
RL   Neurology 43:1581-1585(1993).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 21021-22120, AND NUCLEOTIDE SEQUENCE
RP   [GENOMIC DNA] OF 23754-24284.
RX   MEDLINE=92258380; PubMed=1582406;
RA   Labeit S., Gautel M., Lakey A., Trinick J.;
RT   "Towards a molecular understanding of titin.";
RL   EMBO J. 11:1711-1716(1992).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 29701-34350, AND PHOSPHORYLATION.
RX   MEDLINE=94008990; PubMed=8404852;
RA   Gautel M., Leonard K., Labeit S.;
RT   "Phosphorylation of KSF motifs in the C-terminal region of titin in
RT   differentiating myoblasts.";
RL   EMBO J. 12:3827-3834(1993).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 33119-34350.
RC   TISSUE=Skeletal muscle;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [16]
RP   INTERACTION WITH TCAP.
RX   MEDLINE=98307394; PubMed=9645487; DOI=10.1016/S0014-5793(98)00501-8;
RA   Mues A., van der Ven P.F.M., Young P., Furst D.O., Gautel M.;
RT   "Two immunoglobulin-like domains of the Z-disc portion of titin
RT   interact in a conformation-dependent way with telethonin.";
RL   FEBS Lett. 428:111-114(1998).
RN   [17]
RP   INTERACTION WITH NEB.
RX   PubMed=12482578; DOI=10.1016/S0014-5793(02)03655-4;
RA   Ma K., Wang K.;
RT   "Interaction of nebulin SH3 domain with titin PEVK and myopalladin:
RT   implications for the signaling and assembly role of titin and
RT   nebulin.";
RL   FEBS Lett. 532:273-278(2002).
RN   [18]
RP   INTERACTION WITH FHL2.
RX   PubMed=12432079; DOI=10.1242/jcs.00181;
RA   Lange S., Auerbach D., McLoughlin P., Perriard E., Schafer B.W.,
RA   Perriard J.-C., Ehler E.;
RT   "Subcellular targeting of metabolic enzymes to titin in heart muscle
RT   may be mediated by DRAL/FHL-2.";
RL   J. Cell Sci. 115:4925-4936(2002).
RN   [19]
RP   INTERACTION WITH ANK1.
RX   PubMed=12444090; DOI=10.1074/jbc.M209012200;
RA   Kontrogianni-Konstantopoulos A., Bloch R.J.;
RT   "The hydrophilic domain of small ankyrin-1 interacts with the two N-
RT   terminal immunoglobulin domains of titin.";
RL   J. Biol. Chem. 278:3985-3991(2003).
RN   [20]
RP   INTERACTION WITH ANKRD1; ANKRD2; ANKRD23 AND CAPN3.
RX   PubMed=14583192; DOI=10.1016/j.jmb.2003.09.012;
RA   Miller M.K., Bang M.-L., Witt C.C., Labeit D., Trombitas C.,
RA   Watanabe K., Granzier H., McElhinny A.S., Gregorio C.C., Labeit S.;
RT   "The muscle ankyrin repeat proteins: CARP, ankrd2/Arpp and DARP as a
RT   family of titin filament-based stress response molecules.";
RL   J. Mol. Biol. 333:951-964(2003).
RN   [21]
RP   INTERACTION WITH CRYAB.
RX   PubMed=14676215; DOI=10.1074/jbc.M307473200;
RA   Bullard B., Ferguson C., Minajeva A., Leake M.C., Gautel M.,
RA   Labeit D., Ding L., Labeit S., Horwitz J., Leonard K.R., Linke W.A.;
RT   "Association of the chaperone alphaB-crystallin with titin in heart
RT   muscle.";
RL   J. Biol. Chem. 279:7917-7924(2004).
RN   [22]
RP   INTERACTION WITH TRIM63 AND TRIM55.
RX   PubMed=15967462; DOI=10.1016/j.jmb.2005.05.021;
RA   Witt S.H., Granzier H., Witt C.C., Labeit S.;
RT   "MURF-1 and MURF-2 target a specific subset of myofibrillar proteins
RT   redundantly: towards understanding MURF-dependent muscle
RT   ubiquitination.";
RL   J. Mol. Biol. 350:713-722(2005).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-8490, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=17053785; DOI=10.1038/sj.emboj.7601384;
RA   Wang Y., Du D., Fang L., Yang G., Zhang C., Zeng R., Ullrich A.,
RA   Lottspeich F., Chen Z.;
RT   "Tyrosine phosphorylated Par3 regulates epithelial tight junction
RT   assembly promoted by EGFR signaling.";
RL   EMBO J. 25:5058-5070(2006).
RN   [24]
RP   INTERACTION WITH LAMIN, AND SUBCELLULAR LOCATION.
RX   PubMed=16410549; DOI=10.1242/jcs.02728;
RA   Zastrow M.S., Flaherty D.B., Benian G.M., Wilson K.L.;
RT   "Nuclear titin interacts with A- and B-type lamins in vitro and in
RT   vivo.";
RL   J. Cell Sci. 119:239-249(2006).
RN   [25]
RP   REVIEW.
RX   PubMed=16537787; DOI=10.1152/ajpheart.00816.2005;
RA   Hoshijima M.;
RT   "Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z
RT   disk, titin, and associated structures.";
RL   Am. J. Physiol. 290:H1313-H1325(2006).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-33938 AND SER-33942,
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-5304 AND SER-5306
RP   (ISOFORM 6), AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.-R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa
RT   cells and high confident phosphopeptide identification by cross-
RT   validation of MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-22525 AND SER-22534, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=17287340; DOI=10.1073/pnas.0611217104;
RA   Molina H., Horn D.M., Tang N., Mathivanan S., Pandey A.;
RT   "Global proteomic profiling of phosphopeptides using electron transfer
RT   dissociation tandem mass spectrometry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:2199-2204(2007).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9203 AND THR-9207, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-4065 AND SER-4068, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18187866; DOI=10.2116/analsci.24.161;
RA   Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.;
RT   "Automated phosphoproteome analysis for cultured cancer cells by two-
RT   dimensional nanoLC-MS using a calcined titania/C18 biphasic column.";
RL   Anal. Sci. 24:161-166(2008).
RN   [30]
RP   STRUCTURE BY NMR OF 33483-33579.
RX   PubMed=7613868; DOI=10.1016/S0969-2126(01)00170-8;
RA   Pfuhl M., Pastore A.;
RT   "Tertiary structure of an immunoglobulin-like domain from the giant
RT   muscle protein titin: a new member of the I set.";
RL   Structure 3:391-401(1995).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 32172-32489, FUNCTION, ENZYME
RP   REGULATION, INTERACTION WITH CALM, PHOSPHORYLATION AT TYR-32341, AND
RP   MUTAGENESIS OF LYS-32207 AND TYR-32341.
RX   PubMed=9804419; DOI=10.1038/27603;
RA   Mayans O., van der Ven P.F.M., Wilm M., Mues A., Young P., Furst D.O.,
RA   Wilmanns M., Gautel M.;
RT   "Structural basis for activation of the titin kinase domain during
RT   myofibrillogenesis.";
RL   Nature 395:863-869(1998).
RN   [32]
RP   STRUCTURE BY NMR OF 22283-22385.
RX   PubMed=9782056; DOI=10.1016/S0969-2126(98)00129-4;
RA   Goll C.M., Pastore A., Nilges M.;
RT   "The three-dimensional structure of a type I module from titin: a
RT   prototype of intracellular fibronectin type III domains.";
RL   Structure 6:1291-1302(1998).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 2073-2171, AND DISULFIDE
RP   BOND.
RX   PubMed=11525170; DOI=10.1016/S0969-2126(01)00591-3;
RA   Mayans O., Wuerges J., Canela S., Gautel M., Wilmanns M.;
RT   "Structural evidence for a possible role of reversible disulphide
RT   bridge formation in the elasticity of the muscle protein titin.";
RL   Structure 9:331-340(2001).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.44 ANGSTROMS) OF 1-196 IN COMPLEX WITH TCAP.
RX   PubMed=16407954; DOI=10.1038/nature04343;
RA   Zou P., Pinotsis N., Lange S., Song Y.-H., Popov A., Mavridis I.,
RA   Mayans O.M., Gautel M., Wilmanns M.;
RT   "Palindromic assembly of the giant muscle protein titin in the
RT   sarcomeric Z-disk.";
RL   Nature 439:229-233(2006).
RN   [35]
RP   VARIANT CMH9 LEU-740.
RX   PubMed=10462489; DOI=10.1006/bbrc.1999.1221;
RA   Satoh M., Takahashi M., Sakamoto T., Hiroe M., Marumo F., Kimura A.;
RT   "Structural analysis of the titin gene in hypertrophic cardiomyopathy:
RT   identification of a novel disease gene.";
RL   Biochem. Biophys. Res. Commun. 262:411-417(1999).
RN   [36]
RP   INVOLVEMENT IN LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 2J, AND VARIANT TMD
RP   PRO-34315.
RX   PubMed=12145747; DOI=10.1086/342380;
RA   Hackman P., Vihola A., Haravuori H., Marchand S., Sarparanta J.,
RA   De Seze J., Labeit S., Witt C., Peltonen L., Richard I., Udd B.;
RT   "Tibial muscular dystrophy is a titinopathy caused by mutations in
RT   TTN, the gene encoding the giant skeletal-muscle protein titin.";
RL   Am. J. Hum. Genet. 71:492-500(2002).
RN   [37]
RP   VARIANTS CMD1G MET-54; VAL-743; TYR-3799 AND ASN-4465, VARIANTS
RP   CYS-328; GLN-4084 AND PRO-4215, AND CHARACTERIZATION OF VARIANTS CMD1G
RP   MET-54 AND VAL-743.
RX   PubMed=11846417; DOI=10.1006/bbrc.2002.6448;
RA   Itoh-Satoh M., Hayashi T., Nishi H., Koga Y., Arimura T., Koyanagi T.,
RA   Takahashi M., Hohda S., Ueda K., Nouchi T., Hiroe M., Marumo F.,
RA   Imaizumi T., Yasunami M., Kimura A.;
RT   "Titin mutations as the molecular basis for dilated cardiomyopathy.";
RL   Biochem. Biophys. Res. Commun. 291:385-393(2002).
RN   [38]
RP   VARIANT CMD1G ARG-976.
RX   PubMed=11788824; DOI=10.1038/ng815;
RA   Gerull B., Gramlich M., Atherton J., McNabb M., Trombitas K.,
RA   Sasse-Klaassen S., Seidman J.G., Seidman C., Granzier H., Labeit S.,
RA   Frenneaux M., Thierfelder L.;
RT   "Mutations of TTN, encoding the giant muscle filament titin, cause
RT   familial dilated cardiomyopathy.";
RL   Nat. Genet. 30:201-204(2002).
RN   [39]
RP   VARIANT TMD ASN-34306.
RX   PubMed=12891679; DOI=10.1002/ana.10647;
RA   Van den Bergh P.Y.K., Bouquiaux O., Verellen C., Marchand S.,
RA   Richard I., Hackman P., Udd B.;
RT   "Tibial muscular dystrophy in a Belgian family.";
RL   Ann. Neurol. 54:248-251(2003).
RN   [40]
RP   VARIANT CMD1G GLN-32996.
RX   PubMed=16465475; DOI=10.1007/s10974-005-9018-5;
RA   Matsumoto Y., Hayashi T., Inagaki N., Takahashi M., Hiroi S.,
RA   Nakamura T., Arimura T., Nakamura K., Ashizawa N., Yasunami M.,
RA   Ohe T., Yano K., Kimura A.;
RT   "Functional analysis of titin/connectin N2-B mutations found in
RT   cardiomyopathy.";
RL   J. Muscle Res. Cell Motil. 26:367-374(2005).
RN   [41]
RP   VARIANT HMERF TRP-279, CHARACTERIZATION OF VARIANT HMERF TRP-279, AND
RP   INTERACTION WITH NBR1.
RX   PubMed=15802564; DOI=10.1126/science.1110463;
RA   Lange S., Xiang F., Yakovenko A., Vihola A., Hackman P., Rostkova E.,
RA   Kristensen J., Brandmeier B., Franzen G., Hedberg B., Gunnarsson L.G.,
RA   Hughes S.M., Marchand S., Sejersen T., Richard I., Edstroem L.,
RA   Ehler E., Udd B., Gautel M.;
RT   "The kinase domain of titin controls muscle gene expression and
RT   protein turnover.";
RL   Science 308:1599-1603(2005).
RN   [42]
RP   INVOLVEMENT IN EOMFC.
RX   PubMed=17444505; DOI=10.1002/ana.21089;
RA   Carmignac V., Salih M.A.M., Quijano-Roy S., Marchand S.,
RA   Al Rayess M.M., Mukhtar M.M., Urtizberea J.A., Labeit S.,
RA   Guicheney P., Leturcq F., Gautel M., Fardeau M., Campbell K.P.,
RA   Richard I., Estournet B., Ferreiro A.;
RT   "C-terminal titin deletions cause a novel early-onset myopathy with
RT   fatal cardiomyopathy.";
RL   Ann. Neurol. 61:340-351(2007).
RN   [43]
RP   VARIANTS [LARGE SCALE ANALYSIS] TYR-60; MET-115; CYS-328; THR-360;
RP   ILE-498; MET-799; ILE-811; HIS-922; ASP-937; THR-1081; ARG-1137;
RP   GLU-1201; ALA-1202; SER-1295; ASP-1345; THR-1347; HIS-1350; LEU-1353;
RP   VAL-1393; CYS-1416; PRO-1441; VAL-1544; ARG-1572; GLY-1658; GLN-1664;
RP   ASP-1692; LEU-1744; GLY-1772; ILE-1907; HIS-1998; LEU-2107; THR-2118;
RP   THR-2164; TYR-2240; SER-2392; PHE-2432; MET-2610; MET-2771; PHE-2823;
RP   SER-2831; ILE-2930; ARG-3154; GLU-3191; LEU-3238; GLY-3250; MET-3261;
RP   GLN-3367; LYS-3482; PRO-3491; LYS-3570; VAL-3590; VAL-3762; PHE-3877;
RP   LEU-3965; PRO-4215; TRP-4238; PHE-4283; THR-4291; ASP-4303; GLU-4427;
RP   GLU-12310; HIS-12383; ALA-12469; CYS-12642; LYS-12657; GLU-12679;
RP   PHE-12720; CYS-12798; GLY-13049; LYS-13083; LEU-13096; ARG-13099;
RP   ALA-13297; MET-13399; THR-13418; VAL-13428; THR-13430; LYS-13434;
RP   ASN-13469; ASN-13495; SER-13785; HIS-13870; ILE-14109; GLN-14131;
RP   THR-14208; VAL-14728; THR-14999; THR-15021; VAL-15520; ILE-15555;
RP   GLN-15620; ILE-15629; CYS-15635; GLN-15700; PRO-15705; MET-15837;
RP   HIS-16058; ILE-16067; THR-16090; HIS-16195; CYS-16409; PRO-16424;
RP   MET-16629; ARG-16877; ASP-17060; VAL-17637; HIS-17838; ASN-17866;
RP   GLU-17906; ALA-18094; SER-18109; THR-18164; LEU-18221; THR-18222;
RP   GLN-18726; ALA-18835; LYS-18881; SER-18939; GLN-19000; GLN-19060;
RP   LYS-19091; SER-19224; ILE-19367; LYS-19392; SER-19480; GLY-19495;
RP   HIS-19665; ILE-19762; ARG-19947; MET-19956; GLN-19992; CYS-20057;
RP   LEU-20075; LYS-20179; THR-20198; VAL-20198; HIS-20331; THR-20408;
RP   LYS-20564; ILE-20718; PRO-20726; ASN-20892; ARG-20894; GLU-21125;
RP   SER-21403; CYS-21730; GLN-21747; ARG-21851; ARG-21851; ARG-21925;
RP   HIS-21995; VAL-22045; HIS-22149; ILE-22160; THR-22261; ASN-22306;
RP   HIS-22357; PRO-22408; HIS-22537; LEU-22584; PRO-22646; ALA-22670;
RP   ASP-22770; THR-22801; TRP-22823; GLN-22968; LEU-23074; PHE-23079;
RP   ASN-23282; TYR-23303; CYS-23306; SER-23515; GLN-23551; ASN-23807;
RP   ASN-23872; ALA-23891; HIS-23933; MET-23939; LEU-23952; GLY-24098;
RP   SER-24119; ILE-24133; ALA-24159; ALA-24239; LYS-24265; THR-24584;
RP   THR-24781; HIS-24799; HIS-24954; MET-24980; HIS-25659; THR-25679;
RP   ALA-25720; LYS-25821; LYS-25859; LYS-25879; VAL-25923; ILE-26045;
RP   GLU-26059; VAL-26134; CYS-26477; TYR-26843; ARG-27346; CYS-27652;
RP   VAL-27728; LEU-27754; THR-27755; VAL-27929; LEU-28132; GLN-28168;
RP   HIS-28538; THR-28572; THR-28948; VAL-28986; GLU-28993; VAL-28998;
RP   MET-29070; VAL-29090; CYS-29419; PRO-29479; LEU-29880; GLU-29976;
RP   GLY-30042; CYS-30107; PHE-30125; PRO-30211; THR-30412; SER-30617;
RP   ILE-30674; ILE-30809; ILE-30818; LYS-30825; THR-30856; ASP-30887;
RP   SER-30887; HIS-30897; HIS-30907; HIS-30946; PHE-31081; CYS-31107;
RP   GLY-31124; SER-31156; THR-31246; HIS-31330; ARG-31690; GLN-31724;
RP   ILE-31725; SER-31732; ILE-31886; CYS-32097; ASN-32171; ILE-32248;
RP   HIS-32281; HIS-32323; TRP-32411; VAL-32558; VAL-32610; VAL-32637;
RP   ALA-32922; ARG-32943; HIS-32953; LEU-33213; CYS-33242; MET-33387;
RP   ASP-33419; MET-33536; GLN-33568; LYS-33616; LEU-33620; VAL-33886;
RP   THR-33899; PRO-33904; ILE-33955 AND ALA-34115.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Key component in the assembly and functioning of
CC       vertebrate striated muscles. By providing connections at the level
CC       of individual microfilaments, it contributes to the fine balance
CC       of forces between the two halves of the sarcomere. The size and
CC       extensibility of the cross-links are the main determinants of
CC       sarcomere extensibility properties of muscle. In non-muscle cells,
CC       seems to play a role in chromosome condensation and chromosome
CC       segregation during mitosis. Might link the lamina network to
CC       chromatin or nuclear actin, or both during interphase.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR: Magnesium.
CC   -!- ENZYME REGULATION: Full activation of the protein kinase domain
CC       requires both phosphorylation of Tyr-32341, preventing it from
CC       blocking the catalytic aspartate residue, and binding of Ca/CALM
CC       to the C-terminal regulatory tail of the molecule which results in
CC       ATP binding to the kinase.
CC   -!- SUBUNIT: Interacts with MYOM1, MYOM2, tropomyosin and myosin.
CC       Interacts with actin, primarily via the PEVK domains and with MYPN
CC       (By similarity). Interacts with FHL2, NEB, CRYAB, LMNA/lamin-A and
CC       LMNB/lamin-B. Interacts with TCAP/telethonin and/or ANK1 isoform
CC       Mu17/ank1.5, via the first two N-terminal immunoglobulin domains.
CC       Interacts with TRIM63 and TRIM55, through several domains
CC       including immunoglobulin domains 141 and 142. Interacts with
CC       ANKRD1, ANKRD2 and ANKRD23, via the region between immunoglobulin
CC       domains 77 and 78 and interacts with CAPN3, via immunoglobulin
CC       domain 79. Interacts with NBR1 through the protein kinase domain.
CC       Interacts with CALM/calmodulin. Isoform 8 interacts with OBSCN
CC       isoform 3.
CC   -!- INTERACTION:
CC       Self; NbExp=1; IntAct=EBI-681210, EBI-681210;
CC       P35609:ACTN2; NbExp=5; IntAct=EBI-681210, EBI-77797;
CC       Q9NVP2:ASF1B; NbExp=1; IntAct=EBI-681210, EBI-1055650;
CC       Q5VST9:OBSCN; NbExp=3; IntAct=EBI-681210, EBI-941850;
CC       Q9UHX1:PUF60; NbExp=1; IntAct=EBI-681210, EBI-1053259;
CC       O15273:TCAP; NbExp=1; IntAct=EBI-681210, EBI-954089;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (Probable). Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC         Comment=A number of isoforms may be produced, ranging from 27000
CC         to 33000 residues in different striated muscle tissues, the size
CC         of the full length protein may be up to 38138 residues;
CC       Name=1;
CC         IsoId=Q8WZ42-1; Sequence=Displayed;
CC         Note=No experimental confirmation available;
CC       Name=2;
CC         IsoId=Q8WZ42-2; Sequence=VSP_019138;
CC         Note=No experimental confirmation available;
CC       Name=3; Synonyms=Small cardiac N2-B;
CC         IsoId=Q8WZ42-3; Sequence=VSP_019139, VSP_019145;
CC       Name=4; Synonyms=Soleus;
CC         IsoId=Q8WZ42-4; Sequence=VSP_019142, VSP_019151;
CC         Note=No experimental confirmation available;
CC       Name=5;
CC         IsoId=Q8WZ42-5; Sequence=VSP_019147, VSP_019148, VSP_019149,
CC                                  VSP_019150, VSP_019152;
CC         Note=No experimental confirmation available;
CC       Name=6; Synonyms=Small cardiac novex-3;
CC         IsoId=Q8WZ42-6; Sequence=VSP_019143, VSP_019146;
CC         Note=Phosphorylated on Thr-5304 and Ser-5306;
CC       Name=7; Synonyms=Cardiac novex-2;
CC         IsoId=Q8WZ42-7; Sequence=VSP_019141, VSP_019144;
CC       Name=8; Synonyms=Cardiac novex-1;
CC         IsoId=Q8WZ42-8; Sequence=VSP_019140;
CC   -!- TISSUE SPECIFICITY: Isoform 3, isoform 7 and isoform 8 are
CC       expressed in cardiac muscle. Isoform 4 is expressed in vertebrate
CC       skeletal muscle. Isoform 6 is expressed in cardiac tissues.
CC   -!- DOMAIN: ZIS1 and ZIS5 regions contain multiple SPXR consensus
CC       sites for ERK- and CDK-like protein kinases as well as multiple SP
CC       motifs. ZIS1 could adopt a closed conformation which would block
CC       the TCAP-binding site.
CC   -!- DOMAIN: The PEVK region may serve as an entropic spring of a chain
CC       of structural folds and may also be an interaction site to other
CC       myofilament proteins to form interfilament connectivity in the
CC       sarcomere.
CC   -!- PTM: Autophosphorylated (By similarity). Phosphorylated upon DNA
CC       damage, probably by ATM or ATR.
CC   -!- DISEASE: Defects in TTN are the cause of hereditary myopathy with
CC       early respiratory failure (HMERF) [MIM:603689]; also known as
CC       Edstrom myopathy. HMERF is an autosomal dominant, adult-onset
CC       myopathy with early respiratory muscle involvement.
CC   -!- DISEASE: Defects in TTN are the cause of cardiomyopathy familial
CC       hypertrophic type 9 (CMH9) [MIM:188840]. Familial hypertrophic
CC       cardiomyopathy is a hereditary heart disorder characterized by
CC       ventricular hypertrophy, which is usually asymmetric and often
CC       involves the interventricular septum. The symptoms include
CC       dyspnea, syncope, collapse, palpitations, and chest pain. They can
CC       be readily provoked by exercise. The disorder has inter- and
CC       intrafamilial variability ranging from benign to malignant forms
CC       with high risk of cardiac failure and sudden cardiac death.
CC   -!- DISEASE: Defects in TTN are the cause of cardiomyopathy dilated
CC       type 1G (CMD1G) [MIM:604145]. Dilated cardiomyopathy is a disorder
CC       characterized by ventricular dilation and impaired systolic
CC       function, resulting in congestive heart failure and arrhythmia.
CC       Patients are at risk of premature death.
CC   -!- DISEASE: Defects in TTN are the cause of tardive tibial muscular
CC       dystrophy (TMD) [MIM:600334]; also known as Udd myopathy. TMD is
CC       an autosomal dominant, late-onset distal myopathy. Muscle weakness
CC       and atrophy are usually confined to the anterior compartment of
CC       the lower leg, in particular the tibialis anterior muscle.
CC       Clinical symptoms usually occur at age 35-45 years or much later.
CC   -!- DISEASE: Defects in TTN are the cause of limb-girdle muscular
CC       dystrophy type 2J (LGMD2J) [MIM:608807]. LGMD2J is an autosomal
CC       recessive degenerative myopathy characterized by progressive
CC       weakness of the pelvic and shoulder girdle muscles. Severe
CC       disability is observed within 20 years of onset.
CC   -!- DISEASE: Defects in TTN are the cause of early-onset myopathy with
CC       fatal cardiomyopathy (EOMFC) [MIM:611705]. Early-onset myopathies
CC       are inherited muscle disorders that manifest typically from birth
CC       or infancy with hypotonia, muscle weakness, and delayed motor
CC       development. EOMFC is a titinopathy that, in contrast with the
CC       previously described examples, involves both heart and skeletal
CC       muscle, has a congenital onset, and is purely recessive. This
CC       phenotype is due to homozygous out-of-frame TTN deletions, which
CC       lead to a total absence of titin's C-terminal end from striated
CC       muscles and to secondary CAPN3 depletion.
CC   -!- MISCELLANEOUS: In some isoforms, after the PEVK repeat region
CC       there is a long PEVK duplicated region. On account of this region,
CC       it has been very difficult to sequence the whole protein. The
CC       length of this region (ranging from 183 to 2174 residues), may be
CC       a key elastic element of titin.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family.
CC   -!- SIMILARITY: Contains 132 fibronectin type-III domains.
CC   -!- SIMILARITY: Contains 152 Ig-like (immunoglobulin-like) domains.
CC   -!- SIMILARITY: Contains 19 Kelch repeats.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 17 RCC1 repeats.
CC   -!- SIMILARITY: Contains 14 TPR repeats.
CC   -!- SIMILARITY: Contains 15 WD repeats.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH58824.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 553;
CC       Sequence=AAH70170.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 627;
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/TTN";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Titin entry;
CC       URL="http://en.wikipedia.org/wiki/Titin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X90568; CAA62188.1; -; mRNA.
DR   EMBL; X90569; CAA62189.1; -; mRNA.
DR   EMBL; AJ277892; CAD12455.1; -; Genomic_DNA.
DR   EMBL; AJ277892; CAD12456.1; -; Genomic_DNA.
DR   EMBL; AJ277892; CAD12457.1; -; Genomic_DNA.
DR   EMBL; AJ277892; CAD12458.1; -; Genomic_DNA.
DR   EMBL; AJ277892; CAD12459.1; -; Genomic_DNA.
DR   EMBL; BC013396; AAH13396.1; -; mRNA.
DR   EMBL; BC058824; AAH58824.1; ALT_SEQ; mRNA.
DR   EMBL; BC070170; AAH70170.1; ALT_SEQ; mRNA.
DR   EMBL; BC107797; AAI07798.1; -; mRNA.
DR   EMBL; X98114; CAA66795.1; -; mRNA.
DR   EMBL; X98115; CAA66796.1; -; mRNA.
DR   EMBL; X83270; CAA58243.1; -; mRNA.
DR   EMBL; AF058332; AAD22603.1; -; Genomic_DNA.
DR   EMBL; AF058332; AAD22604.1; -; Genomic_DNA.
DR   EMBL; AF525413; AAP80791.1; -; mRNA.
DR   EMBL; DQ248309; ABB55264.1; -; mRNA.
DR   EMBL; X64698; CAA45939.1; -; mRNA.
DR   EMBL; X64699; CAA45940.1; -; Genomic_DNA.
DR   EMBL; X64697; CAA45938.1; -; mRNA.
DR   EMBL; X69490; CAA49245.1; -; mRNA.
DR   EMBL; AL713647; CAD28458.1; -; mRNA.
DR   IPI; IPI00023283; -.
DR   IPI; IPI00179357; -.
DR   IPI; IPI00375498; -.
DR   IPI; IPI00759542; -.
DR   IPI; IPI00759613; -.
DR   IPI; IPI00759637; -.
DR   IPI; IPI00759754; -.
DR   IPI; IPI00783950; -.
DR   PIR; I38344; I38344.
DR   PIR; I38346; I38346.
DR   UniGene; Hs.134602; -.
DR   UniGene; Hs.724625; -.
DR   PDB; 1BPV; NMR; -; A=22283-22385.
DR   PDB; 1G1C; X-ray; 2.10 A; A/B=2073-2171.
DR   PDB; 1NCT; NMR; -; A=33483-33579.
DR   PDB; 1NCU; NMR; -; A=33483-33579.
DR   PDB; 1TIT; NMR; -; A=12677-12765.
DR   PDB; 1TIU; NMR; -; A=12677-12765.
DR   PDB; 1TKI; X-ray; 2.00 A; A/B=32172-32492.
DR   PDB; 1TNM; NMR; -; A=33489-33579.
DR   PDB; 1TNN; NMR; -; A=33489-33579.
DR   PDB; 1WAA; X-ray; 1.80 A; A/B/C/D/E/F=12677-12765.
DR   PDB; 1YA5; X-ray; 2.44 A; A/B=1-196.
DR   PDB; 2A38; X-ray; 2.00 A; A/B/C=1-194.
DR   PDB; 2BK8; X-ray; 1.69 A; A=32497-32590.
DR   PDB; 2F8V; X-ray; 2.75 A; A/B/C/D=1-196.
DR   PDB; 2ILL; X-ray; 2.20 A; A=31854-32047.
DR   PDB; 2J8H; X-ray; 1.99 A; A=31854-32047.
DR   PDB; 2J8O; X-ray; 2.49 A; A/B=31854-32047.
DR   PDB; 2NZI; X-ray; 2.90 A; A/B=31854-32155.
DR   PDB; 2RQ8; NMR; -; A=12677-12765.
DR   PDB; 2WP3; X-ray; 1.48 A; T=34252-34350.
DR   PDB; 2WWK; X-ray; 1.70 A; T=34252-34350.
DR   PDB; 2WWM; X-ray; 2.30 A; D/T=34252-34350.
DR   PDB; 3B43; X-ray; 3.30 A; A=7945-8511.
DR   PDB; 3KNB; X-ray; 1.40 A; A=34253-34350.
DR   PDBsum; 1BPV; -.
DR   PDBsum; 1G1C; -.
DR   PDBsum; 1NCT; -.
DR   PDBsum; 1NCU; -.
DR   PDBsum; 1TIT; -.
DR   PDBsum; 1TIU; -.
DR   PDBsum; 1TKI; -.
DR   PDBsum; 1TNM; -.
DR   PDBsum; 1TNN; -.
DR   PDBsum; 1WAA; -.
DR   PDBsum; 1YA5; -.
DR   PDBsum; 2A38; -.
DR   PDBsum; 2BK8; -.
DR   PDBsum; 2F8V; -.
DR   PDBsum; 2ILL; -.
DR   PDBsum; 2J8H; -.
DR   PDBsum; 2J8O; -.
DR   PDBsum; 2NZI; -.
DR   PDBsum; 2RQ8; -.
DR   PDBsum; 2WP3; -.
DR   PDBsum; 2WWK; -.
DR   PDBsum; 2WWM; -.
DR   PDBsum; 3B43; -.
DR   PDBsum; 3KNB; -.
DR   ProteinModelPortal; Q8WZ42; -.
DR   DIP; DIP-29145N; -.
DR   DIP; DIP-33449N; -.
DR   IntAct; Q8WZ42; 29.
DR   MINT; MINT-2881875; -.
DR   STRING; Q8WZ42; -.
DR   PhosphoSite; Q8WZ42; -.
DR   PRIDE; Q8WZ42; -.
DR   GeneCards; GC02M179355; -.
DR   H-InvDB; HIX0002636; -.
DR   HGNC; HGNC:12403; TTN.
DR   HPA; CAB022682; -.
DR   HPA; HPA007042; -.
DR   MIM; 188840; gene+phenotype.
DR   MIM; 600334; phenotype.
DR   MIM; 603689; phenotype.
DR   MIM; 604145; phenotype.
DR   MIM; 608807; phenotype.
DR   MIM; 611705; phenotype.
DR   Orphanet; 140922; Autosomal recessive limb-girdle muscular dystrophy type 2J.
DR   Orphanet; 154; Familial isolated dilated cardiomyopathy.
DR   Orphanet; 155; Familial isolated hypertrophic cardiomyopathy.
DR   Orphanet; 178464; Hereditary myopathy with early respiratory failure.
DR   Orphanet; 609; Tibial muscular dystrophy.
DR   PharmGKB; PA27775; -.
DR   eggNOG; prNOG15623; -.
DR   HOVERGEN; HBG080472; -.
DR   BRENDA; 2.7.11.1; 247.
DR   Reactome; REACT_17044; Muscle contraction.
DR   Reactome; REACT_604; Hemostasis.
DR   NextBio; 28431; -.
DR   Genevestigator; Q8WZ42; -.
DR   GermOnline; ENSG00000155657; Homo sapiens.
DR   GO; GO:0000794; C:condensed nuclear chromosome; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0005576; C:extracellular region; EXP:Reactome.
DR   GO; GO:0031430; C:M band; IDA:BHF-UCL.
DR   GO; GO:0005865; C:striated muscle thin filament; IDA:BHF-UCL.
DR   GO; GO:0030018; C:Z disc; IDA:BHF-UCL.
DR   GO; GO:0030018; C:Z disc; IDA:UniProtKB.
DR   GO; GO:0051015; F:actin filament binding; IDA:BHF-UCL.
DR   GO; GO:0051393; F:alpha-actinin binding; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL.
DR   GO; GO:0004198; F:calcium-dependent cysteine-type endopeptida...; IEA:InterPro.
DR   GO; GO:0005516; F:calmodulin binding; TAS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0003676; F:nucleic acid binding; IEA:InterPro.
DR   GO; GO:0005515; F:protein binding; IPI:BHF-UCL.
DR   GO; GO:0043621; F:protein self-association; IDA:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:InterPro.
DR   GO; GO:0008307; F:structural constituent of muscle; IEP:BHF-UCL.
DR   GO; GO:0008307; F:structural constituent of muscle; TAS:UniProtKB.
DR   GO; GO:0031433; F:telethonin binding; IPI:BHF-UCL.
DR   GO; GO:0048739; P:cardiac muscle fiber development; IMP:BHF-UCL.
DR   GO; GO:0055008; P:cardiac muscle tissue morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0055003; P:cardiac myofibril assembly; IMP:BHF-UCL.
DR   GO; GO:0007076; P:mitotic chromosome condensation; IEP:BHF-UCL.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IEA:InterPro.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045859; P:regulation of protein kinase activity; IMP:BHF-UCL.
DR   GO; GO:0051592; P:response to calcium ion; IDA:BHF-UCL.
DR   GO; GO:0045214; P:sarcomere organization; IMP:BHF-UCL.
DR   GO; GO:0030241; P:skeletal muscle myosin thick filament assembly; IMP:BHF-UCL.
DR   GO; GO:0030240; P:skeletal muscle thin filament assembly; IMP:BHF-UCL.
DR   GO; GO:0006941; P:striated muscle contraction; TAS:UniProtKB.
DR   InterPro; IPR022682; Calpain_domain_III.
DR   InterPro; IPR008957; Fibronectin_III_dom.
DR   InterPro; IPR003961; FN_III.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR012337; PolynucTfrase_RNaseH_fold.
DR   InterPro; IPR004168; PPAK_motif.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   InterPro; IPR015129; Titin_Z.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 299.
DR   Pfam; PF00041; fn3; 132.
DR   Pfam; PF07679; I-set; 162.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF02818; PPAK; 15.
DR   Pfam; PF09042; Titin_Z; 6.
DR   SMART; SM00060; FN3; 132.
DR   SMART; SM00409; IG; 95.
DR   SMART; SM00408; IGc2; 65.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF49265; FN_III-like; 132.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   SUPFAM; SSF49758; Peptidase_C2; 1.
DR   SUPFAM; SSF53098; RNaseH_fold; 1.
DR   PROSITE; PS50853; FN3; 132.
DR   PROSITE; PS50835; IG_LIKE; 143.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; FALSE_NEG.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; FALSE_NEG.
DR   PROSITE; PS00625; RCC1_1; FALSE_NEG.
DR   PROSITE; PS00626; RCC1_2; FALSE_NEG.
DR   PROSITE; PS50012; RCC1_3; FALSE_NEG.
DR   PROSITE; PS50005; TPR; FALSE_NEG.
DR   PROSITE; PS50293; TPR_REGION; FALSE_NEG.
DR   PROSITE; PS00678; WD_REPEATS_1; FALSE_NEG.
DR   PROSITE; PS50082; WD_REPEATS_2; FALSE_NEG.
DR   PROSITE; PS50294; WD_REPEATS_REGION; FALSE_NEG.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Calcium;
KW   Calmodulin-binding; Cardiomyopathy; Coiled coil; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Immunoglobulin domain; Isopeptide bond; Kelch repeat;
KW   Kinase; Limb-girdle muscular dystrophy; Magnesium; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism; Repeat;
KW   Serine/threonine-protein kinase; TPR repeat; Transferase;
KW   Ubl conjugation; WD repeat.
FT   CHAIN         1  34350       Titin.
FT                                /FTId=PRO_0000239311.
FT   DOMAIN        6     96       Ig-like 1.
FT   DOMAIN      104    192       Ig-like 2.
FT   REPEAT      417    462       Z-repeat 1.
FT   REPEAT      466    511       Z-repeat 2.
FT   REPEAT      512    554       Z-repeat 3.
FT   REPEAT      555    600       Z-repeat 4.
FT   REPEAT      601    646       Z-repeat 5.
FT   REPEAT      647    691       Z-repeat 6.
FT   REPEAT      692    740       Z-repeat 7.
FT   DOMAIN      943   1031       Ig-like 3.
FT   DOMAIN     1082   1172       Ig-like 4.
FT   DOMAIN     1291   1382       Ig-like 5.
FT   DOMAIN     1457   1546       Ig-like 6.
FT   DOMAIN     1556   1646       Ig-like 7.
FT   DOMAIN     1703   1793       Ig-like 8.
FT   DOMAIN     1841   1928       Ig-like 9.
FT   DOMAIN     2078   2167       Ig-like 10.
FT   REPEAT     2089   2122       TPR 1.
FT   DOMAIN     2171   2262       Ig-like 11.
FT   DOMAIN     2264   2354       Ig-like 12.
FT   DOMAIN     2353   2443       Ig-like 13.
FT   DOMAIN     2430   2529       Ig-like 14.
FT   DOMAIN     2620   2703       Ig-like 15.
FT   REPEAT     2804   2838       TPR 2.
FT   DOMAIN     2880   2965       Ig-like 16.
FT   DOMAIN     2968   3050       Ig-like 17.
FT   REPEAT     3022   3062       WD 1.
FT   DOMAIN     3058   3141       Ig-like 18.
FT   DOMAIN     3239   3327       Ig-like 19.
FT   DOMAIN     3344   3432       Ig-like 20.
FT   DOMAIN     3503   3586       Ig-like 21.
FT   DOMAIN     3621   3712       Ig-like 22.
FT   REPEAT     4168   4203       TPR 3.
FT   DOMAIN     4289   4376       Ig-like 23.
FT   DOMAIN     4383   4471       Ig-like 24.
FT   DOMAIN     4478   4566       Ig-like 25.
FT   DOMAIN     4571   4659       Ig-like 26.
FT   DOMAIN     4664   4753       Ig-like 27.
FT   DOMAIN     4758   4846       Ig-like 28.
FT   DOMAIN     4851   4936       Ig-like 29.
FT   REPEAT     4860   4904       Kelch 1.
FT   DOMAIN     4943   5032       Ig-like 30.
FT   DOMAIN     5040   5128       Ig-like 31.
FT   DOMAIN     5133   5221       Ig-like 32.
FT   REPEAT     5170   5203       TPR 4.
FT   DOMAIN     5225   5314       Ig-like 33.
FT   DOMAIN     5320   5408       Ig-like 34.
FT   DOMAIN     5413   5501       Ig-like 35.
FT   DOMAIN     5505   5594       Ig-like 36.
FT   DOMAIN     5602   5690       Ig-like 37.
FT   DOMAIN     5695   5783       Ig-like 38.
FT   DOMAIN     5788   5877       Ig-like 39.
FT   DOMAIN     5882   5970       Ig-like 40.
FT   DOMAIN     5975   6063       Ig-like 41.
FT   DOMAIN     6067   6156       Ig-like 42.
FT   DOMAIN     6164   6252       Ig-like 43.
FT   DOMAIN     6257   6347       Ig-like 44.
FT   DOMAIN     6350   6440       Ig-like 45.
FT   DOMAIN     6444   6534       Ig-like 46.
FT   REPEAT     6474   6507       TPR 5.
FT   DOMAIN     6537   6626       Ig-like 47.
FT   DOMAIN     6630   6721       Ig-like 48.
FT   REPEAT     6654   6692       WD 2.
FT   DOMAIN     6727   6815       Ig-like 49.
FT   DOMAIN     6820   6908       Ig-like 50.
FT   DOMAIN     6912   7001       Ig-like 51.
FT   DOMAIN     7005   7093       Ig-like 52.
FT   DOMAIN     7102   7190       Ig-like 53.
FT   DOMAIN     7198   7286       Ig-like 54.
FT   DOMAIN     7291   7380       Ig-like 55.
FT   DOMAIN     7385   7473       Ig-like 56.
FT   REPEAT     7415   7448       TPR 6.
FT   DOMAIN     7478   7567       Ig-like 57.
FT   DOMAIN     7571   7662       Ig-like 58.
FT   DOMAIN     7668   7756       Ig-like 59.
FT   DOMAIN     7761   7849       Ig-like 60.
FT   DOMAIN     7853   7942       Ig-like 61.
FT   DOMAIN     7946   8035       Ig-like 62.
FT   DOMAIN     8042   8133       Ig-like 63.
FT   DOMAIN     8138   8229       Ig-like 64.
FT   DOMAIN     8232   8321       Ig-like 65.
FT   DOMAIN     8326   8414       Ig-like 66.
FT   DOMAIN     8419   8508       Ig-like 67.
FT   DOMAIN     8512   8603       Ig-like 68.
FT   DOMAIN     8609   8697       Ig-like 69.
FT   DOMAIN     8702   8790       Ig-like 70.
FT   DOMAIN     8794   8883       Ig-like 71.
FT   DOMAIN     8888   8976       Ig-like 72.
FT   DOMAIN     8984   9074       Ig-like 73.
FT   DOMAIN     9079   9168       Ig-like 74.
FT   DOMAIN     9176   9265       Ig-like 75.
FT   REPEAT     9184   9221       TPR 7.
FT   DOMAIN     9272   9361       Ig-like 76.
FT   DOMAIN     9366   9470       Ig-like 77.
FT   DOMAIN     9660   9755       Ig-like 78.
FT   REPEAT     9701   9734       TPR 8.
FT   DOMAIN     9760   9851       Ig-like 79.
FT   REPEAT    10031  10064       TPR 9.
FT   REPEAT    10041  10087       Kelch 2.
FT   REPEAT    10216  10242       PEVK 1.
FT   REPEAT    10244  10270       PEVK 2.
FT   REPEAT    10272  10298       PEVK 3.
FT   REPEAT    10300  10326       PEVK 4.
FT   REPEAT    10327  10353       PEVK 5.
FT   REPEAT    10355  10381       PEVK 6.
FT   REPEAT    10508  10534       PEVK 7.
FT   REPEAT    10536  10562       PEVK 8.
FT   REPEAT    10592  10618       PEVK 9.
FT   REPEAT    10878  10904       PEVK 10.
FT   REPEAT    10906  10930       PEVK 11.
FT   REPEAT    10932  10958       PEVK 12.
FT   REPEAT    10960  10986       PEVK 13.
FT   REPEAT    10987  11014       PEVK 14.
FT   REPEAT    11363  11396       PEVK 15.
FT   REPEAT    11397  11421       PEVK 16.
FT   REPEAT    11453  11479       PEVK 17.
FT   REPEAT    11481  11507       PEVK 18.
FT   REPEAT    11509  11535       PEVK 19.
FT   REPEAT    11537  11563       PEVK 20.
FT   REPEAT    11565  11591       PEVK 21.
FT   REPEAT    11657  11683       PEVK 22.
FT   REPEAT    11703  11729       PEVK 23.
FT   REPEAT    11745  11771       PEVK 24.
FT   REPEAT    11775  11801       PEVK 25.
FT   REPEAT    11836  11862       PEVK 26.
FT   REPEAT    11864  11890       PEVK 27.
FT   REPEAT    11893  11919       PEVK 28.
FT   REPEAT    11929  11955       PEVK 29.
FT   REPEAT    11966  11992       PEVK 30.
FT   REPEAT    11996  12022       PEVK 31.
FT   DOMAIN    12041  12133       Ig-like 80.
FT   DOMAIN    12138  12222       Ig-like 81.
FT   DOMAIN    12233  12318       Ig-like 82.
FT   DOMAIN    12499  12584       Ig-like 83.
FT   DOMAIN    12590  12672       Ig-like 84.
FT   DOMAIN    12766  12850       Ig-like 85.
FT   DOMAIN    12945  13032       Ig-like 86.
FT   REPEAT    12955  12988       TPR 10.
FT   DOMAIN    13120  13206       Ig-like 87.
FT   DOMAIN    13210  13295       Ig-like 88.
FT   DOMAIN    13299  13384       Ig-like 89.
FT   DOMAIN    13388  13478       Ig-like 90.
FT   REPEAT    13391  13432       WD 3.
FT   REPEAT    13443  13485       WD 4.
FT   DOMAIN    13479  13562       Ig-like 91.
FT   DOMAIN    13565  13655       Ig-like 92.
FT   DOMAIN    13659  13748       Ig-like 93.
FT   REPEAT    13714  13753       WD 5.
FT   DOMAIN    13749  13833       Ig-like 94.
FT   DOMAIN    13927  14012       Ig-like 95.
FT   DOMAIN    14017  14109       Fibronectin type-III 1.
FT   REPEAT    14084  14136       RCC1 1.
FT   DOMAIN    14118  14210       Fibronectin type-III 2.
FT   REPEAT    14185  14238       RCC1 2.
FT   DOMAIN    14219  14311       Fibronectin type-III 3.
FT   DOMAIN    14415  14506       Fibronectin type-III 4.
FT   DOMAIN    14515  14606       Fibronectin type-III 5.
FT   DOMAIN    14615  14708       Ig-like 96.
FT   DOMAIN    14711  14802       Fibronectin type-III 6.
FT   DOMAIN    14809  14902       Fibronectin type-III 7.
FT   REPEAT    14828  14876       Kelch 3.
FT   DOMAIN    14910  15002       Fibronectin type-III 8.
FT   REPEAT    14986  15036       Kelch 4.
FT   DOMAIN    15010  15104       Fibronectin type-III 9.
FT   REPEAT    15077  15130       RCC1 3.
FT   DOMAIN    15111  15203       Fibronectin type-III 10.
FT   DOMAIN    15211  15305       Fibronectin type-III 11.
FT   DOMAIN    15314  15402       Ig-like 97.
FT   DOMAIN    15407  15500       Fibronectin type-III 12.
FT   DOMAIN    15506  15599       Fibronectin type-III 13.
FT   REPEAT    15574  15630       RCC1 4.
FT   DOMAIN    15608  15724       Ig-like 98.
FT   DOMAIN    15729  15822       Fibronectin type-III 14.
FT   DOMAIN    15829  15923       Fibronectin type-III 15.
FT   DOMAIN    15929  16021       Fibronectin type-III 16.
FT   DOMAIN    16029  16119       Ig-like 99.
FT   DOMAIN    16124  16214       Fibronectin type-III 17.
FT   REPEAT    16134  16180       WD 6.
FT   DOMAIN    16221  16314       Fibronectin type-III 18.
FT   DOMAIN    16322  16420       Ig-like 100.
FT   DOMAIN    16425  16518       Fibronectin type-III 19.
FT   DOMAIN    16526  16623       Fibronectin type-III 20.
FT   DOMAIN    16631  16726       Fibronectin type-III 21.
FT   DOMAIN    16727  16834       Ig-like 101.
FT   DOMAIN    16839  16930       Fibronectin type-III 22.
FT   DOMAIN    16938  17036       Fibronectin type-III 23.
FT   DOMAIN    17044  17139       Ig-like 102.
FT   DOMAIN    17144  17236       Fibronectin type-III 24.
FT   DOMAIN    17244  17343       Fibronectin type-III 25.
FT   DOMAIN    17348  17440       Fibronectin type-III 26.
FT   DOMAIN    17449  17536       Ig-like 103.
FT   DOMAIN    17543  17637       Fibronectin type-III 27.
FT   DOMAIN    17644  17736       Fibronectin type-III 28.
FT   REPEAT    17711  17769       RCC1 5.
FT   DOMAIN    17745  17834       Ig-like 104.
FT   DOMAIN    17839  17931       Fibronectin type-III 29.
FT   REPEAT    17930  17969       WD 7.
FT   DOMAIN    17939  18031       Fibronectin type-III 30.
FT   REPEAT    18006  18055       RCC1 6.
FT   DOMAIN    18040  18134       Fibronectin type-III 31.
FT   DOMAIN    18143  18228       Ig-like 105.
FT   DOMAIN    18237  18330       Fibronectin type-III 32.
FT   REPEAT    18258  18303       Kelch 5.
FT   REPEAT    18303  18358       RCC1 7.
FT   DOMAIN    18336  18427       Fibronectin type-III 33.
FT   DOMAIN    18435  18526       Ig-like 106.
FT   DOMAIN    18531  18623       Fibronectin type-III 34.
FT   REPEAT    18553  18598       Kelch 6.
FT   DOMAIN    18630  18722       Fibronectin type-III 35.
FT   DOMAIN    18730  18824       Fibronectin type-III 36.
FT   DOMAIN    18833  18924       Ig-like 107.
FT   DOMAIN    18929  19019       Fibronectin type-III 37.
FT   DOMAIN    19028  19121       Fibronectin type-III 38.
FT   DOMAIN    19128  19219       Ig-like 108.
FT   DOMAIN    19224  19315       Fibronectin type-III 39.
FT   REPEAT    19290  19346       RCC1 8.
FT   DOMAIN    19323  19415       Fibronectin type-III 40.
FT   REPEAT    19389  19452       RCC1 9.
FT   DOMAIN    19423  19522       Fibronectin type-III 41.
FT   DOMAIN    19531  19617       Ig-like 109.
FT   DOMAIN    19626  19717       Fibronectin type-III 42.
FT   REPEAT    19647  19692       Kelch 7.
FT   DOMAIN    19726  19818       Fibronectin type-III 43.
FT   DOMAIN    19826  19914       Ig-like 110.
FT   DOMAIN    19919  20011       Fibronectin type-III 44.
FT   DOMAIN    20019  20111       Fibronectin type-III 45.
FT   DOMAIN    20116  20211       Fibronectin type-III 46.
FT   DOMAIN    20220  20311       Ig-like 111.
FT   DOMAIN    20316  20407       Fibronectin type-III 47.
FT   DOMAIN    20414  20507       Fibronectin type-III 48.
FT   DOMAIN    20515  20609       Fibronectin type-III 49.
FT   DOMAIN    20714  20805       Fibronectin type-III 50.
FT   DOMAIN    20811  20900       Fibronectin type-III 51.
FT   REPEAT    20833  20876       Kelch 8.
FT   DOMAIN    20893  20996       Ig-like 112.
FT   DOMAIN    21003  21097       Fibronectin type-III 52.
FT   REPEAT    21069  21125       RCC1 10.
FT   DOMAIN    21103  21195       Fibronectin type-III 53.
FT   DOMAIN    21200  21294       Fibronectin type-III 54.
FT   REPEAT    21222  21267       Kelch 9.
FT   DOMAIN    21303  21395       Ig-like 113.
FT   DOMAIN    21400  21491       Fibronectin type-III 55.
FT   DOMAIN    21498  21591       Fibronectin type-III 56.
FT   REPEAT    21565  21620       RCC1 11.
FT   DOMAIN    21599  21693       Fibronectin type-III 57.
FT   DOMAIN    21701  21793       Ig-like 114.
FT   DOMAIN    21795  21886       Fibronectin type-III 58.
FT   REPEAT    21860  21910       RCC1 12.
FT   DOMAIN    21892  21982       Fibronectin type-III 59.
FT   DOMAIN    21990  22083       Ig-like 115.
FT   DOMAIN    22086  22178       Fibronectin type-III 60.
FT   DOMAIN    22186  22278       Fibronectin type-III 61.
FT   DOMAIN    22283  22377       Fibronectin type-III 62.
FT   REPEAT    22306  22350       Kelch 10.
FT   DOMAIN    22386  22477       Ig-like 116.
FT   DOMAIN    22482  22574       Fibronectin type-III 63.
FT   DOMAIN    22581  22674       Fibronectin type-III 64.
FT   DOMAIN    22683  22776       Fibronectin type-III 65.
FT   DOMAIN    22785  22874       Ig-like 117.
FT   DOMAIN    22879  22970       Fibronectin type-III 66.
FT   DOMAIN    22976  23066       Fibronectin type-III 67.
FT   REPEAT    23041  23091       RCC1 13.
FT   DOMAIN    23075  23163       Ig-like 118.
FT   DOMAIN    23168  23262       Fibronectin type-III 68.
FT   DOMAIN    23268  23360       Fibronectin type-III 69.
FT   DOMAIN    23365  23459       Fibronectin type-III 70.
FT   DOMAIN    23468  23555       Ig-like 119.
FT   DOMAIN    23564  23656       Fibronectin type-III 71.
FT   REPEAT    23651  23694       WD 8.
FT   DOMAIN    23664  23756       Fibronectin type-III 72.
FT   DOMAIN    23765  23858       Fibronectin type-III 73.
FT   DOMAIN    23867  23954       Ig-like 120.
FT   DOMAIN    23961  24052       Fibronectin type-III 74.
FT   REPEAT    24027  24076       RCC1 14.
FT   DOMAIN    24058  24148       Fibronectin type-III 75.
FT   REPEAT    24079  24124       Kelch 11.
FT   DOMAIN    24157  24241       Ig-like 121.
FT   DOMAIN    24250  24344       Fibronectin type-III 76.
FT   REPEAT    24261  24307       WD 9.
FT   DOMAIN    24350  24442       Fibronectin type-III 77.
FT   DOMAIN    24447  24541       Fibronectin type-III 78.
FT   DOMAIN    24550  24641       Ig-like 122.
FT   DOMAIN    24646  24738       Fibronectin type-III 79.
FT   DOMAIN    24746  24838       Fibronectin type-III 80.
FT   DOMAIN    24847  24940       Fibronectin type-III 81.
FT   REPEAT    24868  24916       Kelch 12.
FT   DOMAIN    24949  25038       Ig-like 123.
FT   DOMAIN    25043  25134       Fibronectin type-III 82.
FT   DOMAIN    25139  25230       Fibronectin type-III 83.
FT   DOMAIN    25239  25325       Ig-like 124.
FT   DOMAIN    25332  25424       Fibronectin type-III 84.
FT   REPEAT    25343  25389       WD 10.
FT   REPEAT    25419  25462       WD 11.
FT   DOMAIN    25432  25524       Fibronectin type-III 85.
FT   DOMAIN    25529  25623       Fibronectin type-III 86.
FT   DOMAIN    25632  25722       Ig-like 125.
FT   DOMAIN    25729  25821       Fibronectin type-III 87.
FT   DOMAIN    25828  25921       Fibronectin type-III 88.
FT   DOMAIN    25929  26023       Fibronectin type-III 89.
FT   REPEAT    25951  25997       Kelch 13.
FT   DOMAIN    26032  26121       Ig-like 126.
FT   DOMAIN    26126  26217       Fibronectin type-III 90.
FT   DOMAIN    26222  26313       Fibronectin type-III 91.
FT   REPEAT    26244  26289       Kelch 14.
FT   DOMAIN    26322  26410       Ig-like 127.
FT   DOMAIN    26415  26506       Fibronectin type-III 92.
FT   REPEAT    26501  26544       WD 12.
FT   DOMAIN    26513  26607       Fibronectin type-III 93.
FT   DOMAIN    26611  26705       Fibronectin type-III 94.
FT   DOMAIN    26714  26801       Ig-like 128.
FT   DOMAIN    26810  26902       Fibronectin type-III 95.
FT   DOMAIN    26910  27002       Fibronectin type-III 96.
FT   DOMAIN    27011  27102       Fibronectin type-III 97.
FT   REPEAT    27077  27127       RCC1 15.
FT   DOMAIN    27101  27196       Ig-like 129.
FT   DOMAIN    27205  27296       Fibronectin type-III 98.
FT   REPEAT    27271  27320       RCC1 16.
FT   DOMAIN    27302  27392       Fibronectin type-III 99.
FT   REPEAT    27323  27368       Kelch 15.
FT   DOMAIN    27497  27589       Fibronectin type-III 100.
FT   DOMAIN    27597  27689       Fibronectin type-III 101.
FT   DOMAIN    27694  27788       Fibronectin type-III 102.
FT   DOMAIN    27797  27888       Ig-like 130.
FT   DOMAIN    27893  27985       Fibronectin type-III 103.
FT   DOMAIN    27993  28088       Fibronectin type-III 104.
FT   REPEAT    28062  28095       TPR 11.
FT   DOMAIN    28093  28187       Fibronectin type-III 105.
FT   DOMAIN    28196  28286       Ig-like 131.
FT   DOMAIN    28293  28384       Fibronectin type-III 106.
FT   DOMAIN    28390  28480       Fibronectin type-III 107.
FT   DOMAIN    28488  28577       Ig-like 132.
FT   DOMAIN    28584  28676       Fibronectin type-III 108.
FT   REPEAT    28606  28651       Kelch 16.
FT   REPEAT    28671  28714       WD 13.
FT   DOMAIN    28684  28776       Fibronectin type-III 109.
FT   DOMAIN    28781  28874       Fibronectin type-III 110.
FT   DOMAIN    28882  28974       Ig-like 133.
FT   DOMAIN    28979  29071       Fibronectin type-III 111.
FT   REPEAT    29046  29101       RCC1 17.
FT   DOMAIN    29079  29171       Fibronectin type-III 112.
FT   DOMAIN    29180  29273       Fibronectin type-III 113.
FT   DOMAIN    29282  29367       Ig-like 134.
FT   DOMAIN    29376  29467       Fibronectin type-III 114.
FT   DOMAIN    29473  29563       Fibronectin type-III 115.
FT   DOMAIN    29568  29663       Ig-like 135.
FT   DOMAIN    29668  29760       Fibronectin type-III 116.
FT   DOMAIN    29767  29860       Fibronectin type-III 117.
FT   DOMAIN    29865  29962       Fibronectin type-III 118.
FT   DOMAIN    29971  30059       Ig-like 136.
FT   DOMAIN    30068  30159       Fibronectin type-III 119.
FT   DOMAIN    30167  30260       Fibronectin type-III 120.
FT   DOMAIN    30269  30365       Fibronectin type-III 121.
FT   DOMAIN    30371  30460       Ig-like 137.
FT   DOMAIN    30465  30556       Fibronectin type-III 122.
FT   DOMAIN    30562  30654       Fibronectin type-III 123.
FT   DOMAIN    30663  30754       Ig-like 138.
FT   DOMAIN    30759  30853       Fibronectin type-III 124.
FT   DOMAIN    30859  30951       Fibronectin type-III 125.
FT   REPEAT    30880  30925       Kelch 17.
FT   DOMAIN    30959  31052       Fibronectin type-III 126.
FT   DOMAIN    31061  31150       Ig-like 139.
FT   DOMAIN    31155  31247       Fibronectin type-III 127.
FT   DOMAIN    31256  31351       Fibronectin type-III 128.
FT   DOMAIN    31358  31450       Fibronectin type-III 129.
FT   DOMAIN    31460  31548       Ig-like 140.
FT   DOMAIN    31650  31743       Fibronectin type-III 130.
FT   REPEAT    31739  31782       WD 14.
FT   DOMAIN    31752  31846       Fibronectin type-III 131.
FT   DOMAIN    31855  31945       Ig-like 141.
FT   REPEAT    31892  31937       WD 15.
FT   DOMAIN    31955  32046       Ig-like 142.
FT   DOMAIN    32049  32139       Fibronectin type-III 132.
FT   REPEAT    32070  32115       Kelch 18.
FT   DOMAIN    32178  32432       Protein kinase.
FT   DOMAIN    32496  32584       Ig-like 143.
FT   REPEAT    32503  32549       Kelch 19.
FT   DOMAIN    32617  32710       Ig-like 144.
FT   DOMAIN    32722  32811       Ig-like 145.
FT   REPEAT    32927  32960       TPR 12.
FT   REPEAT    33235  33268       TPR 13.
FT   DOMAIN    33301  33391       Ig-like 146.
FT   DOMAIN    33488  33576       Ig-like 147.
FT   REPEAT    33518  33551       TPR 14.
FT   DOMAIN    33645  33732       Ig-like 148.
FT   DOMAIN    33779  33867       Ig-like 149.
FT   DOMAIN    33963  34052       Ig-like 150.
FT   DOMAIN    34061  34149       Ig-like 151.
FT   DOMAIN    34256  34344       Ig-like 152.
FT   NP_BIND   32184  32192       ATP (By similarity).
FT   REGION      253    341       ZIS1.
FT   REGION     1410   1440       ZIS5.
FT   COILED      529    561       Potential.
FT   COILED     2025   2052       Potential.
FT   COILED     3462   3487       Potential.
FT   COILED     9534   9577       Potential.
FT   COMPBIAS    391    436       Ala-rich.
FT   COMPBIAS    453    456       Poly-Thr.
FT   COMPBIAS   9500   9503       Poly-Glu.
FT   COMPBIAS   9861   9952       Pro-rich.
FT   COMPBIAS   9974  11917       Glu-rich.
FT   COMPBIAS   9974  10089       Glu-rich.
FT   COMPBIAS  10102  10105       Poly-Pro.
FT   COMPBIAS  10211  12032       Pro-rich.
FT   COMPBIAS  33188  33193       Poly-Ser.
FT   COMPBIAS  33197  33200       Poly-Arg.
FT   COMPBIAS  34102  34244       Ser-rich.
FT   ACT_SITE  32298  32298       Proton acceptor (By similarity).
FT   BINDING   32207  32207       ATP (By similarity).
FT   MOD_RES     263    263       Phosphoserine (By similarity).
FT   MOD_RES     265    265       Phosphoserine (By similarity).
FT   MOD_RES     267    267       Phosphothreonine (By similarity).
FT   MOD_RES    4065   4065       Phosphoserine.
FT   MOD_RES    4068   4068       Phosphoserine.
FT   MOD_RES    6920   6920       Phosphoserine (By similarity).
FT   MOD_RES    8490   8490       Phosphotyrosine.
FT   MOD_RES    9122   9122       Phosphoserine (By similarity).
FT   MOD_RES    9203   9203       Phosphoserine.
FT   MOD_RES    9207   9207       Phosphothreonine.
FT   MOD_RES   11503  11503       Phosphoserine (By similarity).
FT   MOD_RES   12007  12007       Phosphothreonine (By similarity).
FT   MOD_RES   12009  12009       Phosphoserine (By similarity).
FT   MOD_RES   12022  12022       Phosphoserine (By similarity).
FT   MOD_RES   22525  22525       Phosphoserine.
FT   MOD_RES   22534  22534       Phosphoserine.
FT   MOD_RES   30443  30443       Phosphothreonine (By similarity).
FT   MOD_RES   32341  32341       Phosphotyrosine.
FT   MOD_RES   33245  33245       Phosphoserine (By similarity).
FT   MOD_RES   33247  33247       Phosphoserine (By similarity).
FT   MOD_RES   33602  33602       Phosphoserine (By similarity).
FT   MOD_RES   33614  33614       Phosphoserine (By similarity).
FT   MOD_RES   33938  33938       Phosphoserine.
FT   MOD_RES   33942  33942       Phosphoserine.
FT   DISULFID    964   1015       By similarity.
FT   DISULFID   1724   1777       By similarity.
FT   DISULFID   2109   2134
FT   DISULFID   2196   2246       By similarity.
FT   DISULFID   3259   3311       By similarity.
FT   DISULFID   4404   4455       By similarity.
FT   DISULFID   4499   4550       By similarity.
FT   DISULFID   4592   4643       By similarity.
FT   DISULFID   4686   4737       By similarity.
FT   DISULFID   4779   4830       By similarity.
FT   DISULFID   5061   5112       By similarity.
FT   DISULFID   5248   5299       By similarity.
FT   DISULFID   5623   5674       By similarity.
FT   DISULFID   5810   5861       By similarity.
FT   DISULFID   5903   5954       By similarity.
FT   DISULFID   6185   6236       By similarity.
FT   DISULFID   6372   6423       By similarity.
FT   DISULFID   6465   6516       By similarity.
FT   DISULFID   6748   6799       By similarity.
FT   DISULFID   7027   7078       By similarity.
FT   DISULFID   7123   7174       By similarity.
FT   DISULFID   7219   7270       By similarity.
FT   DISULFID   7313   7364       By similarity.
FT   DISULFID   7406   7457       By similarity.
FT   DISULFID   7689   7740       By similarity.
FT   DISULFID   7968   8019       By similarity.
FT   DISULFID   8064   8115       By similarity.
FT   DISULFID   8160   8211       By similarity.
FT   DISULFID   8254   8305       By similarity.
FT   DISULFID   8347   8398       By similarity.
FT   DISULFID   8630   8681       By similarity.
FT   DISULFID   8909   8960       By similarity.
FT   DISULFID   9005   9056       By similarity.
FT   DISULFID   9101   9152       By similarity.
FT   DISULFID   9294   9345       By similarity.
FT   DISULFID   9693   9743       By similarity.
FT   DISULFID  12067  12117       By similarity.
FT   DISULFID  12611  12660       By similarity.
FT   DISULFID  12966  13016       By similarity.
FT   DISULFID  13233  13283       By similarity.
FT   DISULFID  13322  13372       By similarity.
FT   DISULFID  13411  13461       By similarity.
FT   DISULFID  13771  13821       By similarity.
FT   DISULFID  31481  31532       By similarity.
FT   DISULFID  32516  32568       By similarity.
FT   DISULFID  33664  33718       By similarity.
FT   CROSSLNK  10718  10718       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   CROSSLNK  10733  10733       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   CROSSLNK  10740  10740       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   CROSSLNK  29566  29566       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   CROSSLNK  30146  30146       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   VAR_SEQ     555    646       Missing (in isoform 2).
FT                                /FTId=VSP_019138.
FT   VAR_SEQ     556    601       Missing (in isoform 3).
FT                                /FTId=VSP_019139.
FT   VAR_SEQ    3434   3434       E -> GFSKFEENTSNSQWHVSLSVSFKKEPLGQKPSFIQP
FT                                LSSLRVHNGETVRFHARVSGIPKPEIQWFHNQQLILPTKDV
FT                                VFHFEESTGMALMLIVDAYSEHAGQYSCKAANSAGEATCAA
FT                                TLTVTPK (in isoform 8).
FT                                /FTId=VSP_019140.
FT   VAR_SEQ    3435   3645       APESILHERIEQEIEMEMKEFSSSFLSAEEEGLHSAELQLS
FT                                KINETLELLSESPVYSTKFDSEKEGTGPIFIKEVSNADISM
FT                                GDVATLSVTVIGIPKPKIQWFFNGVLLTPSADYKFVFDGDD
FT                                HSLIILFTKLEDEGEYTCMASNDYGKTICSAYLKINSKGEG
FT                                HKDTETESAVAKSLEKLGGPCPPHFLKELKPIRCAQGLPAI
FT                                FEYTVV -> VQALDRQSSGKDVRESTKSQAVADSSFTKEE
FT                                SKISQKEIKSFQGSSYEYEVQVFESVSQSSIHTAASVQDTQ
FT                                LCHTASLSQIAESTELSKECAKESTGEAPKIFLHLQDVTVK
FT                                CGDTAQFLCVLKDDSFIDVTWTHEGAKIEESERLKQSQNGN
FT                                IQFLTICNVQLVDQGLYSCIVHNDCGERTTSAVLSVEGAPE
FT                                SILHERIEQEIEMEMK (in isoform 7).
FT                                /FTId=VSP_019141.
FT   VAR_SEQ    3454   4380       Missing (in isoform 4).
FT                                /FTId=VSP_019142.
FT   VAR_SEQ    3455   5604       FSSSFLSAEEEGLHSAELQLSKINETLELLSESPVYSTKFD
FT                                SEKEGTGPIFIKEVSNADISMGDVATLSVTVIGIPKPKIQW
FT                                FFNGVLLTPSADYKFVFDGDDHSLIILFTKLEDEGEYTCMA
FT                                SNDYGKTICSAYLKINSKGEGHKDTETESAVAKSLEKLGGP
FT                                CPPHFLKELKPIRCAQGLPAIFEYTVVGEPAPTVTWFKENK
FT                                QLCTSVYYTIIHNPNGSGTFIVNDPQREDSGLYICKAENML
FT                                GESTCAAELLVLLEDTDMTDTPCKAKSTPEAPEDFPQTPLK
FT                                GPAVEALDSEQEIATFVKDTILKAALITEENQQLSYEHIAK
FT                                ANELSSQLPLGAQELQSILEQDKLTPESTREFLCINGSIHF
FT                                QPLKEPSPNLQLQIVQSQKTFSKEGILMPEEPETQAVLSDT
FT                                EKIFPSAMSIEQINSLTVEPLKTLLAEPEGNYPQSSIEPPM
FT                                HSYLTSVAEEVLSPKEKTVSDTNREQRVTLQKQEAQSALIL
FT                                SQSLAEGHVESLQSPDVMISQVNYEPLVPSEHSCTEGGKIL
FT                                IESANPLENAGQDSAVRIEEGKSLRFPLALEEKQVLLKEEH
FT                                SDNVVMPPDQIIESKREPVAIKKVQEVQGRDLLSKESLLSG
FT                                IPEEQRLNLKIQICRALQAAVASEQPGLFSEWLRNIEKVEV
FT                                EAVNITQEPRHIMCMYLVTSAKSVTEEVTIIIEDVDPQMAN
FT                                LKMELRDALCAIIYEEIDILTAEGPRIQQGAKTSLQEEMDS
FT                                FSGSQKVEPITEPEVESKYLISTEEVSYFNVQSRVKYLDAT
FT                                PVTKGVASAVVSDEKQDESLKPSEEKEESSSESGTEEVATV
FT                                KIQEAEGGLIKEDGPMIHTPLVDTVSEEGDIVHLTTSITNA
FT                                KEVNWYFENKLVPSDEKFKCLQDQNTYTLVIDKVNTEDHQG
FT                                EYVCEALNDSGKTATSAKLTVVKRAAPVIKRKIEPLEVALG
FT                                HLAKFTCEIQSAPNVRFQWFKAGREIYESDKCSIRSSKYIS
FT                                SLEILRTQVVDCGEYTCKASNEYGSVSCTATLTVTEAYPPT
FT                                FLSRPKSLTTFVGKAAKFICTVTGTPVIETIWQKDGAALSP
FT                                SPNWKISDAENKHILELSNLTIQDRGVYSCKASNKFGADIC
FT                                QAELIIIDKPHFIKELEPVQSAINKKVHLECQVDEDRKVTV
FT                                TWSKDGQKLPPGKDYKICFEDKIATLEIPLAKLKDSGTYVC
FT                                TASNEAGSSSCSATVTVREPPSFVKKVDPSYLMLPGESARL
FT                                HCKLKGSPVIQVTWFKNNKELSESNTVRMYFVNSEAILDIT
FT                                DVKVEDSGSYSCEAVNDVGSDSCSTEIVIKEPPSFIKTLEP
FT                                ADIVRGTNALLQCEVSGTGPFEISWFKDKKQIRSSKKYRLF
FT                                SQKSLVCLEIFSFNSADVGEYECVVANEVGKCGCMATHLLK
FT                                EPPTFVKKVDDLIALGGQTVTLQAAVRGSEPISVTWMKGQE
FT                                VIREDGKIKMSFSNGVAVLIIPDVQISFGGKYTCLAENEAG
FT                                SQTSVGELIVKEPAKIIERAELIQVTAGDPATLEYTVAGTP
FT                                ELKPKWYKDGRPLVASKKYRISFKNNVAQLKFYSAELHDSG
FT                                QYTFEISNEVGSSSCETTFTVLDRDIAPFFTKPLRNVDSVV
FT                                NGTCRLDCKIAGSLPMRVSWFKDGKEIAASDRYRIAFVEGT
FT                                ASLEIIRVDMNDAGNFTCRATNSVGSKDSSGALIVQEPPSF
FT                                VTKPGSKDVLPGSAVCLKSTFQGSTPLTIRWFKGNKELVSG
FT                                GSCYITKEALESSLELYLVKTSDSGTYTCKVSNVAGGVECS
FT                                ANLFVKEPATFVEKLEPSQLLKKGDATQLACKVTGTPPIKI
FT                                TWFANDREIKESSKHRMSFVESTAVLRLTDVGIEDSGEYMC
FT                                EAQNEAGSDHCSSIVIVKESPYFTKEFKPIEVLKEYDVMLL
FT                                AEVAGTPPFEITWFKDNTILRSGRKYKTFIQDHLVSLQILK
FT                                FVAADAGEYQCRVTNEVGSSICSARVTLREPPSFIKKIEST
FT                                SSLRGGTAAFQATLKGSLPITVTWLKDSDEITEDDNIRMTF
FT                                ENNVASLYLSGIEVKHDGKYVCQAKNDAGIQRCSALLSVKE
FT                                PATITEEAVSIDVTQGDPATLQVKFSGTKEITAKWFKDGQE
FT                                LTLGSKYKISVTDTVSILKIISTEKKDSGEYTFEVQNDVGR
FT                                SSCKARINVLDLIIPPSF -> LFSEGESEHSERDTRDAFS
FT                                DSEDIDHKSMAAKRYASRISSTSSWPEYFKPSFTQKLTFKY
FT                                VLEGEPVVFTCRLIACPTPEMTWFHNNRPIPTGLRRIIKAE
FT                                SDLHHHSSSLEIKRVQDRDSGSYRLLAINSEGSAESTASLL
FT                                VIQKGQDEKYLEFLKRAERTHENVEALVERGEDRIKVDLRF
FT                                TGSPFNKKQDVEQKGMMRTIHFKTMSSAKKTDYMYDEEYLE
FT                                SKSDIRGWLNVGESFLDKETKVKLQRLREARKTLMEKKKLS
FT                                LLDTSSEISSRTFRSEASDKDILFSREDMKIRSMSDLAESY
FT                                KVDHSAESIVQNPHALSNQMDQNIESEELPTSFQTIVDEEI
FT                                FQTEIRMSQEALVKESLPKDHLYGEILVNENTQARGQLEEI
FT                                MANTTIGESSTYITNVCEKEEVYETPENVSQAITPHASESF
FT                                GTLVNVEESEEIASERIKKDDLRELQLSASTRIDEFKTEQK
FT                                EENMRFFENSFRKRPQRCPPSFLQEIESQEVYEGDSCNFVC
FT                                HFQGYPQPIVTWYNNDMPIPRNQNFIIHSLENYSILTLSSV
FT                                HHQNEGSITCVLFNQYGTVKTTSMLKVKAKQKHDVKAHKVP
FT                                VFHDYLDEEEELALVFDQAKGAHPSMSQEGQTNLHLLKTNP
FT                                PVPPSGDTELLSFPVEIQVTAATPIPEQDKESKEVFQTEEL
FT                                EPKAMPQDQVTQSPKHRFVFLSDITNEPPKMLQEMPKHARC
FT                                REGDSIILECLISGEPQPVVTWFQNGVLLKQNQKFQFEEVN
FT                                CSHQLYIKDVNSQDSGKYKCVAENNSGAVESVSDLTVEPVT
FT                                YRENSQFENIGEIYGKYSRDQQLQDQGESVRAHFYDYPAGP
FT                                FTPWTNVKEYSVRDYFQSLETIEQIDQKEQVRCIPSREKIP
FT                                RFVHGASRTIKISKPIRAEFIQCQAEGKERHVSEKSKLHQA
FT                                EGTVYPFVDDFSDVTIKKEIRNNFGKLGRSEKENVQECAQS
FT                                DYLPNIHSERISDSYNTKDSSAIVYEESLGEEIHYPGKKVK
FT                                HRIIEFEKLHVEKGVLEKRPTRTSIVNPPQKKIDDKAFSLK
FT                                QRESRSSNLNANMYQAEKMSPNTESDSSNIAINLKLLSSQT
FT                                HKEFDAQEREQQEKISLIDKPAISKRAEHESPITFDLKQFH
FT                                TQIKHTDVKFQELDSGQPEEAYFKIQHPADTENIVFDLKQM
FT                                YSHIGDPALEFQGQETREQQEIHYKEKIPSPETLQPDTHNI
FT                                SKSVQNNVFASQEISSSQELSNRTMVEKSSIDENSISLEKE
FT                                VRHVQEQNLDILKTDLSLKSFSEEIYSESCALLPTSSADIE
FT                                ETDLSEKSCPLENGGRSSISHLKKAASEEKPLGVGEMEEEC
FT                                TLEPELAAFPKQDGGTQEYTDATLEDHRGDVQEADTLHRQL
FT                                SLSQCFPLLMTEEQQNPGEQISTNIHASGEEKCYEEVQVQN
FT                                EASFSTLEGEMIETSFSQNIPKLDEAHTTEAAESETSLTQY
FT                                LLAAGKREVPETKDTRDQAKLVQSESITSMEVEEVTFNTVY
FT                                EYYNQKQESLGRPLSPESDISIGVGSTTSEEISELDQFYTP
FT                                PSSVEYFESPKSPDLYFNPSDITKQSSIHSGGETVERYSTP
FT                                LGEVAERYSTPSEGEVGERYSTPPGETLERYSTPPGETLER
FT                                YSTPPGETLERYSTPPGETLERYSTPPGETLERYSTPPGEA
FT                                LERYSIPTGGPNPTGTFKTYPSKIEMEDGTPNEHFYTPTEE
FT                                RGSAYEIWRSDSFGTPNEAIEPKDNEMPPSFIEPLTKRKVY
FT                                ENTTLGFIVEVEGLPVPGVKWYRNKSLLEPDERIKMERVGN
FT                                VCSLEISNIQKGEGGEYMCHAVNIIGEAKSFANVDIMPQEE
FT                                RVVALPPPVTHQHVMEFDLEHTTSSRTPSPQEIVLEVELSE
FT                                KDVKEFEKQVKIVTVPEFTPDHKSMIVSLDVLPFNFVDPNM
FT                                DSREGEDKELKIDLEVFEMPPRFIMPICDFKIPENSDAVFK
FT                                CSVIGIPTPEVKWYKEYMCIEPDNIKYVISEEKGSHTLKIR
FT                                NVCLSDSATYRCRAVNCVGEAICRGFLTMGDSEIFAVIAKK
FT                                SKVTLSSLMEELVLKSNYTDSFFEFQVVEGPPRFIKGISDC
FT                                YAPIGTAAYFQCLVRGSPRPTVYWYKDGKLVQGRRFTVEES
FT                                GTGFHNLFITSLVKSDEGEYRCVATNKSGMAESFAALTLT
FT                                (in isoform 6).
FT                                /FTId=VSP_019143.
FT   VAR_SEQ    3646   4380       Missing (in isoform 7).
FT                                /FTId=VSP_019144.
FT   VAR_SEQ    4474  11851       Missing (in isoform 3).
FT                                /FTId=VSP_019145.
FT   VAR_SEQ    5605  34350       Missing (in isoform 6).
FT                                /FTId=VSP_019146.
FT   VAR_SEQ   10382  10645       Missing (in isoform 5).
FT                                /FTId=VSP_019147.
FT   VAR_SEQ   10742  10931       Missing (in isoform 5).
FT                                /FTId=VSP_019148.
FT   VAR_SEQ   11015  11163       Missing (in isoform 5).
FT                                /FTId=VSP_019149.
FT   VAR_SEQ   11223  11852       Missing (in isoform 5).
FT                                /FTId=VSP_019150.
FT   VAR_SEQ   11507  11507       E -> EVFEEPEESPSAPPKKPEVPPVR (in isoform
FT                                4).
FT                                /FTId=VSP_019151.
FT   VAR_SEQ   11985  12201       Missing (in isoform 5).
FT                                /FTId=VSP_019152.
FT   VARIANT      54     54       V -> M (in CMD1G; affects interaction
FT                                with TCAP/telethonin).
FT                                /FTId=VAR_026685.
FT   VARIANT      60     60       D -> Y (in dbSNP:rs35683768).
FT                                /FTId=VAR_040078.
FT   VARIANT     115    115       V -> M (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_040079.
FT   VARIANT     279    279       R -> W (in HMERF; disrupts NBR1-binding).
FT                                /FTId=VAR_026634.
FT   VARIANT     328    328       R -> C (in dbSNP:rs16866538).
FT                                /FTId=VAR_026686.
FT   VARIANT     360    360       R -> T (in dbSNP:rs56128843).
FT                                /FTId=VAR_040080.
FT   VARIANT     498    498       V -> I.
FT                                /FTId=VAR_040081.
FT   VARIANT     740    740       R -> L (in CMH9; dbSNP:rs28933405).
FT                                /FTId=VAR_026687.
FT   VARIANT     743    743       A -> V (in CMD1G; affects interaction
FT                                with TCAP/telethonin).
FT                                /FTId=VAR_026688.
FT   VARIANT     799    799       T -> M (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040082.
FT   VARIANT     811    811       T -> I (in dbSNP:rs35813871).
FT                                /FTId=VAR_040083.
FT   VARIANT     922    922       R -> H (in dbSNP:rs56046320).
FT                                /FTId=VAR_040084.
FT   VARIANT     937    937       E -> D (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040085.
FT   VARIANT     976    976       W -> R (in CMD1G).
FT                                /FTId=VAR_026689.
FT   VARIANT    1081   1081       A -> T (in dbSNP:rs55914517).
FT                                /FTId=VAR_040086.
FT   VARIANT    1137   1137       G -> R.
FT                                /FTId=VAR_040087.
FT   VARIANT    1201   1201       K -> E (in dbSNP:rs10497520).
FT                                /FTId=VAR_040088.
FT   VARIANT    1202   1202       V -> A.
FT                                /FTId=VAR_040089.
FT   VARIANT    1249   1249       S -> L (in dbSNP:rs1552280).
FT                                /FTId=VAR_056081.
FT   VARIANT    1295   1295       L -> S (in dbSNP:rs1552280).
FT                                /FTId=VAR_040090.
FT   VARIANT    1345   1345       G -> D (in dbSNP:rs36021856).
FT                                /FTId=VAR_040091.
FT   VARIANT    1347   1347       A -> T (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_040092.
FT   VARIANT    1350   1350       R -> H (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040093.
FT   VARIANT    1353   1353       V -> L (in dbSNP:rs36062108).
FT                                /FTId=VAR_040094.
FT   VARIANT    1393   1393       I -> V (in dbSNP:rs16866531).
FT                                /FTId=VAR_040095.
FT   VARIANT    1416   1416       R -> C.
FT                                /FTId=VAR_040096.
FT   VARIANT    1441   1441       R -> P.
FT                                /FTId=VAR_040097.
FT   VARIANT    1544   1544       I -> V.
FT                                /FTId=VAR_040098.
FT   VARIANT    1572   1572       Q -> R (in dbSNP:rs12476289).
FT                                /FTId=VAR_040099.
FT   VARIANT    1658   1658       R -> G (in dbSNP:rs56270960).
FT                                /FTId=VAR_040100.
FT   VARIANT    1664   1664       R -> Q (in an ovarian mucinous carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040101.
FT   VARIANT    1692   1692       G -> D (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040102.
FT   VARIANT    1744   1744       P -> L.
FT                                /FTId=VAR_040103.
FT   VARIANT    1772   1772       S -> G.
FT                                /FTId=VAR_040104.
FT   VARIANT    1907   1907       T -> I (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040105.
FT   VARIANT    1998   1998       R -> H.
FT                                /FTId=VAR_040106.
FT   VARIANT    2107   2107       P -> L (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040107.
FT   VARIANT    2118   2118       I -> T (in dbSNP:rs56404770).
FT                                /FTId=VAR_040108.
FT   VARIANT    2164   2164       A -> T (in dbSNP:rs56285559).
FT                                /FTId=VAR_040109.
FT   VARIANT    2240   2240       D -> Y.
FT                                /FTId=VAR_040110.
FT   VARIANT    2392   2392       G -> S (in dbSNP:rs4894048).
FT                                /FTId=VAR_040111.
FT   VARIANT    2432   2432       L -> F (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_040112.
FT   VARIANT    2610   2610       I -> M (in dbSNP:rs56142888).
FT                                /FTId=VAR_040113.
FT   VARIANT    2771   2771       I -> M (in a breast infiltrating ductal
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_040114.
FT   VARIANT    2823   2823       V -> F (in dbSNP:rs33917087).
FT                                /FTId=VAR_040115.
FT   VARIANT    2831   2831       N -> S (in dbSNP:rs2306636).
FT                                /FTId=VAR_040116.
FT   VARIANT    2930   2930       V -> I (in dbSNP:rs56373393).
FT                                /FTId=VAR_040117.
FT   VARIANT    3026   3026       N -> I (in dbSNP:rs11900987).
FT                                /FTId=VAR_056082.
FT   VARIANT    3154   3154       K -> R.
FT                                /FTId=VAR_040118.
FT   VARIANT    3191   3191       Q -> E.
FT                                /FTId=VAR_040119.
FT   VARIANT    3238   3238       P -> L (in a bladder carcinoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_040120.
FT   VARIANT    3250   3250       V -> G.
FT                                /FTId=VAR_040121.
FT   VARIANT    3261   3261       V -> M.
FT                                /FTId=VAR_040122.
FT   VARIANT    3367   3367       R -> Q.
FT                                /FTId=VAR_040123.
FT   VARIANT    3419   3419       S -> N (in dbSNP:rs2291310).
FT                                /FTId=VAR_056083.
FT   VARIANT    3482   3482       E -> K (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_040124.
FT   VARIANT    3491   3491       S -> P.
FT                                /FTId=VAR_040125.
FT   VARIANT    3570   3570       E -> K (in a breast pleomorphic lobular
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_040126.
FT   VARIANT    3590   3590       L -> V.
FT                                /FTId=VAR_040127.
FT   VARIANT    3637   3637       P -> S (in dbSNP:rs2627037).
FT                                /FTId=VAR_056084.
FT   VARIANT    3762   3762       I -> V.
FT                                /FTId=VAR_040128.
FT   VARIANT    3799   3799       S -> Y (in CMD1G).
FT                                /FTId=VAR_026690.
FT   VARIANT    3877   3877       I -> F.
FT                                /FTId=VAR_040129.
FT   VARIANT    3965   3965       I -> L.
FT                                /FTId=VAR_040130.
FT   VARIANT    4084   4084       R -> Q.
FT                                /FTId=VAR_026691.
FT   VARIANT    4215   4215       T -> P.
FT                                /FTId=VAR_026635.
FT   VARIANT    4238   4238       G -> W.
FT                                /FTId=VAR_040131.
FT   VARIANT    4283   4283       L -> F.
FT                                /FTId=VAR_026636.
FT   VARIANT    4291   4291       I -> T (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040132.
FT   VARIANT    4303   4303       G -> D.
FT                                /FTId=VAR_040133.
FT   VARIANT    4427   4427       D -> E.
FT                                /FTId=VAR_040134.
FT   VARIANT    4465   4465       S -> N (in CMD1G).
FT                                /FTId=VAR_026692.
FT   VARIANT    8288   8288       A -> V (in dbSNP:rs16866412).
FT                                /FTId=VAR_056085.
FT   VARIANT    8474   8474       I -> T (in dbSNP:rs4893852).
FT                                /FTId=VAR_056086.
FT   VARIANT   12310  12310       G -> E.
FT                                /FTId=VAR_040135.
FT   VARIANT   12383  12383       R -> H.
FT                                /FTId=VAR_040136.
FT   VARIANT   12469  12469       V -> A.
FT                                /FTId=VAR_040137.
FT   VARIANT   12642  12642       R -> C (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040138.
FT   VARIANT   12657  12657       E -> K (in a Wilms tumor; somatic
FT                                mutation).
FT                                /FTId=VAR_040139.
FT   VARIANT   12679  12679       K -> E.
FT                                /FTId=VAR_040140.
FT   VARIANT   12720  12720       S -> F (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_040141.
FT   VARIANT   12798  12798       R -> C.
FT                                /FTId=VAR_040142.
FT   VARIANT   13049  13049       E -> G.
FT                                /FTId=VAR_040143.
FT   VARIANT   13083  13083       E -> K (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_040144.
FT   VARIANT   13096  13096       R -> L.
FT                                /FTId=VAR_040145.
FT   VARIANT   13099  13099       Q -> R (in a lung small cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040146.
FT   VARIANT   13297  13297       V -> A.
FT                                /FTId=VAR_040147.
FT   VARIANT   13399  13399       I -> M.
FT                                /FTId=VAR_040148.
FT   VARIANT   13418  13418       A -> T.
FT                                /FTId=VAR_040149.
FT   VARIANT   13428  13428       E -> V.
FT                                /FTId=VAR_040150.
FT   VARIANT   13430  13430       I -> T.
FT                                /FTId=VAR_040151.
FT   VARIANT   13434  13434       R -> K (in a breast pleomorphic lobular
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_040152.
FT   VARIANT   13469  13469       D -> N.
FT                                /FTId=VAR_040153.
FT   VARIANT   13495  13495       K -> N.
FT                                /FTId=VAR_040154.
FT   VARIANT   13785  13785       N -> S (in a breast pleomorphic lobular
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_040155.
FT   VARIANT   13870  13870       Q -> H (in a lung small cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040156.
FT   VARIANT   14109  14109       V -> I.
FT                                /FTId=VAR_040157.
FT   VARIANT   14131  14131       R -> Q.
FT                                /FTId=VAR_040158.
FT   VARIANT   14208  14208       P -> T.
FT                                /FTId=VAR_040159.
FT   VARIANT   14728  14728       L -> V (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_040160.
FT   VARIANT   14999  14999       S -> T.
FT                                /FTId=VAR_040161.
FT   VARIANT   15021  15021       N -> T.
FT                                /FTId=VAR_040162.
FT   VARIANT   15520  15520       A -> V.
FT                                /FTId=VAR_040163.
FT   VARIANT   15555  15555       R -> I (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040164.
FT   VARIANT   15620  15620       R -> Q.
FT                                /FTId=VAR_040165.
FT   VARIANT   15629  15629       S -> I.
FT                                /FTId=VAR_040166.
FT   VARIANT   15635  15635       Y -> C (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040167.
FT   VARIANT   15700  15700       R -> Q.
FT                                /FTId=VAR_040168.
FT   VARIANT   15705  15705       L -> P.
FT                                /FTId=VAR_040169.
FT   VARIANT   15837  15837       I -> M.
FT                                /FTId=VAR_040170.
FT   VARIANT   16058  16058       R -> H.
FT                                /FTId=VAR_040171.
FT   VARIANT   16067  16067       K -> I.
FT                                /FTId=VAR_040172.
FT   VARIANT   16090  16090       I -> T.
FT                                /FTId=VAR_040173.
FT   VARIANT   16195  16195       R -> H (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040174.
FT   VARIANT   16409  16409       R -> C.
FT                                /FTId=VAR_040175.
FT   VARIANT   16424  16424       R -> P.
FT                                /FTId=VAR_040176.
FT   VARIANT   16575  16575       V -> M (in dbSNP:rs3813243).
FT                                /FTId=VAR_056087.
FT   VARIANT   16629  16629       I -> M.
FT                                /FTId=VAR_040177.
FT   VARIANT   16877  16877       K -> R.
FT                                /FTId=VAR_040178.
FT   VARIANT   17060  17060       N -> D.
FT                                /FTId=VAR_040179.
FT   VARIANT   17637  17637       I -> V.
FT                                /FTId=VAR_040180.
FT   VARIANT   17838  17838       R -> H.
FT                                /FTId=VAR_040181.
FT   VARIANT   17866  17866       D -> N.
FT                                /FTId=VAR_040182.
FT   VARIANT   17906  17906       G -> E (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_040183.
FT   VARIANT   18094  18094       E -> A.
FT                                /FTId=VAR_040184.
FT   VARIANT   18109  18109       G -> S.
FT                                /FTId=VAR_040185.
FT   VARIANT   18164  18164       R -> T (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040186.
FT   VARIANT   18221  18221       P -> L.
FT                                /FTId=VAR_040187.
FT   VARIANT   18222  18222       A -> T.
FT                                /FTId=VAR_040188.
FT   VARIANT   18726  18726       R -> Q.
FT                                /FTId=VAR_040189.
FT   VARIANT   18835  18835       V -> A (in a breast infiltrating ductal
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_040190.
FT   VARIANT   18881  18881       R -> K (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_040191.
FT   VARIANT   18939  18939       N -> S.
FT                                /FTId=VAR_040192.
FT   VARIANT   19000  19000       R -> Q.
FT                                /FTId=VAR_040193.
FT   VARIANT   19060  19060       L -> Q (in a lung large cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040194.
FT   VARIANT   19091  19091       R -> K (in a lung large cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040195.
FT   VARIANT   19224  19224       P -> S (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040196.
FT   VARIANT   19367  19367       T -> I.
FT                                /FTId=VAR_040197.
FT   VARIANT   19392  19392       E -> K (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_040198.
FT   VARIANT   19480  19480       A -> S (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040199.
FT   VARIANT   19495  19495       D -> G.
FT                                /FTId=VAR_040200.
FT   VARIANT   19665  19665       R -> H.
FT                                /FTId=VAR_040201.
FT   VARIANT   19762  19762       T -> I.
FT                                /FTId=VAR_040202.
FT   VARIANT   19947  19947       G -> R.
FT                                /FTId=VAR_040203.
FT   VARIANT   19956  19956       V -> M.
FT                                /FTId=VAR_040204.
FT   VARIANT   19992  19992       R -> Q.
FT                                /FTId=VAR_040205.
FT   VARIANT   20057  20057       R -> C.
FT                                /FTId=VAR_040206.
FT   VARIANT   20075  20075       S -> L.
FT                                /FTId=VAR_040207.
FT   VARIANT   20179  20179       T -> K.
FT                                /FTId=VAR_040208.
FT   VARIANT   20198  20198       A -> T.
FT                                /FTId=VAR_040209.
FT   VARIANT   20198  20198       A -> V.
FT                                /FTId=VAR_040210.
FT   VARIANT   20331  20331       R -> H.
FT                                /FTId=VAR_040211.
FT   VARIANT   20359  20359       R -> K (in dbSNP:rs9808036).
FT                                /FTId=VAR_056088.
FT   VARIANT   20408  20408       A -> T (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_040212.
FT   VARIANT   20564  20564       R -> K.
FT                                /FTId=VAR_040213.
FT   VARIANT   20718  20718       V -> I.
FT                                /FTId=VAR_040214.
FT   VARIANT   20726  20726       S -> P.
FT                                /FTId=VAR_040215.
FT   VARIANT   20892  20892       T -> N.
FT                                /FTId=VAR_040216.
FT   VARIANT   20894  20894       S -> R.
FT                                /FTId=VAR_040217.
FT   VARIANT   21125  21125       D -> E.
FT                                /FTId=VAR_040218.
FT   VARIANT   21403  21403       P -> S.
FT                                /FTId=VAR_040219.
FT   VARIANT   21730  21730       R -> C.
FT                                /FTId=VAR_040220.
FT   VARIANT   21747  21747       R -> Q.
FT                                /FTId=VAR_040221.
FT   VARIANT   21851  21851       C -> R (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040222.
FT   VARIANT   21925  21925       G -> R.
FT                                /FTId=VAR_040223.
FT   VARIANT   21995  21995       R -> H.
FT                                /FTId=VAR_040224.
FT   VARIANT   22045  22045       A -> V.
FT                                /FTId=VAR_040225.
FT   VARIANT   22149  22149       R -> H.
FT                                /FTId=VAR_040226.
FT   VARIANT   22160  22160       V -> I.
FT                                /FTId=VAR_040227.
FT   VARIANT   22261  22261       I -> T.
FT                                /FTId=VAR_040228.
FT   VARIANT   22306  22306       K -> N.
FT                                /FTId=VAR_040229.
FT   VARIANT   22357  22357       R -> H.
FT                                /FTId=VAR_040230.
FT   VARIANT   22408  22408       L -> P.
FT                                /FTId=VAR_040231.
FT   VARIANT   22537  22537       Q -> H (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040232.
FT   VARIANT   22584  22584       P -> L.
FT                                /FTId=VAR_040233.
FT   VARIANT   22646  22646       L -> P (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040234.
FT   VARIANT   22670  22670       T -> A.
FT                                /FTId=VAR_040235.
FT   VARIANT   22770  22770       A -> D.
FT                                /FTId=VAR_040236.
FT   VARIANT   22801  22801       A -> T (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_040237.
FT   VARIANT   22823  22823       R -> W (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_040238.
FT   VARIANT   22968  22968       E -> Q.
FT                                /FTId=VAR_040239.
FT   VARIANT   23074  23074       P -> L.
FT                                /FTId=VAR_040240.
FT   VARIANT   23079  23079       L -> F (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_040241.
FT   VARIANT   23282  23282       D -> N (in a breast infiltrating ductal
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_040242.
FT   VARIANT   23303  23303       H -> Y (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_040243.
FT   VARIANT   23306  23306       R -> C.
FT                                /FTId=VAR_040244.
FT   VARIANT   23515  23515       A -> S (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040245.
FT   VARIANT   23551  23551       E -> Q (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040246.
FT   VARIANT   23807  23807       S -> N.
FT                                /FTId=VAR_040247.
FT   VARIANT   23872  23872       D -> N (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040248.
FT   VARIANT   23891  23891       V -> A.
FT                                /FTId=VAR_040249.
FT   VARIANT   23933  23933       Y -> H.
FT                                /FTId=VAR_040250.
FT   VARIANT   23939  23939       T -> M.
FT                                /FTId=VAR_040251.
FT   VARIANT   23952  23952       F -> L (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040252.
FT   VARIANT   24098  24098       A -> G.
FT                                /FTId=VAR_040253.
FT   VARIANT   24098  24098       A -> T (in dbSNP:rs4894028).
FT                                /FTId=VAR_056089.
FT   VARIANT   24119  24119       N -> S.
FT                                /FTId=VAR_040254.
FT   VARIANT   24133  24133       V -> I.
FT                                /FTId=VAR_040255.
FT   VARIANT   24159  24159       V -> A (in a head and neck squamous cell
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_040256.
FT   VARIANT   24239  24239       T -> A.
FT                                /FTId=VAR_040257.
FT   VARIANT   24265  24265       E -> K.
FT                                /FTId=VAR_040258.
FT   VARIANT   24584  24584       I -> T.
FT                                /FTId=VAR_040259.
FT   VARIANT   24781  24781       I -> T.
FT                                /FTId=VAR_040260.
FT   VARIANT   24799  24799       R -> H.
FT                                /FTId=VAR_040261.
FT   VARIANT   24954  24954       D -> H.
FT                                /FTId=VAR_040262.
FT   VARIANT   24980  24980       T -> M.
FT                                /FTId=VAR_040263.
FT   VARIANT   25659  25659       R -> H.
FT                                /FTId=VAR_040264.
FT   VARIANT   25679  25679       A -> T.
FT                                /FTId=VAR_040265.
FT   VARIANT   25720  25720       P -> A.
FT                                /FTId=VAR_040266.
FT   VARIANT   25821  25821       T -> K.
FT                                /FTId=VAR_040267.
FT   VARIANT   25859  25859       E -> K (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_040268.
FT   VARIANT   25879  25879       N -> K.
FT                                /FTId=VAR_040269.
FT   VARIANT   25923  25923       A -> V.
FT                                /FTId=VAR_040270.
FT   VARIANT   26045  26045       V -> I.
FT                                /FTId=VAR_040271.
FT   VARIANT   26059  26059       K -> E (in a lung small cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040272.
FT   VARIANT   26134  26134       I -> V.
FT                                /FTId=VAR_040273.
FT   VARIANT   26477  26477       R -> C.
FT                                /FTId=VAR_040274.
FT   VARIANT   26843  26843       D -> Y.
FT                                /FTId=VAR_040275.
FT   VARIANT   27346  27346       K -> R.
FT                                /FTId=VAR_040276.
FT   VARIANT   27652  27652       R -> C.
FT                                /FTId=VAR_040277.
FT   VARIANT   27728  27728       G -> V.
FT                                /FTId=VAR_040278.
FT   VARIANT   27754  27754       F -> L.
FT                                /FTId=VAR_040279.
FT   VARIANT   27755  27755       I -> T.
FT                                /FTId=VAR_040280.
FT   VARIANT   27929  27929       I -> V.
FT                                /FTId=VAR_040281.
FT   VARIANT   28132  28132       I -> L.
FT                                /FTId=VAR_040282.
FT   VARIANT   28168  28168       R -> Q.
FT                                /FTId=VAR_040283.
FT   VARIANT   28538  28538       R -> H.
FT                                /FTId=VAR_040284.
FT   VARIANT   28572  28572       I -> T.
FT                                /FTId=VAR_040285.
FT   VARIANT   28948  28948       A -> T.
FT                                /FTId=VAR_040286.
FT   VARIANT   28986  28986       I -> V.
FT                                /FTId=VAR_040287.
FT   VARIANT   28993  28993       G -> E.
FT                                /FTId=VAR_040288.
FT   VARIANT   28998  28998       L -> V.
FT                                /FTId=VAR_040289.
FT   VARIANT   29070  29070       V -> M.
FT                                /FTId=VAR_040290.
FT   VARIANT   29090  29090       I -> V.
FT                                /FTId=VAR_040291.
FT   VARIANT   29419  29419       R -> C.
FT                                /FTId=VAR_040292.
FT   VARIANT   29479  29479       L -> P.
FT                                /FTId=VAR_040293.
FT   VARIANT   29880  29880       S -> L (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040294.
FT   VARIANT   29976  29976       D -> E.
FT                                /FTId=VAR_040295.
FT   VARIANT   30042  30042       S -> G.
FT                                /FTId=VAR_040296.
FT   VARIANT   30107  30107       R -> C.
FT                                /FTId=VAR_040297.
FT   VARIANT   30125  30125       S -> F.
FT                                /FTId=VAR_040298.
FT   VARIANT   30211  30211       L -> P.
FT                                /FTId=VAR_040299.
FT   VARIANT   30412  30412       I -> T.
FT                                /FTId=VAR_040300.
FT   VARIANT   30617  30617       T -> S (in a renal chromophobe cancer
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040301.
FT   VARIANT   30674  30674       T -> I.
FT                                /FTId=VAR_040302.
FT   VARIANT   30809  30809       V -> I (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040303.
FT   VARIANT   30818  30818       F -> I.
FT                                /FTId=VAR_040304.
FT   VARIANT   30825  30825       E -> K.
FT                                /FTId=VAR_040305.
FT   VARIANT   30856  30856       I -> T.
FT                                /FTId=VAR_040306.
FT   VARIANT   30887  30887       G -> D.
FT                                /FTId=VAR_040307.
FT   VARIANT   30887  30887       G -> S.
FT                                /FTId=VAR_040308.
FT   VARIANT   30897  30897       R -> H.
FT                                /FTId=VAR_040309.
FT   VARIANT   30907  30907       R -> H.
FT                                /FTId=VAR_040310.
FT   VARIANT   30946  30946       R -> H.
FT                                /FTId=VAR_040311.
FT   VARIANT   31081  31081       I -> F.
FT                                /FTId=VAR_040312.
FT   VARIANT   31107  31107       R -> C.
FT                                /FTId=VAR_040313.
FT   VARIANT   31124  31124       A -> G.
FT                                /FTId=VAR_040314.
FT   VARIANT   31156  31156       N -> S.
FT                                /FTId=VAR_040315.
FT   VARIANT   31246  31246       P -> T.
FT                                /FTId=VAR_040316.
FT   VARIANT   31330  31330       R -> H.
FT                                /FTId=VAR_040317.
FT   VARIANT   31690  31690       C -> R.
FT                                /FTId=VAR_040318.
FT   VARIANT   31724  31724       R -> Q.
FT                                /FTId=VAR_040319.
FT   VARIANT   31725  31725       V -> I.
FT                                /FTId=VAR_040320.
FT   VARIANT   31732  31732       G -> S.
FT                                /FTId=VAR_040321.
FT   VARIANT   31886  31886       V -> I.
FT                                /FTId=VAR_040322.
FT   VARIANT   32097  32097       R -> C.
FT                                /FTId=VAR_040323.
FT   VARIANT   32171  32171       T -> N (in a lung large cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040324.
FT   VARIANT   32248  32248       V -> I.
FT                                /FTId=VAR_040325.
FT   VARIANT   32281  32281       Q -> H.
FT                                /FTId=VAR_040326.
FT   VARIANT   32323  32323       R -> H.
FT                                /FTId=VAR_040327.
FT   VARIANT   32411  32411       R -> W (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040328.
FT   VARIANT   32558  32558       I -> V.
FT                                /FTId=VAR_040329.
FT   VARIANT   32610  32610       M -> V.
FT                                /FTId=VAR_040330.
FT   VARIANT   32637  32637       G -> V.
FT                                /FTId=VAR_040331.
FT   VARIANT   32922  32922       V -> A.
FT                                /FTId=VAR_040332.
FT   VARIANT   32943  32943       L -> R (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040333.
FT   VARIANT   32953  32953       R -> H.
FT                                /FTId=VAR_040334.
FT   VARIANT   32996  32996       R -> Q (in CMD1G).
FT                                /FTId=VAR_026693.
FT   VARIANT   33213  33213       V -> L.
FT                                /FTId=VAR_040335.
FT   VARIANT   33242  33242       R -> C (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040336.
FT   VARIANT   33387  33387       T -> M.
FT                                /FTId=VAR_040337.
FT   VARIANT   33419  33419       E -> D.
FT                                /FTId=VAR_040338.
FT   VARIANT   33536  33536       V -> M.
FT                                /FTId=VAR_040339.
FT   VARIANT   33568  33568       K -> Q.
FT                                /FTId=VAR_040340.
FT   VARIANT   33616  33616       E -> K.
FT                                /FTId=VAR_040341.
FT   VARIANT   33620  33620       P -> L.
FT                                /FTId=VAR_040342.
FT   VARIANT   33886  33886       E -> V.
FT                                /FTId=VAR_040343.
FT   VARIANT   33899  33899       I -> T.
FT                                /FTId=VAR_040344.
FT   VARIANT   33904  33904       L -> P (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040345.
FT   VARIANT   33955  33955       T -> I.
FT                                /FTId=VAR_040346.
FT   VARIANT   34115  34115       V -> A.
FT                                /FTId=VAR_040347.
FT   VARIANT   34306  34306       I -> N (in TMD).
FT                                /FTId=VAR_026694.
FT   VARIANT   34315  34315       L -> P (in TMD).
FT                                /FTId=VAR_026695.
FT   MUTAGEN   32207  32207       K->A: Disrupts catalytic activity.
FT   MUTAGEN   32341  32341       Y->E: No phosphorylation on tyrosine.
FT   CONFLICT    132    132       T -> N (in Ref. 1; CAA62188).
FT   CONFLICT    255    255       H -> P (in Ref. 1; CAA62188 and 5;
FT                                AAH70170/AAH58824/AAH13396).
FT   CONFLICT   1472   1474       QTA -> ANC (in Ref. 1; CAA62188).
FT   CONFLICT   1730   1730       G -> S (in Ref. 1; CAA62188).
FT   CONFLICT   3919   3919       P -> L (in Ref. 1; CAA62188).
FT   CONFLICT   4525   4525       K -> R (in Ref. 1; CAA62189).
FT   CONFLICT   6619   6619       E -> R (in Ref. 1; CAA62189).
FT   CONFLICT   7145   7145       D -> H (in Ref. 1; CAA62189).
FT   CONFLICT   7441   7441       S -> N (in Ref. 1; CAA62189).
FT   CONFLICT   8038   8038       E -> A (in Ref. 1; CAA62189).
FT   CONFLICT   8225   8225       H -> Q (in Ref. 1; CAA62189).
FT   CONFLICT   8850   8850       A -> P (in Ref. 1; CAA62189).
FT   CONFLICT   9693   9693       C -> V (in Ref. 1; CAA62189).
FT   CONFLICT   9892   9892       I -> V (in Ref. 1; CAA62189).
FT   CONFLICT  10305  10305       R -> G (in Ref. 1; CAA62189 and 9).
FT   CONFLICT  10566  10566       R -> K (in Ref. 1; CAA62189).
FT   CONFLICT  10779  10779       R -> H (in Ref. 1; CAA62189).
FT   CONFLICT  11424  11424       D -> E (in Ref. 1; CAA62189).
FT   CONFLICT  11511  11511       A -> V (in Ref. 1; CAA62189).
FT   CONFLICT  11626  11626       K -> N (in Ref. 1; CAA62189).
FT   CONFLICT  11838  11838       K -> N (in Ref. 1; CAA62189).
FT   CONFLICT  12994  12994       A -> T (in Ref. 1; CAA62188).
FT   CONFLICT  13795  13797       YKF -> IQI (in Ref. 11).
FT   CONFLICT  14590  14590       A -> T (in Ref. 1; CAA62188).
FT   CONFLICT  14792  14792       V -> A (in Ref. 1; CAA62188).
FT   CONFLICT  15974  15974       E -> K (in Ref. 1; CAA62188).
FT   CONFLICT  16234  16235       TK -> QR (in Ref. 1; CAA62188).
FT   CONFLICT  17238  17238       R -> H (in Ref. 1; CAA62188).
FT   CONFLICT  19734  19734       V -> A (in Ref. 1; CAA62188).
FT   CONFLICT  20622  20622       L -> H (in Ref. 1; CAA62188).
FT   CONFLICT  20775  20775       A -> P (in Ref. 1; CAA62188).
FT   CONFLICT  21625  21625       Y -> I (in Ref. 13; CAA45939).
FT   CONFLICT  21795  21800       PGPVLN -> ARPSPQ (in Ref. 13; CAA45939).
FT   CONFLICT  22176  22176       C -> W (in Ref. 1; CAA62188).
FT   CONFLICT  22816  22816       A -> D (in Ref. 1; CAA62188).
FT   CONFLICT  22837  22837       T -> A (in Ref. 1; CAA62188).
FT   CONFLICT  24176  24176       I -> M (in Ref. 1; CAA62188 and 13;
FT                                CAA45940).
FT   CONFLICT  24181  24181       S -> F (in Ref. 13; CAA45940).
FT   CONFLICT  25731  25731       P -> S (in Ref. 1; CAA62188).
FT   CONFLICT  26573  26573       M -> V (in Ref. 1; CAA62188).
FT   CONFLICT  26846  26848       IVE -> HRK (in Ref. 1; CAA62188).
FT   CONFLICT  27879  27879       G -> A (in Ref. 1; CAA62188).
FT   CONFLICT  28936  28936       D -> N (in Ref. 1; CAA62188).
FT   CONFLICT  29222  29222       A -> T (in Ref. 1; CAA62188).
FT   CONFLICT  29518  29518       F -> L (in Ref. 1; CAA62188).
FT   CONFLICT  29701  29701       T -> P (in Ref. 14; CAA45938/CAA49245).
FT   CONFLICT  29873  29873       E -> G (in Ref. 14; CAA45938/CAA49245).
FT   CONFLICT  29878  29878       T -> Q (in Ref. 14; CAA45938/CAA49245).
FT   CONFLICT  30209  30209       K -> E (in Ref. 1; CAA62188 and 14;
FT                                CAA45938/CAA49245).
FT   CONFLICT  30256  30256       A -> R (in Ref. 1; CAA62188 and 14;
FT                                CAA45938/CAA49245).
FT   CONFLICT  30496  30496       V -> I (in Ref. 1; CAA62188 and 14;
FT                                CAA45938/CAA49245).
FT   CONFLICT  30534  30534       Y -> H (in Ref. 1; CAA62188 and 14;
FT                                CAA45938/CAA49245).
FT   CONFLICT  30748  30748       S -> L (in Ref. 14; CAA45938/CAA49245).
FT   CONFLICT  31303  31303       W -> V (in Ref. 1; CAA62188 and 14;
FT                                CAA45938/CAA49245).
FT   CONFLICT  32060  32060       V -> A (in Ref. 1; CAA62188 and 14;
FT                                CAA45938/CAA49245).
FT   CONFLICT  33084  33084       D -> N (in Ref. 1; CAA62188 and 14;
FT                                CAA49245).
FT   CONFLICT  33120  33120       R -> W (in Ref. 15; CAD28458).
FT   CONFLICT  33382  33382       A -> R (in Ref. 14; CAA49245).
FT   CONFLICT  33424  33424       S -> P (in Ref. 1; CAA62188 and 14;
FT                                CAA49245).
FT   CONFLICT  33526  33526       Q -> R (in Ref. 14; CAA49245).
FT   CONFLICT  33633  33633       T -> I (in Ref. 1; CAA62188 and 14;
FT                                CAA49245).
FT   CONFLICT  33716  33716       Y -> V (in Ref. 15; CAD28458).
FT   CONFLICT  33995  33995       V -> A (in Ref. 15; CAD28458).
FT   CONFLICT  34071  34071       N -> G (in Ref. 5; AAI07798).
FT   CONFLICT  34082  34082       C -> R (in Ref. 14; CAA49245).
FT   CONFLICT  34253  34253       G -> R (in Ref. 5; AAI07798).
FT   STRAND        4     10
FT   STRAND       15     18
FT   STRAND       23     33
FT   STRAND       36     45
FT   TURN         48     50
FT   STRAND       55     59
FT   STRAND       62     69
FT   HELIX        72     74
FT   STRAND       76     84
FT   STRAND       87     98
FT   STRAND      102    108
FT   STRAND      113    116
FT   STRAND      119    131
FT   STRAND      134    139
FT   STRAND      147    155
FT   STRAND      158    166
FT   HELIX       168    170
FT   STRAND      172    180
FT   STRAND      183    194
FT   STRAND     2076   2082
FT   STRAND     2087   2090
FT   STRAND     2095   2105
FT   STRAND     2108   2113
FT   STRAND     2122   2130
FT   STRAND     2133   2138
FT   HELIX      2143   2145
FT   STRAND     2147   2155
FT   STRAND     2158   2169
FT   STRAND    12680  12682
FT   STRAND    12687  12690
FT   STRAND    12695  12705
FT   STRAND    12709  12712
FT   STRAND    12723  12728
FT   STRAND    12731  12736
FT   HELIX     12741  12743
FT   STRAND    12745  12751
FT   STRAND    12754  12763
FT   STRAND    22291  22296
FT   STRAND    22299  22303
FT   STRAND    22319  22324
FT   STRAND    22340  22345
FT   STRAND    22354  22361
FT   STRAND    22367  22377
FT   HELIX     22381  22384
FT   STRAND    31856  31859
FT   STRAND    31864  31867
FT   STRAND    31872  31879
FT   STRAND    31885  31890
FT   STRAND    31899  31907
FT   TURN      31908  31910
FT   STRAND    31911  31916
FT   HELIX     31921  31923
FT   STRAND    31925  31933
FT   STRAND    31936  31952
FT   STRAND    31955  31958
FT   STRAND    31961  31967
FT   STRAND    31973  31982
FT   STRAND    31985  31995
FT   STRAND    32002  32005
FT   STRAND    32007  32013
FT   HELIX     32020  32022
FT   STRAND    32024  32032
FT   STRAND    32035  32046
FT   STRAND    32053  32059
FT   STRAND    32065  32070
FT   STRAND    32076  32078
FT   STRAND    32080  32089
FT   STRAND    32095  32108
FT   STRAND    32116  32125
FT   TURN      32175  32177
FT   STRAND    32178  32186
FT   STRAND    32188  32197
FT   TURN      32198  32201
FT   STRAND    32202  32209
FT   HELIX     32214  32228
FT   STRAND    32237  32243
FT   STRAND    32246  32251
FT   HELIX     32259  32263
FT   STRAND    32265  32267
FT   HELIX     32272  32291
FT   HELIX     32301  32303
FT   STRAND    32304  32310
FT   STRAND    32314  32316
FT   STRAND    32330  32336
FT   HELIX     32338  32340
FT   HELIX     32343  32346
FT   HELIX     32353  32369
FT   HELIX     32379  32388
FT   HELIX     32395  32398
FT   HELIX     32403  32410
FT   HELIX     32417  32419
FT   HELIX     32423  32428
FT   HELIX     32430  32433
FT   HELIX     32436  32438
FT   HELIX     32447  32457
FT   HELIX     32466  32472
FT   STRAND    32474  32476
FT   STRAND    32483  32489
FT   STRAND    32504  32506
FT   STRAND    32512  32520
FT   STRAND    32526  32531
FT   STRAND    32538  32547
FT   STRAND    32550  32555
FT   HELIX     32560  32562
FT   STRAND    32564  32571
FT   STRAND    32576  32585
FT   TURN      32586  32588
FT   STRAND    33489  33492
FT   STRAND    33497  33503
FT   STRAND    33509  33512
FT   STRAND    33523  33526
FT   STRAND    33532  33538
FT   STRAND    33540  33547
FT   STRAND    33556  33560
FT   STRAND    33571  33577
SQ   SEQUENCE   34350 AA;  3816188 MW;  2558BCFE2922B347 CRC64;
     MTTQAPTFTQ PLQSVVVLEG STATFEAHIS GFPVPEVSWF RDGQVISTST LPGVQISFSD
     GRAKLTIPAV TKANSGRYSL KATNGSGQAT STAELLVKAE TAPPNFVQRL QSMTVRQGSQ
     VRLQVRVTGI PTPVVKFYRD GAEIQSSLDF QISQEGDLYS LLIAEAYPED SGTYSVNATN
     SVGRATSTAE LLVQGEEEVP AKKTKTIVST AQISESRQTR IEKKIEAHFD ARSIATVEMV
     IDGAAGQQLP HKTPHRIPPK PKSRSPTPPS IAAKAQLARQ QSPSPIRHSP SPVRHVRAPT
     PSPVRSVSPA ARISTSPIRS VRSPLLMRKT QASTVATGPE VPPPWKQEGY VASSSEAEMR
     ETTLTTSTQI RTEERWEGRY GVQEQVTISG AAGAAASVSA SASYAAEAVA TGAKEVKQDA
     DKSAAVATVV AAVDMARVRE PVISAVEQTA QRTTTTAVHI QPAQEQVRKE AEKTAVTKVV
     VAADKAKEQE LKSRTKEVIT TKQEQMHVTH EQIRKETEKT FVPKVVISAA KAKEQETRIS
     EEITKKQKQV TQEAIRQETE ITAASMVVVA TAKSTKLETV PGAQEETTTQ QDQMHLSYEK
     IMKETRKTVV PKVIVATPKV KEQDLVSRGR EGITTKREQV QITQEKMRKE AEKTALSTIA
     VATAKAKEQE TILRTRETMA TRQEQIQVTH GKVDVGKKAE AVATVVAAVD QARVREPREP
     GHLEESYAQQ TTLEYGYKER ISAAKVAEPP QRPASEPHVV PKAVKPRVIQ APSETHIKTT
     DQKGMHISSQ IKKTTDLTTE RLVHVDKRPR TASPHFTVSK ISVPKTEHGY EASIAGSAIA
     TLQKELSATS SAQKITKSVK APTVKPSETR VRAEPTPLPQ FPFADTPDTY KSEAGVEVKK
     EVGVSITGTT VREERFEVLH GREAKVTETA RVPAPVEIPV TPPTLVSGLK NVTVIEGESV
     TLECHISGYP SPTVTWYRED YQIESSIDFQ ITFQSGIARL MIREAFAEDS GRFTCSAVNE
     AGTVSTSCYL AVQVSEEFEK ETTAVTEKFT TEEKRFVESR DVVMTDTSLT EEQAGPGEPA
     APYFITKPVV QKLVEGGSVV FGCQVGGNPK PHVYWKKSGV PLTTGYRYKV SYNKQTGECK
     LVISMTFADD AGEYTIVVRN KHGETSASAS LLEEADYELL MKSQQEMLYQ TQVTAFVQEP
     KVGETAPGFV YSEYEKEYEK EQALIRKKMA KDTVVVRTYV EDQEFHISSF EERLIKEIEY
     RIIKTTLEEL LEEDGEEKMA VDISESEAVE SGFDLRIKNY RILEGMGVTF HCKMSGYPLP
     KIAWYKDGKR IKHGERYQMD FLQDGRASLR IPVVLPEDEG IYTAFASNIK GNAICSGKLY
     VEPAAPLGAP TYIPTLEPVS RIRSLSPRSV SRSPIRMSPA RMSPARMSPA RMSPARMSPG
     RRLEETDESQ LERLYKPVFV LKPVSFKCLE GQTARFDLKV VGRPMPETFW FHDGQQIVND
     YTHKVVIKED GTQSLIIVPA TPSDSGEWTV VAQNRAGRSS ISVILTVEAV EHQVKPMFVE
     KLKNVNIKEG SQLEMKVRAT GNPNPDIVWL KNSDIIVPHK YPKIRIEGTK GEAALKIDST
     VSQDSAWYTA TAINKAGRDT TRCKVNVEVE FAEPEPERKL IIPRGTYRAK EIAAPELEPL
     HLRYGQEQWE EGDLYDKEKQ QKPFFKKKLT SLRLKRFGPA HFECRLTPIG DPTMVVEWLH
     DGKPLEAANR LRMINEFGYC SLDYGVAYSR DSGIITCRAT NKYGTDHTSA TLIVKDEKSL
     VEESQLPEGR KGLQRIEELE RMAHEGALTG VTTDQKEKQK PDIVLYPEPV RVLEGETARF
     RCRVTGYPQP KVNWYLNGQL IRKSKRFRVR YDGIHYLDIV DCKSYDTGEV KVTAENPEGV
     IEHKVKLEIQ QREDFRSVLR RAPEPRPEFH VHEPGKLQFE VQKVDRPVDT TETKEVVKLK
     RAERITHEKV PEESEELRSK FKRRTEEGYY EAITAVELKS RKKDESYEEL LRKTKDELLH
     WTKELTEEEK KALAEEGKIT IPTFKPDKIE LSPSMEAPKI FERIQSQTVG QGSDAHFRVR
     VVGKPDPECE WYKNGVKIER SDRIYWYWPE DNVCELVIRD VTAEDSASIM VKAINIAGET
     SSHAFLLVQA KQLITFTQEL QDVVAKEKDT MATFECETSE PFVKVKWYKD GMEVHEGDKY
     RMHSDRKVHF LSILTIDTSD AEDYSCVLVE DENVKTTAKL IVEGAVVEFV KELQDIEVPE
     SYSGELECIV SPENIEGKWY HNDVELKSNG KYTITSRRGR QNLTVKDVTK EDQGEYSFVI
     DGKKTTCKLK MKPRPIAILQ GLSDQKVCEG DIVQLEVKVS LESVEGVWMK DGQEVQPSDR
     VHIVIDKQSH MLLIEDMTKE DAGNYSFTIP ALGLSTSGRV SVYSVDVITP LKDVNVIEGT
     KAVLECKVSV PDVTSVKWYL NDEQIKPDDR VQAIVKGTKQ RLVINRTHAS DEGPYKLIVG
     RVETNCNLSV EKIKIIRGLR DLTCTETQNV VFEVELSHSG IDVLWNFKDK EIKPSSKYKI
     EAHGKIYKLT VLNMMKDDEG KYTFYAGENI TSGKLTVAGG AISKPLTDQT VAESQEAVFE
     CEVANPDSKG EWLRDGKHLP LTNNIRSESD GHKRRLIIAA TKLDDIGEYT YKVATSKTSA
     KLKVEAVKIK KTLKNLTVTE TQDAVFTVEL THPNVKGVQW IKNGVVLESN EKYAISVKGT
     IYSLRIKNCA IVDESVYGFR LGRLGASARL HVETVKIIKK PKDVTALENA TVAFEVSVSH
     DTVPVKWFHK NVEIKPSDKH RLVSERKVHK LMLQNISPSD AGEYTAVVGQ LECKAKLFVE
     TLHITKTMKN IEVPETKTAS FECEVSHFNV PSMWLKNGVE IEMSEKFKIV VQGKLHQLII
     MNTSTEDSAE YTFVCGNDQV SATLTVTPIM ITSMLKDINA EEKDTITFEV TVNYEGISYK
     WLKNGVEIKS TDKCQMRTKK LTHSLNIRNV HFGDAADYTF VAGKATSTAT LYVEARHIEF
     RKHIKDIKVL EKKRAMFECE VSEPDITVQW MKDDQELQIT DRIKIQKEKY VHRLLIPSTR
     MSDAGKYTVV AGGNVSTAKL FVEGRDVRIR SIKKEVQVIE KQRAVVEFEV NEDDVDAHWY
     KDGIEINFQV QERHKYVVER RIHRMFISET RQSDAGEYTF VAGRNRSSVT LYVNAPEPPQ
     VLQELQPVTV QSGKPARFCA VISGRPQPKI SWYKEEQLLS TGFKCKFLHD GQEYTLLLIE
     AFPEDAAVYT CEAKNDYGVA TTSASLSVEV PEVVSPDQEM PVYPPAIITP LQDTVTSEGQ
     PARFQCRVSG TDLKVSWYSK DKKIKPSRFF RMTQFEDTYQ LEIAEAYPED EGTYTFVASN
     AVGQVSSTAN LSLEAPESIL HERIEQEIEM EMKEFSSSFL SAEEEGLHSA ELQLSKINET
     LELLSESPVY STKFDSEKEG TGPIFIKEVS NADISMGDVA TLSVTVIGIP KPKIQWFFNG
     VLLTPSADYK FVFDGDDHSL IILFTKLEDE GEYTCMASND YGKTICSAYL KINSKGEGHK
     DTETESAVAK SLEKLGGPCP PHFLKELKPI RCAQGLPAIF EYTVVGEPAP TVTWFKENKQ
     LCTSVYYTII HNPNGSGTFI VNDPQREDSG LYICKAENML GESTCAAELL VLLEDTDMTD
     TPCKAKSTPE APEDFPQTPL KGPAVEALDS EQEIATFVKD TILKAALITE ENQQLSYEHI
     AKANELSSQL PLGAQELQSI LEQDKLTPES TREFLCINGS IHFQPLKEPS PNLQLQIVQS
     QKTFSKEGIL MPEEPETQAV LSDTEKIFPS AMSIEQINSL TVEPLKTLLA EPEGNYPQSS
     IEPPMHSYLT SVAEEVLSPK EKTVSDTNRE QRVTLQKQEA QSALILSQSL AEGHVESLQS
     PDVMISQVNY EPLVPSEHSC TEGGKILIES ANPLENAGQD SAVRIEEGKS LRFPLALEEK
     QVLLKEEHSD NVVMPPDQII ESKREPVAIK KVQEVQGRDL LSKESLLSGI PEEQRLNLKI
     QICRALQAAV ASEQPGLFSE WLRNIEKVEV EAVNITQEPR HIMCMYLVTS AKSVTEEVTI
     IIEDVDPQMA NLKMELRDAL CAIIYEEIDI LTAEGPRIQQ GAKTSLQEEM DSFSGSQKVE
     PITEPEVESK YLISTEEVSY FNVQSRVKYL DATPVTKGVA SAVVSDEKQD ESLKPSEEKE
     ESSSESGTEE VATVKIQEAE GGLIKEDGPM IHTPLVDTVS EEGDIVHLTT SITNAKEVNW
     YFENKLVPSD EKFKCLQDQN TYTLVIDKVN TEDHQGEYVC EALNDSGKTA TSAKLTVVKR
     AAPVIKRKIE PLEVALGHLA KFTCEIQSAP NVRFQWFKAG REIYESDKCS IRSSKYISSL
     EILRTQVVDC GEYTCKASNE YGSVSCTATL TVTEAYPPTF LSRPKSLTTF VGKAAKFICT
     VTGTPVIETI WQKDGAALSP SPNWKISDAE NKHILELSNL TIQDRGVYSC KASNKFGADI
     CQAELIIIDK PHFIKELEPV QSAINKKVHL ECQVDEDRKV TVTWSKDGQK LPPGKDYKIC
     FEDKIATLEI PLAKLKDSGT YVCTASNEAG SSSCSATVTV REPPSFVKKV DPSYLMLPGE
     SARLHCKLKG SPVIQVTWFK NNKELSESNT VRMYFVNSEA ILDITDVKVE DSGSYSCEAV
     NDVGSDSCST EIVIKEPPSF IKTLEPADIV RGTNALLQCE VSGTGPFEIS WFKDKKQIRS
     SKKYRLFSQK SLVCLEIFSF NSADVGEYEC VVANEVGKCG CMATHLLKEP PTFVKKVDDL
     IALGGQTVTL QAAVRGSEPI SVTWMKGQEV IREDGKIKMS FSNGVAVLII PDVQISFGGK
     YTCLAENEAG SQTSVGELIV KEPAKIIERA ELIQVTAGDP ATLEYTVAGT PELKPKWYKD
     GRPLVASKKY RISFKNNVAQ LKFYSAELHD SGQYTFEISN EVGSSSCETT FTVLDRDIAP
     FFTKPLRNVD SVVNGTCRLD CKIAGSLPMR VSWFKDGKEI AASDRYRIAF VEGTASLEII
     RVDMNDAGNF TCRATNSVGS KDSSGALIVQ EPPSFVTKPG SKDVLPGSAV CLKSTFQGST
     PLTIRWFKGN KELVSGGSCY ITKEALESSL ELYLVKTSDS GTYTCKVSNV AGGVECSANL
     FVKEPATFVE KLEPSQLLKK GDATQLACKV TGTPPIKITW FANDREIKES SKHRMSFVES
     TAVLRLTDVG IEDSGEYMCE AQNEAGSDHC SSIVIVKESP YFTKEFKPIE VLKEYDVMLL
     AEVAGTPPFE ITWFKDNTIL RSGRKYKTFI QDHLVSLQIL KFVAADAGEY QCRVTNEVGS
     SICSARVTLR EPPSFIKKIE STSSLRGGTA AFQATLKGSL PITVTWLKDS DEITEDDNIR
     MTFENNVASL YLSGIEVKHD GKYVCQAKND AGIQRCSALL SVKEPATITE EAVSIDVTQG
     DPATLQVKFS GTKEITAKWF KDGQELTLGS KYKISVTDTV SILKIISTEK KDSGEYTFEV
     QNDVGRSSCK ARINVLDLII PPSFTKKLKK MDSIKGSFID LECIVAGSHP ISIQWFKDDQ
     EISASEKYKF SFHDNTAFLE ISQLEGTDSG TYTCSATNKA GHNQCSGHLT VKEPPYFVEK
     PQSQDVNPNT RVQLKALVGG TAPMTIKWFK DNKELHSGAA RSVWKDDTST SLELFAAKAT
     DSGTYICQLS NDVGTATSKA TLFVKEPPQF IKKPSPVLVL RNGQSTTFEC QITGTPKIRV
     SWYLDGNEIT AIQKHGISFI DGLATFQISG ARVENSGTYV CEARNDAGTA SCSIELKVKE
     PPTFIRELKP VEVVKYSDVE LECEVTGTPP FEVTWLKNNR EIRSSKKYTL TDRVSVFNLH
     ITKCDPSDTG EYQCIVSNEG GSCSCSTRVA LKEPPSFIKK IENTTTVLKS SATFQSTVAG
     SPPISITWLK DDQILDEDDN VYISFVDSVA TLQIRSVDNG HSGRYTCQAK NESGVERCYA
     FLLVQEPAQI VEKAKSVDVT EKDPMTLECV VAGTPELKVK WLKDGKQIVP SRYFSMSFEN
     NVASFRIQSV MKQDSGQYTF KVENDFGSSS CDAYLRVLDQ NIPPSFTKKL TKMDKVLGSS
     IHMECKVSGS LPISAQWFKD GKEISTSAKY RLVCHERSVS LEVNNLELED TANYTCKVSN
     VAGDDACSGI LTVKEPPSFL VKPGRQQAIP DSTVEFKAIL KGTPPFKIKW FKDDVELVSG
     PKCFIGLEGS TSFLNLYSVD ASKTGQYTCH VTNDVGSDSC TTMLLVTEPP KFVKKLEASK
     IVKAGDSSRL ECKIAGSPEI RVVWFRNEHE LPASDKYRMT FIDSVAVIQM NNLSTEDSGD
     FICEAQNPAG STSCSTKVIV KEPPVFSSFP PIVETLKNAE VSLECELSGT PPFEVVWYKD
     KRQLRSSKKY KIASKNFHTS IHILNVDTSD IGEYHCKAQN EVGSDTCVCT VKLKEPPRFV
     SKLNSLTVVA GEPAELQASI EGAQPIFVQW LKEKEEVIRE SENIRITFVE NVATLQFAKA
     EPANAGKYIC QIKNDGGMEE NMATLMVLEP AVIVEKAGPM TVTVGETCTL ECKVAGTPEL
     SVEWYKDGKL LTSSQKHKFS FYNKISSLRI LSVERQDAGT YTFQVQNNVG KSSCTAVVDV
     SDRAVPPSFT RRLKNTGGVL GASCILECKV AGSSPISVAW FHEKTKIVSG AKYQTTFSDN
     VCTLQLNSLD SSDMGNYTCV AANVAGSDEC RAVLTVQEPP SFVKEPEPLE VLPGKNVTFT
     SVIRGTPPFK VNWFRGAREL VKGDRCNIYF EDTVAELELF NIDISQSGEY TCVVSNNAGQ
     ASCTTRLFVK EPAAFLKRLS DHSVEPGKSI ILESTYTGTL PISVTWKKDG FNITTSEKCN
     IVTTEKTCIL EILNSTKRDA GQYSCEIENE AGRDVCGALV STLEPPYFVT ELEPLEAAVG
     DSVSLQCQVA GTPEITVSWY KGDTKLRPTP EYRTYFTNNV ATLVFNKVNI NDSGEYTCKA
     ENSIGTASSK TVFRIQERQL PPSFARQLKD IEQTVGLPVT LTCRLNGSAP IQVCWYRDGV
     LLRDDENLQT SFVDNVATLK ILQTDLSHSG QYSCSASNPL GTASSSARLT AREPKKSPFF
     DIKPVSIDVI AGESADFECH VTGAQPMRIT WSKDNKEIRP GGNYTITCVG NTPHLRILKV
     GKGDSGQYTC QATNDVGKDM CSAQLSVKEP PKFVKKLEAS KVAKQGESIQ LECKISGSPE
     IKVSWFRNDS ELHESWKYNM SFINSVALLT INEASAEDSG DYICEAHNGV GDASCSTALT
     VKAPPVFTQK PSPVGALKGS DVILQCEISG TPPFEVVWVK DRKQVRNSKK FKITSKHFDT
     SLHILNLEAS DVGEYHCKAT NEVGSDTCSC SVKFKEPPRF VKKLSDTSTL IGDAVELRAI
     VEGFQPISVV WLKDRGEVIR ESENTRISFI DNIATLQLGS PEASNSGKYI CQIKNDAGMR
     ECSAVLTVLE PARIIEKPEP MTVTTGNPFA LECVVTGTPE LSAKWFKDGR ELSADSKHHI
     TFINKVASLK IPCAEMSDKG LYSFEVKNSV GKSNCTVSVH VSDRIVPPSF IRKLKDVNAI
     LGASVVLECR VSGSAPISVG WFQDGNEIVS GPKCQSSFSE NVCTLNLSLL EPSDTGIYTC
     VAANVAGSDE CSAVLTVQEP PSFEQTPDSV EVLPGMSLTF TSVIRGTPPF KVKWFKGSRE
     LVPGESCNIS LEDFVTELEL FEVQPLESGD YSCLVTNDAG SASCTTHLFV KEPATFVKRL
     ADFSVETGSP IVLEATYTGT PPISVSWIKD EYLISQSERC SITMTEKSTI LEILESTIED
     YAQYSCLIEN EAGQDICEAL VSVLEPPYFI EPLEHVEAVI GEPATLQCKV DGTPEIRISW
     YKEHTKLRSA PAYKMQFKNN VASLVINKVD HSDVGEYSCK ADNSVGAVAS SAVLVIKERK
     LPPFFARKLK DVHETLGFPV AFECRINGSE PLQVSWYKDG VLLKDDANLQ TSFVHNVATL
     QILQTDQSHI GQYNCSASNP LGTASSSAKL ILSEHEVPPF FDLKPVSVDL ALGESGTFKC
     HVTGTAPIKI TWAKDNREIR PGGNYKMTLV ENTATLTVLK VGKGDAGQYT CYASNIAGKD
     SCSAHLGVQE PPRFIKKLEP SRIVKQDEFT RYECKIGGSP EIKVLWYKDE TEIQESSKFR
     MSFVDSVAVL EMHNLSVEDS GDYTCEAHNA AGSASSSTSL KVKEPPIFRK KPHPIETLKG
     ADVHLECELQ GTPPFHVSWY KDKRELRSGK KYKIMSENFL TSIHILNVDA ADIGEYQCKA
     TNDVGSDTCV GSIALKAPPR FVKKLSDIST VVGKEVQLQT TIEGAEPISV VWFKDKGEIV
     RESDNIWISY SENIATLQFS RVEPANAGKY TCQIKNDAGM QECFATLSVL EPATIVEKPE
     SIKVTTGDTC TLECTVAGTP ELSTKWFKDG KELTSDNKYK ISFFNKVSGL KIINVAPSDS
     GVYSFEVQNP VGKDSCTASL QVSDRTVPPS FTRKLKETNG LSGSSVVMEC KVYGSPPISV
     SWFHEGNEIS SGRKYQTTLT DNTCALTVNM LEESDSGDYT CIATNMAGSD ECSAPLTVRE
     PPSFVQKPDP MDVLTGTNVT FTSIVKGTPP FSVSWFKGSS ELVPGDRCNV SLEDSVAELE
     LFDVDTSQSG EYTCIVSNEA GKASCTTHLY IKAPAKFVKR LNDYSIEKGK PLILEGTFTG
     TPPISVTWKK NGINVTPSQR CNITTTEKSA ILEIPSSTVE DAGQYNCYIE NASGKDSCSA
     QILILEPPYF VKQLEPVKVS VGDSASLQCQ LAGTPEIGVS WYKGDTKLRP TTTYKMHFRN
     NVATLVFNQV DINDSGEYIC KAENSVGEVS ASTFLTVQEQ KLPPSFSRQL RDVQETVGLP
     VVFDCAISGS EPISVSWYKD GKPLKDSPNV QTSFLDNTAT LNIFKTDRSL AGQYSCTATN
     PIGSASSSAR LILTEGKNPP FFDIRLAPVD AVVGESADFE CHVTGTQPIK VSWAKDSREI
     RSGGKYQISY LENSAHLTVL KVDKGDSGQY TCYAVNEVGK DSCTAQLNIK ERLIPPSFTK
     RLSETVEETE GNSFKLEGRV AGSQPITVAW YKNNIEIQPT SNCEITFKNN TLVLQVRKAG
     MNDAGLYTCK VSNDAGSALC TSSIVIKEPK KPPVFDQHLT PVTVSEGEYV QLSCHVQGSE
     PIRIQWLKAG REIKPSDRCS FSFASGTAVL ELRDVAKADS GDYVCKASNV AGSDTTKSKV
     TIKDKPAVAP ATKKAAVDGR LFFVSEPQSI RVVEKTTATF IAKVGGDPIP NVKWTKGKWR
     QLNQGGRVFI HQKGDEAKLE IRDTTKTDSG LYRCVAFNEH GEIESNVNLQ VDERKKQEKI
     EGDLRAMLKK TPILKKGAGE EEEIDIMELL KNVDPKEYEK YARMYGITDF RGLLQAFELL
     KQSQEEETHR LEIEEIERSE RDEKEFEELV SFIQQRLSQT EPVTLIKDIE NQTVLKDNDA
     VFEIDIKINY PEIKLSWYKG TEKLEPSDKF EISIDGDRHT LRVKNCQLKD QGNYRLVCGP
     HIASAKLTVI EPAWERHLQD VTLKEGQTCT MTCQFSVPNV KSEWFRNGRI LKPQGRHKTE
     VEHKVHKLTI ADVRAEDQGQ YTCKYEDLET SAELRIEAEP IQFTKRIQNI VVSEHQSATF
     ECEVSFDDAI VTWYKGPTEL TESQKYNFRN DGRCHYMTIH NVTPDDEGVY SVIARLEPRG
     EARSTAELYL TTKEIKLELK PPDIPDSRVP IPTMPIRAVP PEEIPPVVAP PIPLLLPTPE
     EKKPPPKRIE VTKKAVKKDA KKVVAKPKEM TPREEIVKKP PPPTTLIPAK APEIIDVSSK
     AEEVKIMTIT RKKEVQKEKE AVYEKKQAVH KEKRVFIESF EEPYDELEVE PYTEPFEQPY
     YEEPDEDYEE IKVEAKKEVH EEWEEDFEEG QEYYEREEGY DEGEEEWEEA YQEREVIQVQ
     KEVYEESHER KVPAKVPEKK APPPPKVIKK PVIEKIEKTS RRMEEEKVQV TKVPEVSKKI
     VPQKPSRTPV QEEVIEVKVP AVHTKKMVIS EEKMFFASHT EEEVSVTVPE VQKEIVTEEK
     IHVAVSKRVE PPPKVPELPE KPAPEEVAPV PIPKKVEPPA PKVPEVPKKP VPEEKKPVPV
     PKKEPAAPPK VPEVPKKPVP EEKIPVPVAK KKEAPPAKVP EVQKRVVTEE KITIVTQREE
     SPPPAVPEIP KKKVPEERKP VPRKEEEVPP PPKVPALPKK PVPEEKVAVP VPVAKKAPPP
     RAEVSKKTVV EEKRFVAEEK LSFAVPQRVE VTRHEVSAEE EWSYSEEEEG VSISVYREEE
     REEEEEAEVT EYEVMEEPEE YVVEEKLHII SKRVEAEPAE VTERQEKKIV LKPKIPAKIE
     EPPPAKVPEA PKKIVPEKKV PAPVPKKEKV PPPKVPEEPK KPVPEKKVPP KVIKMEEPLP
     AKVTERHMQI TQEEKVLVAV TKKEAPPKAR VPEEPKRAVP EEKVLKLKPK REEEPPAKVT
     EFRKRVVKEE KVSIEAPKRE PQPIKEVTIM EEKERAYTLE EEAVSVQREE EYEEYEEYDY
     KEFEEYEPTE EYDQYEEYEE REYERYEEHE EYITEPEKPI PVKPVPEEPV PTKPKAPPAK
     VLKKAVPEEK VPVPIPKKLK PPPPKVPEEP KKVFEEKIRI SITKREKEQV TEPAAKVPMK
     PKRVVAEEKV PVPRKEVAPP VRVPEVPKEL EPEEVAFEEE VVTHVEEYLV EEEEEYIHEE
     EEFITEEEVV PVIPVKVPEV PRKPVPEEKK PVPVPKKKEA PPAKVPEVPK KPEEKVPVLI
     PKKEKPPPAK VPEVPKKPVP EEKVPVPVPK KVEAPPAKVP EVPKKPVPEK KVPVPAPKKV
     EAPPAKVPEV PKKLIPEEKK PTPVPKKVEA PPPKVPKKRE PVPVPVALPQ EEEVLFEEEI
     VPEEEVLPEE EEVLPEEEEV LPEEEEVLPE EEEIPPEEEE VPPEEEYVPE EEEFVPEEEV
     LPEVKPKVPV PAPVPEIKKK VTEKKVVIPK KEEAPPAKVP EVPKKVEEKR IILPKEEEVL
     PVEVTEEPEE EPISEEEIPE EPPSIEEVEE VAPPRVPEVI KKAVPEAPTP VPKKVEAPPA
     KVSKKIPEEK VPVPVQKKEA PPAKVPEVPK KVPEKKVLVP KKEAVPPAKG RTVLEEKVSV
     AFRQEVVVKE RLELEVVEAE VEEIPEEEEF HEVEEYFEEG EFHEVEEFIK LEQHRVEEEH
     RVEKVHRVIE VFEAEEVEVF EKPKAPPKGP EISEKIIPPK KPPTKVVPRK EPPAKVPEVP
     KKIVVEEKVR VPEEPRVPPT KVPDVLPPKE VVPEKKVPVP PAKKPEAPPP KVPEAPKEVV
     PEKKVPVPPP KKPEVPPTKV PEVPKAAVPE KKVPEAIPPK PESPPPEVPE APKEVVPEKK
     VPAAPPKKPE VTPVKVPEAP KEVVPEKKVP VPPPKKPEVP PTKVPEVPKV AVPEKKVPEA
     IPPKPESPPP EVFEEPEEVA LEEPPAEVVE EPEPAAPPQV TVPPKKPVPE KKAPAVVAKK
     PELPPVKVPE VPKEVVPEKK VPLVVPKKPE APPAKVPEVP KEVVPEKKVA VPKKPEVPPA
     KVPEVPKKPV LEEKPAVPVP ERAESPPPEV YEEPEEIAPE EEIAPEEEKP VPVAEEEEPE
     VPPPAVPEEP KKIIPEKKVP VIKKPEAPPP KEPEPEKVIE KPKLKPRPPP PPPAPPKEDV
     KEKIFQLKAI PKKKVPEKPQ VPEKVELTPL KVPGGEKKVR KLLPERKPEP KEEVVLKSVL
     RKRPEEEEPK VEPKKLEKVK KPAVPEPPPP KPVEEVEVPT VTKRERKIPE PTKVPEIKPA
     IPLPAPEPKP KPEAEVKTIK PPPVEPEPTP IAAPVTVPVV GKKAEAKAPK EEAAKPKGPI
     KGVPKKTPSP IEAERRKLRP GSGGEKPPDE APFTYQLKAV PLKFVKEIKD IILTESEFVG
     SSAIFECLVS PSTAITTWMK DGSNIRESPK HRFIADGKDR KLHIIDVQLS DAGEYTCVLR
     LGNKEKTSTA KLVVEELPVR FVKTLEEEVT VVKGQPLYLS CELNKERDVV WRKDGKIVVE
     KPGRIVPGVI GLMRALTIND ADDTDAGTYT VTVENANNLE CSSCVKVVEV IRDWLVKPIR
     DQHVKPKGTA IFACDIAKDT PNIKWFKGYD EIPAEPNDKT EILRDGNHLY LKIKNAMPED
     IAEYAVEIEG KRYPAKLTLG EREVELLKPI EDVTIYEKES ASFDAEISEA DIPGQWKLKG
     ELLRPSPTCE IKAEGGKRFL TLRKVKLDQA GEVLYQALNA ITTAILTVKE IELDFAVPLK
     DVTVPERRQA RFECVLTREA NVIWSKGPDI IKSSDKFDII ADGKKHILVI NDSQFDDEGV
     YTAEVEGKKT SARLFVTGIR LKFMSPLEDQ TVKEGETATF VCELSHEKMH VVWFKNDAKL
     HTSRTVLISS EGKTHKLEMK EVTLDDISQI KAQVKELSST AQLKVLEADP YFTVKLHDKT
     AVEKDEITLK CEVSKDVPVK WFKDGEEIVP SPKYSIKADG LRRILKIKKA DLKDKGEYVC
     DCGTDKTKAN VTVEARLIKV EKPLYGVEVF VGETAHFEIE LSEPDVHGQW KLKGQPLTAS
     PDCEIIEDGK KHILILHNCQ LGMTGEVSFQ AANAKSAANL KVKELPLIFI TPLSDVKVFE
     KDEAKFECEV SREPKTFRWL KGTQEITGDD RFELIKDGTK HSMVIKSAAF EDEAKYMFEA
     EDKHTSGKLI IEGIRLKFLT PLKDVTAKEK ESAVFTVELS HDNIRVKWFK NDQRLHTTRS
     VSMQDEGKTH SITFKDLSID DTSQIRVEAM GMSSEAKLTV LEGDPYFTGK LQDYTGVEKD
     EVILQCEISK ADAPVKWFKD GKEIKPSKNA VIKADGKKRM LILKKALKSD IGQYTCDCGT
     DKTSGKLDIE DREIKLVRPL HSVEVMETET ARFETEISED DIHANWKLKG EALLQTPDCE
     IKEEGKIHSL VLHNCRLDQT GGVDFQAANV KSSAHLRVKP RVIGLLRPLK DVTVTAGETA
     TFDCELSYED IPVEWYLKGK KLEPSDKVVP RSEGKVHTLT LRDVKLEDAG EVQLTAKDFK
     THANLFVKEP PVEFTKPLED QTVEEGATAV LECEVSRENA KVKWFKNGTE ILKSKKYEIV
     ADGRVRKLVI HDCTPEDIKT YTCDAKDFKT SCNLNVVPPH VEFLRPLTDL QVREKEMARF
     ECELSRENAK VKWFKDGAEI KKGKKYDIIS KGAVRILVIN KCLLDDEAEY SCEVRTARTS
     GMLTVLEEEA VFTKNLANIE VSETDTIKLV CEVSKPGAEV IWYKGDEEII ETGRYEILTE
     GRKRILVIQN AHLEDAGNYN CRLPSSRTDG KVKVHELAAE FISKPQNLEI LEGEKAEFVC
     SISKESFPVQ WKRDDKTLES GDKYDVIADG KKRVLVVKDA TLQDMGTYVV MVGAARAAAH
     LTVIEKLRIV VPLKDTRVKE QQEVVFNCEV NTEGAKAKWF RNEEAIFDSS KYIILQKDLV
     YTLRIRDAHL DDQANYNVSL TNHRGENVKS AANLIVEEED LRIVEPLKDI ETMEKKSVTF
     WCKVNRLNVT LKWTKNGEEV PFDNRVSYRV DKYKHMLTIK DCGFPDEGEY IVTAGQDKSV
     AELLIIEAPT EFVEHLEDQT VTEFDDAVFS CQLSREKANV KWYRNGREIK EGKKYKFEKD
     GSIHRLIIKD CRLDDECEYA CGVEDRKSRA RLFVEEIPVE IIRPPQDILE APGADVVFLA
     ELNKDKVEVQ WLRNNMVVVQ GDKHQMMSEG KIHRLQICDI KPRDQGEYRF IAKDKEARAK
     LELAAAPKIK TADQDLVVDV GKPLTMVVPY DAYPKAEAEW FKENEPLSTK TIDTTAEQTS
     FRILEAKKGD KGRYKIVLQN KHGKAEGFIN LKVIDVPGPV RNLEVTETFD GEVSLAWEEP
     LTDGGSKIIG YVVERRDIKR KTWVLATDRA ESCEFTVTGL QKGGVEYLFR VSARNRVGTG
     EPVETDNPVE ARSKYDVPGP PLNVTITDVN RFGVSLTWEP PEYDGGAEIT NYVIELRDKT
     SIRWDTAMTV RAEDLSATVT DVVEGQEYSF RVRAQNRIGV GKPSAATPFV KVADPIERPS
     PPVNLTSSDQ TQSSVQLKWE PPLKDGGSPI LGYIIERCEE GKDNWIRCNM KLVPELTYKV
     TGLEKGNKYL YRVSAENKAG VSDPSEILGP LTADDAFVEP TMDLSAFKDG LEVIVPNPIT
     ILVPSTGYPR PTATWCFGDK VLETGDRVKM KTLSAYAELV ISPSERSDKG IYTLKLENRV
     KTISGEIDVN VIARPSAPKE LKFGDITKDS VHLTWEPPDD DGGSPLTGYV VEKREVSRKT
     WTKVMDFVTD LEFTVPDLVQ GKEYLFKVCA RNKCGPGEPA YVDEPVNMST PATVPDPPEN
     VKWRDRTANS IFLTWDPPKN DGGSRIKGYI VERCPRGSDK WVACGEPVAE TKMEVTGLEE
     GKWYAYRVKA LNRQGASKPS RPTEEIQAVD TQEAPEIFLD VKLLAGLTVK AGTKIELPAT
     VTGKPEPKIT WTKADMILKQ DKRITIENVP KKSTVTIVDS KRSDTGTYII EAVNVCGRAT
     AVVEVNVLDK PGPPAAFDIT DVTNESCLLT WNPPRDDGGS KITNYVVERR ATDSEVWHKL
     SSTVKDTNFK ATKLIPNKEY IFRVAAENMY GVGEPVQASP ITAKYQFDPP GPPTRLEPSD
     ITKDAVTLTW CEPDDDGGSP ITGYWVERLD PDTDKWVRCN KMPVKDTTYR VKGLTNKKKY
     RFRVLAENLA GPGKPSKSTE PILIKDPIDP PWPPGKPTVK DVGKTSVRLN WTKPEHDGGA
     KIESYVIEML KTGTDEWVRV AEGVPTTQHL LPGLMEGQEY SFRVRAVNKA GESEPSEPSD
     PVLCREKLYP PSPPRWLEVI NITKNTADLK WTVPEKDGGS PITNYIVEKR DVRRKGWQTV
     DTTVKDTKCT VTPLTEGSLY VFRVAAENAI GQSDYTEIED SVLAKDTFTT PGPPYALAVV
     DVTKRHVDLK WEPPKNDGGR PIQRYVIEKK ERLGTRWVKA GKTAGPDCNF RVTDVIEGTE
     VQFQVRAENE AGVGHPSEPT EILSIEDPTS PPSPPLDLHV TDAGRKHIAI AWKPPEKNGG
     SPIIGYHVEM CPVGTEKWMR VNSRPIKDLK FKVEEGVVPD KEYVLRVRAV NAIGVSEPSE
     ISENVVAKDP DCKPTIDLET HDIIVIEGEK LSIPVPFRAV PVPTVSWHKD GKEVKASDRL
     TMKNDHISAH LEVPKSVRAD AGIYTITLEN KLGSATASIN VKVIGLPGPC KDIKASDITK
     SSCKLTWEPP EFDGGTPILH YVLERREAGR RTYIPVMSGE NKLSWTVKDL IPNGEYFFRV
     KAVNKVGGGE YIELKNPVIA QDPKQPPDPP VDVEVHNPTA EAMTITWKPP LYDGGSKIMG
     YIIEKIAKGE ERWKRCNEHL VPILTYTAKG LEEGKEYQFR VRAENAAGIS EPSRATPPTK
     AVDPIDAPKV ILRTSLEVKR GDEIALDASI SGSPYPTITW IKDENVIVPE EIKKRAAPLV
     RRRKGEVQEE EPFVLPLTQR LSIDNSKKGE SQLRVRDSLR PDHGLYMIKV ENDHGIAKAP
     CTVSVLDTPG PPINFVFEDI RKTSVLCKWE PPLDDGGSEI INYTLEKKDK TKPDSEWIVV
     TSTLRHCKYS VTKLIEGKEY LFRVRAENRF GPGPPCVSKP LVAKDPFGPP DAPDKPIVED
     VTSNSMLVKW NEPKDNGSPI LGYWLEKREV NSTHWSRVNK SLLNALKANV DGLLEGLTYV
     FRVCAENAAG PGKFSPPSDP KTAHDPISPP GPPIPRVTDT SSTTIELEWE PPAFNGGGEI
     VGYFVDKQLV GTNEWSRCTE KMIKVRQYTV KEIREGADYK LRVSAVNAAG EGPPGETQPV
     TVAEPQEPPA VELDVSVKGG IQIMAGKTLR IPAVVTGRPV PTKVWTKEEG ELDKDRVVID
     NVGTKSELII KDALRKDHGR YVITATNSCG SKFAAARVEV FDVPGPVLDL KPVVTNRKMC
     LLNWSDPEDD GGSEITGFII ERKDAKMHTW RQPIETERSK CDITGLLEGQ EYKFRVIAKN
     KFGCGPPVEI GPILAVDPLG PPTSPERLTY TERTKSTITL DWKEPRSNGG SPIQGYIIEK
     RRHDKPDFER VNKRLCPTTS FLVENLDEHQ MYEFRVKAVN EIGESEPSLP LNVVIQDDEV
     PPTIKLRLSV RGDTIKVKAG EPVHIPADVT GLPMPKIEWS KNETVIEKPT DALQITKEEV
     SRSEAKTELS IPKAVREDKG TYTVTASNRL GSVFRNVHVE VYDRPSPPRN LAVTDIKAES
     CYLTWDAPLD NGGSEITHYV IDKRDASRKK AEWEEVTNTA VEKRYGIWKL IPNGQYEFRV
     RAVNKYGISD ECKSDKVVIQ DPYRLPGPPG KPKVLARTKG SMLVSWTPPL DNGGSPITGY
     WLEKREEGSP YWSRVSRAPI TKVGLKGVEF NVPRLLEGVK YQFRAMAINA AGIGPPSEPS
     DPEVAGDPIF PPGPPSCPEV KDKTKSSISL GWKPPAKDGG SPIKGYIVEM QEEGTTDWKR
     VNEPDKLITT CECVVPNLKE LRKYRFRVKA VNEAGESEPS DTTGEIPATD IQEEPEVFID
     IGAQDCLVCK AGSQIRIPAV IKGRPTPKSS WEFDGKAKKA MKDGVHDIPE DAQLETAENS
     SVIIIPECKR SHTGKYSITA KNKAGQKTAN CRVKVMDVPG PPKDLKVSDI TRGSCRLSWK
     MPDDDGGDRI KGYVIEKRTI DGKAWTKVNP DCGSTTFVVP DLLSEQQYFF RVRAENRFGI
     GPPVETIQRT TARDPIYPPD PPIKLKIGLI TKNTVHLSWK PPKNDGGSPV THYIVECLAW
     DPTGTKKEAW RQCNKRDVEE LQFTVEDLVE GGEYEFRVKA VNAAGVSKPS ATVGPCDCQR
     PDMPPSIDLK EFMEVEEGTN VNIVAKIKGV PFPTLTWFKA PPKKPDNKEP VLYDTHVNKL
     VVDDTCTLVI PQSRRSDTGL YTITAVNNLG TASKEMRLNV LGRPGPPVGP IKFESVSADQ
     MTLSWFPPKD DGGSKITNYV IEKREANRKT WVHVSSEPKE CTYTIPKLLE GHEYVFRIMA
     QNKYGIGEPL DSEPETARNL FSVPGAPDKP TVSSVTRNSM TVNWEEPEYD GGSPVTGYWL
     EMKDTTSKRW KRVNRDPIKA MTLGVSYKVT GLIEGSDYQF RVYAINAAGV GPASLPSDPA
     TARDPIAPPG PPFPKVTDWT KSSADLEWSP PLKDGGSKVT GYIVEYKEEG KEEWEKGKDK
     EVRGTKLVVT GLKEGAFYKF RVSAVNIAGI GEPGEVTDVI EMKDRLVSPD LQLDASVRDR
     IVVHAGGVIR IIAYVSGKPP PTVTWNMNER TLPQEATIET TAISSSMVIK NCQRSHQGVY
     SLLAKNEAGE RKKTIIVDVL DVPGPVGTPF LAHNLTNESC KLTWFSPEDD GGSPITNYVI
     EKRESDRRAW TPVTYTVTRQ NATVQGLIQG KAYFFRIAAE NSIGMGPFVE TSEALVIREP
     ITVPERPEDL EVKEVTKNTV TLTWNPPKYD GGSEIINYVL ESRLIGTEKF HKVTNDNLLS
     RKYTVKGLKE GDTYEYRVSA VNIVGQGKPS FCTKPITCKD ELAPPTLHLD FRDKLTIRVG
     EAFALTGRYS GKPKPKVSWF KDEADVLEDD RTHIKTTPAT LALEKIKAKR SDSGKYCVVV
     ENSTGSRKGF CQVNVVDRPG PPVGPVSFDE VTKDYMVISW KPPLDDGGSK ITNYIIEKKE
     VGKDVWMPVT SASAKTTCKV SKLLEGKDYI FRIHAENLYG ISDPLVSDSM KAKDRFRVPD
     APDQPIVTEV TKDSALVTWN KPHDGGKPIT NYILEKRETM SKRWARVTKD PIHPYTKFRV
     PDLLEGCQYE FRVSAENEIG IGDPSPPSKP VFAKDPIAKP SPPVNPEAID TTCNSVDLTW
     QPPRHDGGSK ILGYIVEYQK VGDEEWRRAN HTPESCPETK YKVTGLRDGQ TYKFRVLAVN
     AAGESDPAHV PEPVLVKDRL EPPELILDAN MAREQHIKVG DTLRLSAIIK GVPFPKVTWK
     KEDRDAPTKA RIDVTPVGSK LEIRNAAHED GGIYSLTVEN PAGSKTVSVK VLVLDKPGPP
     RDLEVSEIRK DSCYLTWKEP LDDGGSVITN YVVERRDVAS AQWSPLSATS KKKSHFAKHL
     NEGNQYLFRV AAENQYGRGP FVETPKPIKA LDPLHPPGPP KDLHHVDVDK TEVSLVWNKP
     DRDGGSPITG YLVEYQEEGT QDWIKFKTVT NLECVVTGLQ QGKTYRFRVK AENIVGLGLP
     DTTIPIECQE KLVPPSVELD VKLIEGLVVK AGTTVRFPAI IRGVPVPTAK WTTDGSEIKT
     DEHYTVETDN FSSVLTIKNC LRRDTGEYQI TVSNAAGSKT VAVHLTVLDV PGPPTGPINI
     LDVTPEHMTI SWQPPKDDGG SPVINYIVEK QDTRKDTWGV VSSGSSKTKL KIPHLQKGCE
     YVFRVRAENK IGVGPPLDST PTVAKHKFSP PSPPGKPVVT DITENAATVS WTLPKSDGGS
     PITGYYMERR EVTGKWVRVN KTPIADLKFR VTGLYEGNTY EFRVFAENLA GLSKPSPSSD
     PIKACRPIKP PGPPINPKLK DKSRETADLV WTKPLSDGGS PILGYVVECQ KPGTAQWNRI
     NKDELIRQCA FRVPGLIEGN EYRFRIKAAN IVGEGEPREL AESVIAKDIL HPPEVELDVT
     CRDVITVRVG QTIRILARVK GRPEPDITWT KEGKVLVREK RVDLIQDLPR VELQIKEAVR
     ADHGKYIISA KNSSGHAQGS AIVNVLDRPG PCQNLKVTNV TKENCTISWE NPLDNGGSEI
     TNFIVEYRKP NQKGWSIVAS DVTKRLIKAN LLANNEYYFR VCAENKVGVG PTIETKTPIL
     AINPIDRPGE PENLHIADKG KTFVYLKWRR PDYDGGSPNL SYHVERRLKG SDDWERVHKG
     SIKETHYMVD RCVENQIYEF RVQTKNEGGE SDWVKTEEVV VKEDLQKPVL DLKLSGVLTV
     KAGDTIRLEA GVRGKPFPEV AWTKDKDATD LTRSPRVKID TRADSSKFSL TKAKRSDGGK
     YVVTATNTAG SFVAYATVNV LDKPGPVRNL KIVDVSSDRC TVCWDPPEDD GGCEIQNYIL
     EKCETKRMVW STYSATVLTP GTTVTRLIEG NEYIFRVRAE NKIGTGPPTE SKPVIAKTKY
     DKPGRPDPPE VTKVSKEEMT VVWNPPEYDG GKSITGYFLE KKEKHSTRWV PVNKSAIPER
     RMKVQNLLPD HEYQFRVKAE NEIGIGEPSL PSRPVVAKDP IEPPGPPTNF RVVDTTKHSI
     TLGWGKPVYD GGAPIIGYVV EMRPKIADAS PDEGWKRCNA AAQLVRKEFT VTSLDENQEY
     EFRVCAQNQV GIGRPAELKE AIKPKEILEP PEIDLDASMR KLVIVRAGCP IRLFAIVRGR
     PAPKVTWRKV GIDNVVRKGQ VDLVDTMAFL VIPNSTRDDS GKYSLTLVNP AGEKAVFVNV
     RVLDTPGPVS DLKVSDVTKT SCHVSWAPPE NDGGSQVTHY IVEKREADRK TWSTVTPEVK
     KTSFHVTNLV PGNEYYFRVT AVNEYGPGVP TDVPKPVLAS DPLSEPDPPR KLEVTEMTKN
     SATLAWLPPL RDGGAKIDGY ITSYREEEQP ADRWTEYSVV KDLSLVVTGL KEGKKYKFRV
     AARNAVGVSL PREAEGVYEA KEQLLPPKIL MPEQITIKAG KKLRIEAHVY GKPHPTCKWK
     KGEDEVVTSS HLAVHKADSS SILIIKDVTR KDSGYYSLTA ENSSGTDTQK IKVVVMDAPG
     PPQPPFDISD IDADACSLSW HIPLEDGGSN ITNYIVEKCD VSRGDWVTAL ASVTKTSCRV
     GKLIPGQEYI FRVRAENRFG ISEPLTSPKM VAQFPFGVPS EPKNARVTKV NKDCIFVAWD
     RPDSDGGSPI IGYLIERKER NSLLWVKAND TLVRSTEYPC AGLVEGLEYS FRIYALNKAG
     SSPPSKPTEY VTARMPVDPP GKPEVIDVTK STVSLIWARP KHDGGSKIIG YFVEACKLPG
     DKWVRCNTAP HQIPQEEYTA TGLEEKAQYQ FRAIARTAVN ISPPSEPSDP VTILAENVPP
     RIDLSVAMKS LLTVKAGTNV CLDATVFGKP MPTVSWKKDG TLLKPAEGIK MAMQRNLCTL
     ELFSVNRKDS GDYTITAENS SGSKSATIKL KVLDKPGPPA SVKINKMYSD RAMLSWEPPL
     EDGGSEITNY IVDKRETSRP NWAQVSATVP ITSCSVEKLI EGHEYQFRIC AENKYGVGDP
     VFTEPAIAKN PYDPPGRCDP PVISNITKDH MTVSWKPPAD DGGSPITGYL LEKRETQAVN
     WTKVNRKPII ERTLKATGLQ EGTEYEFRVT AINKAGPGKP SDASKAAYAR DPQYPPAPPA
     FPKVYDTTRS SVSLSWGKPA YDGGSPIIGY LVEVKRADSD NWVRCNLPQN LQKTRFEVTG
     LMEDTQYQFR VYAVNKIGYS DPSDVPDKHY PKDILIPPEG ELDADLRKTL ILRAGVTMRL
     YVPVKGRPPP KITWSKPNVN LRDRIGLDIK STDFDTFLRC ENVNKYDAGK YILTLENSCG
     KKEYTIVVKV LDTPGPPVNV TVKEISKDSA YVTWEPPIID GGSPIINYVV QKRDAERKSW
     STVTTECSKT SFRVANLEEG KSYFFRVFAE NEYGIGDPGE TRDAVKASQT PGPVVDLKVR
     SVSKSSCSIG WKKPHSDGGS RIIGYVVDFL TEENKWQRVM KSLSLQYSAK DLTEGKEYTF
     RVSAENENGE GTPSEITVVA RDDVVAPDLD LKGLPDLCYL AKENSNFRLK IPIKGKPAPS
     VSWKKGEDPL ATDTRVSVES SAVNTTLIVY DCQKSDAGKY TITLKNVAGT KEGTISIKVV
     GKPGIPTGPI KFDEVTAEAM TLKWAPPKDD GGSEITNYIL EKRDSVNNKW VTCASAVQKT
     TFRVTRLHEG MEYTFRVSAE NKYGVGEGLK SEPIVARHPF DVPDAPPPPN IVDVRHDSVS
     LTWTDPKKTG GSPITGYHLE FKERNSLLWK RANKTPIRMR DFKVTGLTEG LEYEFRVMAI
     NLAGVGKPSL PSEPVVALDP IDPPGKPEVI NITRNSVTLI WTEPKYDGGH KLTGYIVEKR
     DLPSKSWMKA NHVNVPECAF TVTDLVEGGK YEFRIRAKNT AGAISAPSES TETIICKDEY
     EAPTIVLDPT IKDGLTIKAG DTIVLNAISI LGKPLPKSSW SKAGKDIRPS DITQITSTPT
     SSMLTIKYAT RKDAGEYTIT ATNPFGTKVE HVKVTVLDVP GPPGPVEISN VSAEKATLTW
     TPPLEDGGSP IKSYILEKRE TSRLLWTVVS EDIQSCRHVA TKLIQGNEYI FRVSAVNHYG
     KGEPVQSEPV KMVDRFGPPG PPEKPEVSNV TKNTATVSWK RPVDDGGSEI TGYHVERREK
     KSLRWVRAIK TPVSDLRCKV TGLQEGSTYE FRVSAENRAG IGPPSEASDS VLMKDAAYPP
     GPPSNPHVTD TTKKSASLAW GKPHYDGGLE ITGYVVEHQK VGDEAWIKDT TGTALRITQF
     VVPDLQTKEK YNFRISAIND AGVGEPAVIP DVEIVEREMA PDFELDAELR RTLVVRAGLS
     IRIFVPIKGR PAPEVTWTKD NINLKNRANI ENTESFTLLI IPECNRYDTG KFVMTIENPA
     GKKSGFVNVR VLDTPGPVLN LRPTDITKDS VTLHWDLPLI DGGSRITNYI VEKREATRKS
     YSTATTKCHK CTYKVTGLSE GCEYFFRVMA ENEYGIGEPT ETTEPVKASE APSPPDSLNI
     MDITKSTVSL AWPKPKHDGG SKITGYVIEA QRKGSDQWTH ITTVKGLECV VRNLTEGEEY
     TFQVMAVNSA GRSAPRESRP VIVKEQTMLP ELDLRGIYQK LVIAKAGDNI KVEIPVLGRP
     KPTVTWKKGD QILKQTQRVN FETTATSTIL NINECVRSDS GPYPLTARNI VGEVGDVITI
     QVHDIPGPPT GPIKFDEVSS DFVTFSWDPP ENDGGVPISN YVVEMRQTDS TTWVELATTV
     IRTTYKATRL TTGLEYQFRV KAQNRYGVGP GITSACIVAN YPFKVPGPPG TPQVTAVTKD
     SMTISWHEPL SDGGSPILGY HVERKERNGI LWQTVSKALV PGNIFKSSGL TDGIAYEFRV
     IAENMAGKSK PSKPSEPMLA LDPIDPPGKP VPLNITRHTV TLKWAKPEYT GGFKITSYIV
     EKRDLPNGRW LKANFSNILE NEFTVSGLTE DAAYEFRVIA KNAAGAISPP SEPSDAITCR
     DDVEAPKIKV DVKFKDTVIL KAGEAFRLEA DVSGRPPPTM EWSKDGKELE GTAKLEIKIA
     DFSTNLVNKD STRRDSGAYT LTATNPGGFA KHIFNVKVLD RPGPPEGPLA VTEVTSEKCV
     LSWFPPLDDG GAKIDHYIVQ KRETSRLAWT NVASEVQVTK LKVTKLLKGN EYIFRVMAVN
     KYGVGEPLES EPVLAVNPYG PPDPPKNPEV TTITKDSMVV CWGHPDSDGG SEIINYIVER
     RDKAGQRWIK CNKKTLTDLR YKVSGLTEGH EYEFRIMAEN AAGISAPSPT SPFYKACDTV
     FKPGPPGNPR VLDTSRSSIS IAWNKPIYDG GSEITGYMVE IALPEEDEWQ IVTPPAGLKA
     TSYTITGLTE NQEYKIRIYA MNSEGLGEPA LVPGTPKAED RMLPPEIELD ADLRKVVTIR
     ACCTLRLFVP IKGRPAPEVK WARDHGESLD KASIESTSSY TLLIVGNVNR FDSGKYILTV
     ENSSGSKSAF VNVRVLDTPG PPQDLKVKEV TKTSVTLTWD PPLLDGGSKI KNYIVEKRES
     TRKAYSTVAT NCHKTSWKVD QLQEGCSYYF RVLAENEYGI GLPAETAESV KASERPLPPG
     KITLMDVTRN SVSLSWEKPE HDGGSRILGY IVEMQTKGSD KWATCATVKV TEATITGLIQ
     GEEYSFRVSA QNEKGISDPR QLSVPVIAKD LVIPPAFKLL FNTFTVLAGE DLKVDVPFIG
     RPTPAVTWHK DNVPLKQTTR VNAESTENNS LLTIKDACRE DVGHYVVKLT NSAGEAIETL
     NVIVLDKPGP PTGPVKMDEV TADSITLSWG PPKYDGGSSI NNYIVEKRDT STTTWQIVSA
     TVARTTIKAC RLKTGCEYQF RIAAENRYGK STYLNSEPTV AQYPFKVPGP PGTPVVTLSS
     RDSMEVQWNE PISDGGSRVI GYHLERKERN SILWVKLNKT PIPQTKFKTT GLEEGVEYEF
     RVSAENIVGI GKPSKVSECY VARDPCDPPG RPEAIIVTRN SVTLQWKKPT YDGGSKITGY
     IVEKKELPEG RWMKASFTNI IDTHFEVTGL VEDHRYEFRV IARNAAGVFS EPSESTGAIT
     ARDEVDPPRI SMDPKYKDTI VVHAGESFKV DADIYGKPIP TIQWIKGDQE LSNTARLEIK
     STDFATSLSV KDAVRVDSGN YILKAKNVAG ERSVTVNVKV LDRPGPPEGP VVISGVTAEK
     CTLAWKPPLQ DGGSDIINYI VERRETSRLV WTVVDANVQT LSCKVTKLLE GNEYTFRIMA
     VNKYGVGEPL ESEPVVAKNP FVVPDAPKAP EVTTVTKDSM IVVWERPASD GGSEILGYVL
     EKRDKEGIRW TRCHKRLIGE LRLRVTGLIE NHDYEFRVSA ENAAGLSEPS PPSAYQKACD
     PIYKPGPPNN PKVIDITRSS VFLSWSKPIY DGGCEIQGYI VEKCDVSVGE WTMCTPPTGI
     NKTNIEVEKL LEKHEYNFRI CAINKAGVGE HADVPGPIIV EEKLEAPDID LDLELRKIIN
     IRAGGSLRLF VPIKGRPTPE VKWGKVDGEI RDAAIIDVTS SFTSLVLDNV NRYDSGKYTL
     TLENSSGTKS AFVTVRVLDT PSPPVNLKVT EITKDSVSIT WEPPLLDGGS KIKNYIVEKR
     EATRKSYAAV VTNCHKNSWK IDQLQEGCSY YFRVTAENEY GIGLPAQTAD PIKVAEVPQP
     PGKITVDDVT RNSVSLSWTK PEHDGGSKII QYIVEMQAKH SEKWSECARV KSLQAVITNL
     TQGEEYLFRV VAVNEKGRSD PRSLAVPIVA KDLVIEPDVK PAFSSYSVQV GQDLKIEVPI
     SGRPKPTITW TKDGLPLKQT TRINVTDSLD LTTLSIKETH KDDGGQYGIT VANVVGQKTA
     SIEIVTLDKP DPPKGPVKFD DVSAESITLS WNPPLYTGGC QITNYIVQKR DTTTTVWDVV
     SATVARTTLK VTKLKTGTEY QFRIFAENRY GQSFALESDP IVAQYPYKEP GPPGTPFATA
     ISKDSMVIQW HEPVNNGGSP VIGYHLERKE RNSILWTKVN KTIIHDTQFK AQNLEEGIEY
     EFRVYAENIV GVGKASKNSE CYVARDPCDP PGTPEPIMVK RNEITLQWTK PVYDGGSMIT
     GYIVEKRDLP DGRWMKASFT NVIETQFTVS GLTEDQRYEF RVIAKNAAGA ISKPSDSTGP
     ITAKDEVELP RISMDPKFRD TIVVNAGETF RLEADVHGKP LPTIEWLRGD KEIEESARCE
     IKNTDFKALL IVKDAIRIDG GQYILRASNV AGSKSFPVNV KVLDRPGPPE GPVQVTGVTS
     EKCSLTWSPP LQDGGSDISH YVVEKRETSR LAWTVVASEV VTNSLKVTKL LEGNEYVFRI
     MAVNKYGVGE PLESAPVLMK NPFVLPGPPK SLEVTNIAKD SMTVCWNRPD SDGGSEIIGY
     IVEKRDRSGI RWIKCNKRRI TDLRLRVTGL TEDHEYEFRV SAENAAGVGE PSPATVYYKA
     CDPVFKPGPP TNAHIVDTTK NSITLAWGKP IYDGGSEILG YVVEICKADE EEWQIVTPQT
     GLRVTRFEIS KLTEHQEYKI RVCALNKVGL GEATSVPGTV KPEDKLEAPE LDLDSELRKG
     IVVRAGGSAR IHIPFKGRPT PEITWSREEG EFTDKVQIEK GVNYTQLSID NCDRNDAGKY
     ILKLENSSGS KSAFVTVKVL DTPGPPQNLA VKEVRKDSAF LVWEPPIIDG GAKVKNYVID
     KRESTRKAYA NVSSKCSKTS FKVENLTEGA IYYFRVMAEN EFGVGVPVET VDAVKAAEPP
     SPPGKVTLTD VSQTSASLMW EKPEHDGGSR VLGYVVEMQP KGTEKWSIVA ESKVCNAVVT
     GLSSGQEYQF RVKAYNEKGK SDPRVLGVPV IAKDLTIQPS LKLPFNTYSI QAGEDLKIEI
     PVIGRPRPNI SWVKDGEPLK QTTRVNVEET ATSTVLHIKE GNKDDFGKYT VTATNSAGTA
     TENLSVIVLE KPGPPVGPVR FDEVSADFVV ISWEPPAYTG GCQISNYIVE KRDTTTTTWH
     MVSATVARTT IKITKLKTGT EYQFRIFAEN RYGKSAPLDS KAVIVQYPFK EPGPPGTPFV
     TSISKDQMLV QWHEPVNDGG TKIIGYHLEQ KEKNSILWVK LNKTPIQDTK FKTTGLDEGL
     EYEFKVSAEN IVGIGKPSKV SECFVARDPC DPPGRPEAIV ITRNNVTLKW KKPAYDGGSK
     ITGYIVEKKD LPDGRWMKAS FTNVLETEFT VSGLVEDQRY EFRVIARNAA GNFSEPSDSS
     GAITARDEID APNASLDPKY KDVIVVHAGE TFVLEADIRG KPIPDVVWSK DGKELEETAA
     RMEIKSTIQK TTLVVKDCIR TDGGQYILKL SNVGGTKSIP ITVKVLDRPG PPEGPLKVTG
     VTAEKCYLAW NPPLQDGGAN ISHYIIEKRE TSRLSWTQVS TEVQALNYKV TKLLPGNEYI
     FRVMAVNKYG IGEPLESGPV TACNPYKPPG PPSTPEVSAI TKDSMVVTWA RPVDDGGTEI
     EGYILEKRDK EGVRWTKCNK KTLTDLRLRV TGLTEGHSYE FRVAAENAAG VGEPSEPSVF
     YRACDALYPP GPPSNPKVTD TSRSSVSLAW SKPIYDGGAP VKGYVVEVKE AAADEWTTCT
     PPTGLQGKQF TVTKLKENTE YNFRICAINS EGVGEPATLP GSVVAQERIE PPEIELDADL
     RKVVVLRASA TLRLFVTIKG RPEPEVKWEK AEGILTDRAQ IEVTSSFTML VIDNVTRFDS
     GRYNLTLENN SGSKTAFVNV RVLDSPSAPV NLTIREVKKD SVTLSWEPPL IDGGAKITNY
     IVEKRETTRK AYATITNNCT KTTFRIENLQ EGCSYYFRVL ASNEYGIGLP AETTEPVKVS
     EPPLPPGRVT LVDVTRNTAT IKWEKPESDG GSKITGYVVE MQTKGSEKWS TCTQVKTLEA
     TISGLTAGEE YVFRVAAVNE KGRSDPRQLG VPVIARDIEI KPSVELPFHT FNVKAREQLK
     IDVPFKGRPQ ATVNWRKDGQ TLKETTRVNV SSSKTVTSLS IKEASKEDVG TYELCVSNSA
     GSITVPITII VLDRPGPPGP IRIDEVSCDS ITISWNPPEY DGGCQISNYI VEKKETTSTT
     WHIVSQAVAR TSIKIVRLTT GSEYQFRVCA ENRYGKSSYS ESSAVVAEYP FSPPGPPGTP
     KVVHATKSTM LVTWQVPVND GGSRVIGYHL EYKERSSILW SKANKILIAD TQMKVSGLDE
     GLMYEYRVYA ENIAGIGKCS KSCEPVPARD PCDPPGQPEV TNITRKSVSL KWSKPHYDGG
     AKITGYIVER RELPDGRWLK CNYTNIQETY FEVTELTEDQ RYEFRVFARN AADSVSEPSE
     STGPIIVKDD VEPPRVMMDV KFRDVIVVKA GEVLKINADI AGRPLPVISW AKDGIEIEER
     ARTEIISTDN HTLLTVKDCI RRDTGQYVLT LKNVAGTRSV AVNCKVLDKP GPPAGPLEIN
     GLTAEKCSLS WGRPQEDGGA DIDYYIVEKR ETSHLAWTIC EGELQMTSCK VTKLLKGNEY
     IFRVTGVNKY GVGEPLESVA IKALDPFTVP SPPTSLEITS VTKESMTLCW SRPESDGGSE
     ISGYIIERRE KNSLRWVRVN KKPVYDLRVK STGLREGCEY EYRVYAENAA GLSLPSETSP
     LIRAEDPVFL PSPPSKPKIV DSGKTTITIA WVKPLFDGGA PITGYTVEYK KSDDTDWKTS
     IQSLRGTEYT ISGLTTGAEY VFRVKSVNKV GASDPSDSSD PQIAKEREEE PLFDIDSEMR
     KTLIVKAGAS FTMTVPFRGR PVPNVLWSKP DTDLRTRAYV DTTDSRTSLT IENANRNDSG
     KYTLTIQNVL SAASLTLVVK VLDTPGPPTN ITVQDVTKES AVLSWDVPEN DGGAPVKNYH
     IEKREASKKA WVSVTNNCNR LSYKVTNLQE GAIYYFRVSG ENEFGVGIPA ETKEGVKITE
     KPSPPEKLGV TSISKDSVSL TWLKPEHDGG SRIVHYVVEA LEKGQKNWVK CAVAKSTHHV
     VSGLRENSEY FFRVFAENQA GLSDPRELLL PVLIKEQLEP PEIDMKNFPS HTVYVRAGSN
     LKVDIPISGK PLPKVTLSRD GVPLKATMRF NTEITAENLT INLKESVTAD AGRYEITAAN
     SSGTTKAFIN IVVLDRPGPP TGPVVISDIT EESVTLKWEP PKYDGGSQVT NYILLKRETS
     TAVWTEVSAT VARTMMKVMK LTTGEEYQFR IKAENRFGIS DHIDSACVTV KLPYTTPGPP
     STPWVTNVTR ESITVGWHEP VSNGGSAVVG YHLEMKDRNS ILWQKANKLV IRTTHFKVTT
     ISAGLIYEFR VYAENAAGVG KPSHPSEPVL AIDACEPPRN VRITDISKNS VSLSWQQPAF
     DGGSKITGYI VERRDLPDGR WTKASFTNVT ETQFIISGLT QNSQYEFRVF ARNAVGSISN
     PSEVVGPITC IDSYGGPVID LPLEYTEVVK YRAGTSVKLR AGISGKPAPT IEWYKDDKEL
     QTNALVCVEN TTDLASILIK DADRLNSGCY ELKLRNAMGS ASATIRVQIL DKPGPPGGPI
     EFKTVTAEKI TLLWRPPADD GGAKITHYIV EKRETSRVVW SMVSEHLEEC IITTTKIIKG
     NEYIFRVRAV NKYGIGEPLE SDSVVAKNAF VTPGPPGIPE VTKITKNSMT VVWSRPIADG
     GSDISGYFLE KRDKKSLGWF KVLKETIRDT RQKVTGLTEN SDYQYRVCAV NAAGQGPFSE
     PSEFYKAADP IDPPGPPAKI RIADSTKSSI TLGWSKPVYD GGSAVTGYVV EIRQGEEEEW
     TTVSTKGEVR TTEYVVSNLK PGVNYYFRVS AVNCAGQGEP IEMNEPVQAK DILEAPEIDL
     DVALRTSVIA KAGEDVQVLI PFKGRPPPTV TWRKDEKNLG SDARYSIENT DSSSLLTIPQ
     VTRNDTGKYI LTIENGVGEP KSSTVSVKVL DTPAACQKLQ VKHVSRGTVT LLWDPPLIDG
     GSPIINYVIE KRDATKRTWS VVSHKCSSTS FKLIDLSEKT PFFFRVLAEN EIGIGEPCET
     TEPVKAAEVP APIRDLSMKD STKTSVILSW TKPDFDGGSV ITEYVVERKG KGEQTWSHAG
     ISKTCEIEVS QLKEQSVLEF RVFAKNEKGL SDPVTIGPIT VKELIITPEV DLSDIPGAQV
     TVRIGHNVHL ELPYKGKPKP SISWLKDGLP LKESEFVRFS KTENKITLSI KNAKKEHGGK
     YTVILDNAVC RIAVPITVIT LGPPSKPKGP IRFDEIKADS VILSWDVPED NGGGEITCYS
     IEKRETSQTN WKMVCSSVAR TTFKVPNLVK DAEYQFRVRA ENRYGVSQPL VSSIIVAKHQ
     FRIPGPPGKP VIYNVTSDGM SLTWDAPVYD GGSEVTGFHV EKKERNSILW QKVNTSPISG
     REYRATGLVE GLDYQFRVYA ENSAGLSSPS DPSKFTLAVS PVDPPGTPDY IDVTRETITL
     KWNPPLRDGG SKIVGYSIEK RQGNERWVRC NFTDVSECQY TVTGLSPGDR YEFRIIARNA
     VGTISPPSQS SGIIMTRDEN VPPIVEFGPE YFDGLIIKSG ESLRIKALVQ GRPVPRVTWF
     KDGVEIEKRM NMEITDVLGS TSLFVRDATR DHRGVYTVEA KNASGSAKAE IKVKVQDTPG
     KVVGPIRFTN ITGEKMTLWW DAPLNDGCAP ITHYIIEKRE TSRLAWALIE DKCEAQSYTA
     IKLINGNEYQ FRVSAVNKFG VGRPLDSDPV VAQIQYTVPD APGIPEPSNI TGNSITLTWA
     RPESDGGSEI QQYILERREK KSTRWVKVIS KRPISETRFK VTGLTEGNEY EFHVMAENAA
     GVGPASGISR LIKCREPVNP PGPPTVVKVT DTSKTTVSLE WSKPVFDGGM EIIGYIIEMC
     KADLGDWHKV NAEACVKTRY TVTDLQAGEE YKFRVSAING AGKGDSCEVT GTIKAVDRLT
     APELDIDANF KQTHVVRAGA SIRLFIAYQG RPTPTAVWSK PDSNLSLRAD IHTTDSFSTL
     TVENCNRNDA GKYTLTVENN SGSKSITFTV KVLDTPGPPG PITFKDVTRG SATLMWDAPL
     LDGGARIHHY VVEKREASRR SWQVISEKCT RQIFKVNDLA EGVPYYFRVS AVNEYGVGEP
     YEMPEPIVAT EQPAPPRRLD VVDTSKSSAV LAWLKPDHDG GSRITGYLLE MRQKGSDFWV
     EAGHTKQLTF TVERLVEKTE YEFRVKAKND AGYSEPREAF SSVIIKEPQI EPTADLTGIT
     NQLITCKAGS PFTIDVPISG RPAPKVTWKL EEMRLKETDR VSITTTKDRT TLTVKDSMRG
     DSGRYFLTLE NTAGVKTFSV TVVVIGRPGP VTGPIEVSSV SAESCVLSWG EPKDGGGTEI
     TNYIVEKRES GTTAWQLVNS SVKRTQIKVT HLTKYMEYSF RVSSENRFGV SKPLESAPII
     AEHPFVPPSA PTRPEVYHVS ANAMSIRWEE PYHDGGSKII GYWVEKKERN TILWVKENKV
     PCLECNYKVT GLVEGLEYQF RTYALNAAGV SKASEASRPI MAQNPVDAPG RPEVTDVTRS
     TVSLIWSAPA YDGGSKVVGY IIERKPVSEV GDGRWLKCNY TIVSDNFFTV TALSEGDTYE
     FRVLAKNAAG VISKGSESTG PVTCRDEYAP PKAELDARLH GDLVTIRAGS DLVLDAAVGG
     KPEPKIIWTK GDKELDLCEK VSLQYTGKRA TAVIKFCDRS DSGKYTLTVK NASGTKAVSV
     MVKVLDSPGP CGKLTVSRVT QEKCTLAWSL PQEDGGAEIT HYIVERRETS RLNWVIVEGE
     CPTLSYVVTR LIKNNEYIFR VRAVNKYGPG VPVESEPIVA RNSFTIPSPP GIPEEVGTGK
     EHIIIQWTKP ESDGGNEISN YLVDKREKKS LRWTRVNKDY VVYDTRLKVT SLMEGCDYQF
     RVTAVNAAGN SEPSEASNFI SCREPSYTPG PPSAPRVVDT TKHSISLAWT KPMYDGGTDI
     VGYVLEMQEK DTDQWYRVHT NATIRNTEFT VPDLKMGQKY SFRVAAVNVK GMSEYSESIA
     EIEPVERIEI PDLELADDLK KTVTIRAGAS LRLMVSVSGR PPPVITWSKQ GIDLASRAII
     DTTESYSLLI VDKVNRYDAG KYTIEAENQS GKKSATVLVK VYDTPGPCPS VKVKEVSRDS
     VTITWEIPTI DGGAPVNNYI VEKREAAMRA FKTVTTKCSK TLYRISGLVE GTMYYFRVLP
     ENIYGIGEPC ETSDAVLVSE VPLVPAKLEV VDVTKSTVTL AWEKPLYDGG SRLTGYVLEA
     CKAGTERWMK VVTLKPTVLE HTVTSLNEGE QYLFRIRAQN EKGVSEPRET VTAVTVQDLR
     VLPTIDLSTM PQKTIHVPAG RPVELVIPIA GRPPPAASWF FAGSKLRESE RVTVETHTKV
     AKLTIRETTI RDTGEYTLEL KNVTGTTSET IKVIILDKPG PPTGPIKIDE IDATSITISW
     EPPELDGGAP LSGYVVEQRD AHRPGWLPVS ESVTRSTFKF TRLTEGNEYV FRVAATNRFG
     IGSYLQSEVI ECRSSIRIPG PPETLQIFDV SRDGMTLTWY PPEDDGGSQV TGYIVERKEV
     RADRWVRVNK VPVTMTRYRS TGLTEGLEYE HRVTAINARG SGKPSRPSKP IVAMDPIAPP
     GKPQNPRVTD TTRTSVSLAW SVPEDEGGSK VTGYLIEMQK VDQHEWTKCN TTPTKIREYT
     LTHLPQGAEY RFRVLACNAG GPGEPAEVPG TVKVTEMLEY PDYELDERYQ EGIFVRQGGV
     IRLTIPIKGK PFPICKWTKE GQDISKRAMI ATSETHTELV IKEADRGDSG TYDLVLENKC
     GKKAVYIKVR VIGSPNSPEG PLEYDDIQVR SVRVSWRPPA DDGGADILGY ILERREVPKA
     AWYTIDSRVR GTSLVVKGLK ENVEYHFRVS AENQFGISKP LKSEEPVTPK TPLNPPEPPS
     NPPEVLDVTK SSVSLSWSRP KDDGGSRVTG YYIERKETST DKWVRHNKTQ ITTTMYTVTG
     LVPDAEYQFR IIAQNDVGLS ETSPASEPVV CKDPFDKPSQ PGELEILSIS KDSVTLQWEK
     PECDGGKEIL GYWVEYRQSG DSAWKKSNKE RIKDKQFTIG GLLEATEYEF RVFAENETGL
     SRPRRTAMSI KTKLTSGEAP GIRKEMKDVT TKLGEAAQLS CQIVGRPLPD IKWYRFGKEL
     IQSRKYKMSS DGRTHTLTVM TEEQEDEGVY TCIATNEVGE VETSSKLLLQ ATPQFHPGYP
     LKEKYYGAVG STLRLHVMYI GRPVPAMTWF HGQKLLQNSE NITIENTEHY THLVMKNVQR
     KTHAGKYKVQ LSNVFGTVDA ILDVEIQDKP DKPTGPIVIE ALLKNSAVIS WKPPADDGGS
     WITNYVVEKC EAKEGAEWQL VSSAISVTTC RIVNLTENAG YYFRVSAQNT FGISDPLEVS
     SVVIIKSPFE KPGAPGKPTI TAVTKDSCVV AWKPPASDGG AKIRNYYLEK REKKQNKWIS
     VTTEEIRETV FSVKNLIEGL EYEFRVKCEN LGGESEWSEI SEPITPKSDV PIQAPHFKEE
     LRNLNVRYQS NATLVCKVTG HPKPIVKWYR QGKEIIADGL KYRIQEFKGG YHQLIIASVT
     DDDATVYQVR ATNQGGSVSG TASLEVEVPA KIHLPKTLEG MGAVHALRGE VVSIKIPFSG
     KPDPVITWQK GQDLIDNNGH YQVIVTRSFT SLVFPNGVER KDAGFYVVCA KNRFGIDQKT
     VELDVADVPD PPRGVKVSDV SRDSVNLTWT EPASDGGSKI TNYIVEKCAT TAERWLRVGQ
     ARETRYTVIN LFGKTSYQFR VIAENKFGLS KPSEPSEPTI TKEDKTRAMN YDEEVDETRE
     VSMTKASHSS TKELYEKYMI AEDLGRGEFG IVHRCVETSS KKTYMAKFVK VKGTDQVLVK
     KEISILNIAR HRNILHLHES FESMEELVMI FEFISGLDIF ERINTSAFEL NEREIVSYVH
     QVCEALQFLH SHNIGHFDIR PENIIYQTRR SSTIKIIEFG QARQLKPGDN FRLLFTAPEY
     YAPEVHQHDV VSTATDMWSL GTLVYVLLSG INPFLAETNQ QIIENIMNAE YTFDEEAFKE
     ISIEAMDFVD RLLVKERKSR MTASEALQHP WLKQKIERVS TKVIRTLKHR RYYHTLIKKD
     LNMVVSAARI SCGGAIRSQK GVSVAKVKVA SIEIGPVSGQ IMHAVGEEGG HVKYVCKIEN
     YDQSTQVTWY FGVRQLENSE KYEITYEDGV AILYVKDITK LDDGTYRCKV VNDYGEDSSY
     AELFVKGVRE VYDYYCRRTM KKIKRRTDTM RLLERPPEFT LPLYNKTAYV GENVRFGVTI
     TVHPEPHVTW YKSGQKIKPG DNDKKYTFES DKGLYQLTIN SVTTDDDAEY TVVARNKYGE
     DSCKAKLTVT LHPPPTDSTL RPMFKRLLAN AECQEGQSVC FEIRVSGIPP PTLKWEKDGQ
     PLSLGPNIEI IHEGLDYYAL HIRDTLPEDT GYYRVTATNT AGSTSCQAHL QVERLRYKKQ
     EFKSKEEHER HVQKQIDKTL RMAEILSGTE SVPLTQVAKE ALREAAVLYK PAVSTKTVKG
     EFRLEIEEKK EERKLRMPYD VPEPRKYKQT TIEEDQRIKQ FVPMSDMKWY KKIRDQYEMP
     GKLDRVVQKR PKRIRLSRWE QFYVMPLPRI TDQYRPKWRI PKLSQDDLEI VRPARRRTPS
     PDYDFYYRPR RRSLGDISDE ELLLPIDDYL AMKRTEEERL RLEEELELGF SASPPSRSPP
     HFELSSLRYS SPQAHVKVEE TRKDFRYSTY HIPTKAEAST SYAELRERHA QAAYRQPKQR
     QRIMAEREDE ELLRPVTTTQ HLSEYKSELD FMSKEEKSRK KSRRQREVTE ITEIEEEYEI
     SKHAQRESSS SASRLLRRRR SLSPTYIELM RPVSELIRSR PQPAEEYEDD TERRSPTPER
     TRPRSPSPVS SERSLSRFER SARFDIFSRY ESMKAALKTQ KTSERKYEVL SQQPFTLDHA
     PRITLRMRSH RVPCGQNTRF ILNVQSKPTA EVKWYHNGVE LQESSKIHYT NTSGVLTLEI
     LDCHTDDSGT YRAVCTNYKG EASDYATLDV TGGDYTTYAS QRRDEEVPRS VFPELTRTEA
     YAVSSFKKTS EMEASSSVRE VKSQMTETRE SLSSYEHSAS AEMKSAALEE KSLEEKSTTR
     KIKTTLAARI LTKPRSMTVY EGESARFSCD TDGEPVPTVT WLRKGQVLST SARHQVTTTK
     YKSTFEISSV QASDEGNYSV VVENSEGKQE AEFTLTIQKA RVTEKAVTSP PRVKSPEPRV
     KSPEAVKSPK RVKSPEPSHP KAVSPTETKP TPTEKVQHLP VSAPPKITQF LKAEASKEIA
     KLTCVVESSV LRAKEVTWYK DGKKLKENGH FQFHYSADGT YELKINNLTE SDQGEYVCEI
     SGEGGTSKTN LQFMGQAFKS IHEKVSKISE TKKSDQKTTE STVTRKTEPK APEPISSKPV
     IVTGLQDTTV SSDSVAKFAV KATGEPRPTA IWTKDGKAIT QGGKYKLSED KGGFFLEIHK
     TDTSDSGLYT CTVKNSAGSV SSSCKLTIKA IKDTEAQKVS TQKTSEITPQ KKAVVQEEIS
     QKALRSEEIK MSEAKSQEKL ALKEEASKVL ISEEVKKSAA TSLEKSIVHE EITKTSQASE
     EVRTHAEIKA FSTQMSINEG QRLVLKANIA GATDVKWVLN GVELTNSEEY RYGVSGSDQT
     LTIKQASHRD EGILTCISKT KEGIVKCQYD LTLSKELSDA PAFISQPRSQ NINEGQNVLF
     TCEISGEPSP EIEWFKNNLP ISISSNVSIS RSRNVYSLEI RNASVSDSGK YTIKAKNFRG
     QCSATASLMV LPLVEEPSRE VVLRTSGDTS LQGSFSSQSV QMSASKQEAS FSSFSSSSAS
     SMTEMKFASM SAQSMSSMQE SFVEMSSSSF MGISNMTQLE SSTSKMLKAG IRGIPPKIEA
     LPSDISIDEG KVLTVACAFT GEPTPEVTWS CGGRKIHSQE QGRFHIENTD DLTTLIIMDV
     QKQDGGLYTL SLGNEFGSDS ATVNIHIRSI
//
